Exogenous corticosteroids and dog behaviour by Notari, Lorella
Exogenous Corticosteroids and Dog
Behaviour
L. Notari
Doctor of Philosophy
2016
Exogenous Corticosteroids and Dog
Behaviour
Author
Lorella Notari
A thesis submitted in partial fulﬁllment of the requirements
for the degree of Doctor of Philosophy
Supervisor Second Supervisor
Professor Daniel Mills Dr. Oliver Burman
2016

Acknowledgements
As ﬁrst thing I would like to thank my supervisors, Professor Daniel Mills and Doctor
Oliver Burman. They made me test myself in doing this research and provided inputs,
critics and ideas that made this work possible. They were also very patient with my
English skills, which made their work for the correction of my writings harder than it
should have been.
Sincere thanks to my examiners. Thanks to Professor Ádám Miklósi, Dr. Tamás
Faragó, Dr. Péter Pongrácz, Dr. Friederike Range, and Dr. Zsóﬁa Virányi for the
opportunity to use the same growl sounds used in their studies.
Sincere thanks are extended to all the owners that ﬁlled the questionnaires and all
owners and dogs that participated in our behavioural tests.
A very special thanks to Doctor Alessia Colombo for her help in statistical analysis.
Thanks to Catalina Ramos, who drew the cartoons illustrating the test.
Thanks to the colleagues who have contributed to the spread of questionnaires and
to ﬁnd patients for behavioural tests: Barbara Gallicchio, Elena Severi, Monica Ant-
oni, Annalisa Riceputi, Gianbattista Galli, Gianluca Zanaboni, Cristina Dedè, Petra
Hofmann, Clara Palestrini.
Sincere thanks to the Order of Veterinary Surgeons of Varese for their help with the
spread of questionnaires.
And ﬁnally, thanks to my family who has endured my commitment that was added
to all the other professional commitments and helped me to ﬁnd the time to be part
of the family in spite of my very busy professional life throughout these years.
II

To my family, Giuseppe, Francesco and Margherita
Preface
Some of the work contained in this thesis has been published in two peer-reviewed
journals (Appendix H), presented in two peer-reviewed International and European
conferences as well as in one invited talk in UK and in two invited talks in Italy.
Journals
Notari L., Mills D. (2011). Possible behavioural eﬀects of exogenous corticoster-
oids on dog behaviour: a preliminary investigation. Journal of Veterinary Behaviour:
Clinical Applications and Research. Vol 6, Issue 6, Pages 321-327.
Notari L., Burman O., and Mills D. (2015) Behavioural changes in dogs treated with
corticosteroids, Physiology & Behaviour.
Conferences
Notari L., Mills D. The eﬀects of exogenous corticosteroids on dog behaviour: a pre-
liminary study. 7th International Veterinary Behaviour Meeting-IVBM-Edinburgh,
28-31 October 2009.
Notari L, Burman O., and Mills D. Behavioural Changes in Dogs Treated with
Corticosteroids. International Veterinary Behaviour Meeting-Avignone, 27 Novem-
ber 2011.
V
Invited talks
Notari L. Corticosteroidi e alterazioni comportamentali (Corticosteroids and beha-
vioural changes). AIVPA National Veterinary Meeting - Lo stress causa e eﬀetto dei
disturbi comportamentali. Pisa 6 Novembre 2010.
Notari L. Glucocorticoidi esogeni e alterazioni comportamentali nel cane (Exogen-
ous corticosteroids and behavioural changes in dogs). AIVPA National Veterinary
Meeting - Problema dermatologico o comportamentale? - Varese 17 November 2012.
Notari L., Burman O., and Mills. D. Behavioural changes in dogs treated with cor-
ticosteroids. University of Lincoln - Clinical Animal Behaviour Research Seminar, 8th
November 2014.
VI
Abstract
Arousal and distress are considered important factors when dogs show problematic
behaviours and the crucial role of hormones and neurotransmitters involved in stress
responses is widely recognized.
Corticosteroids are important players in stress responses and, along with other hor-
mones and neurotransmitters, contribute to the onset of both physiological and beha-
vioural changes that can be either normal and adaptive or excessive and maladaptive
depending on several factors. A literature review revealed that exogenous corticoster-
oids have been reported to change behaviour in human beings and laboratory animals
but no data were available as far as similar eﬀects in dogs.
The aim of this research was to identify possible behavioural changes in dogs treated
with corticosteroids. In the ﬁrst study, the perception of behavioural changes in dogs
during corticosteroid therapy was investigated through semi-structured open inter-
views of the owners of 31 dogs of diﬀerent breeds, genders, and ages. All dogs had
received corticosteroid therapies in the past six months. Owners were asked to de-
scribe their dog's behaviours both on and oﬀ corticosteroid therapy.
Eleven owners reported behavioural changes in their dogs; nine dogs were reported
to show more than one behavioural change. Six dogs reportedly showed nervousness
and/or restlessness, three showed an increase in startle responses, three showed food
guarding, two showed a decrease in their activity level, three showed an increase in
avoidance responses, four showed irritable aggression, and two dogs increased bark-
ing. Semi-structured interviews can be useful preliminary tools for the identiﬁcation
of areas of future investigation, and the outcomes of the interviews were then used
to investigate more rigorously the possible relationship between these signs and cor-
ticosteroid use in dogs.
In the second study 99 dog owners were asked to complete a 12 item questionnaire,
developed following the results of the previous survey. Owners were asked to eval-
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uate their dogs' behaviour on and oﬀ therapy, using a seven point scale. A sample
of owners whose dogs were receiving treatment for dermatological, orthopaedic or
other conditions completed the survey. The survey was completed by 44 dog owners
with animals receiving treatment with a range of corticosteroid preparations (mainly
prednisolone and methylprednisolone) and 54 dog owners with dogs receiving treat-
ment with other drugs, mainly antibiotics and non-steroidal anti-inﬂammatory drugs.
Dogs under corticosteroid treatment were reported to be signiﬁcantly less playful,
more nervous/restless, more fearful/less conﬁdent, more aggressive in the presence of
food, more prone to barking, more prone to startle, more prone to reacting aggress-
ively when disturbed, and more prone to avoiding people or unusual situations. The
last part of this study involved behavioural tests of dogs.
Eleven treatment dogs were then tested twice: before and during corticosteroid
treatment with either methyl-prednisolone or prednisolone to assess their sensitivity
to a potentially aversive stimulus. Eleven control dogs, not receiving corticosteroid
therapy, were also tested at the same time intervals in the same environment. Dogs
were exposed to a brief dog growl while they explored some bowls containing food
and their behaviour was video recorded. Treatment dogs investigated the area for
signiﬁcantly less time and ate signiﬁcantly less food in the second test trial when on
corticosteroid compared to control dogs.
In ﬁnal study, exploring relationships between corticosteroid therapy and dogs with
behaviour problems, a review of the caseload of the author of 345 dogs reported for
behaviour and management problems was analyzed. It was found that 16 % of them
had a history of previous treatments with corticosteroids.
Previous treatment with corticosteroid was found to be signiﬁcantly associated with
negative aﬀective states.
These results support earlier preliminary ﬁndings concerning possible adverse beha-
vioural side eﬀects following the use of corticosteroids in dogs, and the possible need
for concomitant behavioural advice when these drugs are used in general veterinary
practice.
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Sommario
I livelli di eccitazione e stress sono considerati importanti fattori quando i cani mo-
strano comportamenti problematici e il ruolo cruciale di ormoni e neurotrasmettitori
coinvolti nelle risposte allo stress è stato ampiamente riconosciuto. I corticosteroidi
sono protagonisti importanti nelle risposte da stress e, insieme ad altri ormoni e neu-
rotrasmettitori, contribuiscono all'instaurarsi di cambiamenti sia ﬁsiologici sia com-
portamentali che possono essere normali e adattativi oppure eccessivi e non adattativi
a seconda di diversi fattori. Una approfondita rassegna della letteratura scientiﬁca ha
mostrato che i corticosteroidi esogeni sono stati segnalati come possibili fattori che
cambiano il comportamento negli esseri umani e negli animali da laboratorio ma non
sono stati trovati dati disponibili per quanto riguarda simili eﬀetti nei cani.
Lo scopo di questa ricerca era di identiﬁcare possibili cambiamenti comportamentali
nei cani trattati con corticosteroidi usando diverse metodologie .
Nella prima fase di questa ricerca, le percezioni di cambiamenti comportamentali nei
cani in corso di terapia con corticosteroidi è stata investigata attraverso interviste
aperte semi-strutturate ai proprietari di 31 cani di diverse razze, sesso e età. Tutti i
cani avevano assunto terapie corticosteroidee negli ultimi sei mesi.
Ai proprietari era stato chiesto di descrivere il comportamento dei loro cani sia du-
rante la terapia che senza terapia.
Nel complesso, 11 proprietari riferirono cambiamenti nel comportamento dei loro cani:
nove proprietari riferirono che i loro cani avevano mostrato più di un cambiamento
comportamentale. Sei cani avevano mostrato nervosismo o agitazione, 3 avevano mo-
strato un aumento nelle risposte di soprassalto, tre avevano mostrato la tendenza a
difendere il cibo aggressivamente, due avevano mostrato una diminuzione nel livello
di attività, tre avevano mostrato un aumento delle risposte di evitamento, quattro
avevano mostrato aggressività per irritazione e due un aumento dell'abbaio.
Le interviste semi-strutturate possono essere utili come strumenti per identiﬁcare le
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aree da investigare nel futuro e i risultati delle interviste riportati in questa prima fase
della ricerca sono stati poi usati per investigare in maniera più rigorosa le possibili
relazioni tra questi segni e l'uso di corticosteroidi nei cani.
Nel secondo stadio della ricerca 99 proprietari di cani hanno compilato un questionario
con 12 domande che etè stato sviluppato a partire dei risultati dello studio precedente.
Ai proprietari è stato chiesto di valutare il comportamento dei loro cani in terapia e
senza terapia usando una scala di sette punti. Un campione di proprietari di cani che
avevano ricevuto una terapia per problemi dermatologici, ortopedici e altri problemi
hanno completato lo studio. Lo studio è stato completato da 44 proprietari di cani
che avevano ricevuto terapie costituite da diversi tipi di corticosteroidi (soprattutto
prednisolone e metilprednisolone) e 54 proprietari di cani che avevano ricevuto tera-
pie costituite da altri farmaci, soprattutto antibiotici e antiinﬁammatori non steroidei.
Una analisi multivariata General Linear Model (GLM) e GLM con correzione post
hoc per test multipli ha rivelato che i cani in terapia con corticosteroidi sono stati
descritti dai proprietari come signiﬁcativamente meno giocosi, più nervosi/agitati, più
paurosi/meno sicuri di sé, più aggressive in presenza di cibo, più portati ad abbaiare,
più portati a mostrare reazioni di soprassalto, più portati a reagire aggressivamente
quando disturbati e più portati a evitare persone o situazioni inusuali.
Nell'ultima parte di questa ricerca sono stati svolti test comportamentali su alcuni
cani.
Undici cani in trattamento sono stati testati due volte: prima e durante la tera-
pia con corticosteroidi attuata con metilprednisolone o prednisolone per valutarne la
sensibilità a uno stimolo potenzialmente avversativo. Undici cani di controllo sono
stati testati allo stesso intervallo di tempo e nello stesso contesto . I cani sono stati
esposti a un breve ringhio mentre esploravano alcune ciotole contenti cibo e il loro
comportamento è stato videoregistrato. I cani del gruppo trattamento hanno inve-
stigato l'area del test per un tempo signiﬁcativamente minore e hanno mangiato un
numero signiﬁcativamente minore di bocconi di cibo nel secondo test, quando erano
in terapia, diversamente dai cani di controllo.
Per dare una dimensione dell'importanza di questi risultati, una casistica di 345 cani
portati alla visita per problemi di comportamento e di gestione è stata analizzata ed è
stato trovato che il 16% di questi cani aveva avuto una storia di precedenti terapie con
corticosteroidi. Una signiﬁcativa correlazione è stata trovata tra precedenti terapie
con corticosteroidi e stati aﬀettivi negativi.
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Questi dati supportano i dati preliminari riguardo a possibili eﬀetti collaterali com-
portamentali a seguito di impiego di corticosteroidi nei cani e la necessità di fornire
indicazione comportamentali quando questi farmaci vengono impiegati nella pratica
clinica veterinaria.
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Chapter 1. General Introduction
1.1 Introduction
Increasing attention is being given to the prevention and treatment of dog be-
haviour problems (Adams and Clark, 1989; Herron et al., 2008; Ibáñez and Anzola,
2009; Seksel and Lindeman, 2001; Sherman and Mills, 2008; Takeuchi et al., 2001;
Wright and Nesselrote, 1987).
The inﬂuence of environmental factors and health problems on the onset of dog be-
haviour problems has been dealt with by many authors and the roles of stress and
anxiety, concepts that are often used as if they are interchangeable (although anxiety
is only a form of stressor that a dog may be subjected to), have been recognized
in both the onset and continuation of problematic behaviours in companion animals
(Aronson and Dodds, 2005; Casey et al., 2013; Fatjó et al., 2002; Galac and Knol,
1997; Kobelt et al., 2007; O'Farrell, 1997; Westgarth et al., 2010). It has been stated
that most dog behaviour problems are stress related and cortisol level is often used as
a behavioural indicator of stress conditions in dogs (Beerda et al., 2000; Ottenheimer
Carrier et al., 2013). The term stress is certainly overused and often poorly deﬁned
or oversimpliﬁed. Therefore the main aim of the following introductory part of this
chapter is to show how such a common word might refer to very complex mechanisms
in the brain, often mediated through a cortisol response. The experimental research
concerns the eﬀects of corticosteroid drugs on dog behaviour and so it is important to
put the function of this chemical in both a biological and historical context, as ideas
have changed since its discovery in the last century.
1.2 Stress And The Hypothalamic-Pituitary-Adrenal
Axis (HPA)
The words stress and distress are used to describe emotionally and physiolo-
gically challenging experiences that result in change in both behavioural and physical
signs with the brain being the target and the master of stress responses. Positive
adaptation to challenges was called eustress and the negative adaptation to chal-
lenges was called distress. Positive stress (eustress) is generally short term, perceived
as whithin the coping ability of an individual and it improves adaptation (Lazarus,
1993). Distress can be a short or long term challenging experience that has negat-
ive implications for the individual's adaptation and welfare (Selye, 1974). Diﬀerent
9
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stress responses are also performed as a consequence of challenges of diﬀerent in-
tensity, duration and frequency of exposure. A single exposure of a single intense
challenge elicits what is called an acute stress response. The exposure to challenges
repeated over time or long term exposure to stressful events can lead to chronic stress
(McEwen, 2004). Hans Seyle is widely recognized as the pioneer investigator into the
non-speciﬁc physiological response of the body to any demand for change. In 1936
he wrote the seminal article A syndrome produced by diverse nocuous agents, as a
brief letter published in Nature in which he described signs that he called general
alarm reactions of the organism such as gastric ulcers, thymicolymphatic involutions
and morphological changes in the adrenal glands. He interpreted these changes as a
non-speciﬁc adaptive response to various kinds of agents. Notably, he did not use the
word stress in this ﬁrst article, but his ﬁrst comprehensive monography published
in 1950, was simply titled Stress (Figure 1.1), and has caused debate ever since.
Figure 1.1: The ﬁrst monograph published by Hans Seyle in 1950 (Selye, 1950).
In 1950, his article in the British Medical Journal entitled Stress and the gen-
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eral adaptation syndrome, described initial observations about his hypothesis that
stimuli that challenge an organism, either physically (e.g. infectious agents) and psy-
chologically (e.g. exposure to fearful stimuli), can increase the risk of illness and even
death.
Figure 1.2: The story of the Adaptation Syndrome, by Hans Selye 1952.
Left panel: pictures from the publication. From top to bottom: adrenals,
thymus, iliac lymph nodes, and gastric mucosa of a normal rat (left) and
the same organs of a rat immobilized on a metal board for 24h (right). In
the distressed rat there is evident enlargement of the adrenals, atrophy of
the thymus and lymph nodes and gastric erosions. Right panel: Cover to
the text (Selye, 1952).
He hypothesized that stress acted through a mechanism that he called the general
adaptation system, which caused both defense and damage. The defense modulated
the responses to injuries, but stress also caused some degree of damage. He concluded
that the diﬀerent stressors can provoke similar consequences in diﬀerent individuals
and one of the main eﬀects was the enlargement of the adrenal glands (see Figure
1.2).
Before Hans Selye another scientist, Walter B. Cannon, investigated the neurochem-
ical and neuroanatomical implications of stress responses and investigated the role of
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catecholamines in the ﬁght and ﬂight reactions as an emergency response to threat
in laboratory animals (Brown and Fee, 2002; Cannon, 1936). Selye was therefore not
the only early researcher to investigate stress responses and the adrenal glands, but he
was the ﬁrst to suggest that not only catecholamines produced by the adrenal medulla
but also steroids produced by the adrenal cortex, under the inﬂuence of adrenocorti-
cotrophic hormone (ACTH) and hypothalamic releasing factors/hormones play a role
in the stress reaction.
Figure 1.3: Hans Selye (Szabo et al., 2012).
From then on, the role of the Hypothalamic-Pituitary-Adrenal (HPA) axis system,
also called the endocrine stress system, was considered of paramount importance in
the regulation of mammal behaviour, and the role of adrenocortical hormones, along
with the other components of the stress system, has been recognized as crucial to the
organism's ability to cope with threats and successfully adapt during its life.
Selye's papers now have more historical than scientiﬁc value but remain highly inﬂu-
ential, especially in the popular understanding of stress. A large volume of research
12
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in the last 75+ years has shown that neurological, cardiovascular and endocrine mech-
anisms are involved in complex and integrated stress mechanisms and responses; with
stress hormone receptors found in areas of the brain that are crucial for both emotional
and cognitive activities.
1.3 HPA, Stress, Corticosteroids And Behaviour
The principal components of the stress response consist of the hypothalamic-
pituitary-adrenal (HPA) system (most commonly known as the HPA axis), the locus
coeruleus-norepinephrine (LC-NE) system, and the extrahypothalamic corticotropin
releasing hormone (CRH) system.
The locus coeruleus (LC) is a small, compact group of norepinephrine (NE) concen-
trating cells located in the pons, which send projections to every distinct functional
region of the neocortex, thalamus, limbic system and hypothalamus, as well as the
brainstem nuclei and the spinal cord. Stressful events stimulate the HPA axis and the
LC-NE system, which results in a wide range of physiological, endocrine and behavi-
oural eﬀects.
The HPA axis is essential for the control of neural, endocrine and immune responses
to challenges. Hypothalamic secretions constantly control the pituitary gland via
biochemical feedback messages from the periphery. Corticotrophin releasing hor-
mone/factor (CRH/CRF) and another important hormone, arginine vasopressin (AVP)
are secreted by neurons in the hypothalamus.
These hypothalamic factors modulate corticotroph cells in the pituitary gland and
increase the synthesis and secretion of adrenocorticotrophic hormone (ACTH).
Both CRH and CRH receptors are important for the secretion of ACTH under stress-
ful conditions whose basal level regulation depends on AVP and its receptors (Gibbs,
1986; Zimmermann et al., 2004). When an animal is stimulated by a stressor, CRH
stimulates the production of ACTH in the pituitary: this hormone induces the re-
lease of corticosteroids from the adrenal glands. Corticosteroids are a class of steroid
hormones secreted from adrenal cortex that are deeply involved in the regulation of
energy, immune responses and stress responses. The main corticosteroid in humans is
cortisol, while in other species as rats and birds, the main corticosteroid is corticoster-
one (Carlson, 2010). As mentioned above, stress response can be elicited by a negative
threat or a positive challenge. Prolactin and growth hormone are also secreted in the
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pituitary in response to stress. Cortisol, prolactin and growth hormone inﬂuence the
immune system, and have been used to assess the level of stress in animals in experi-
mental situations (Cuatrecasas Cambra, 2009).
Corticosteroids and cathecolamines inhibit the production of proinﬂammatory cy-
tokines and stimulate the production of antinﬂammatory cytokines and stress condi-
tions may supress or potentiate cytokine actions by potentially disrupting the balance
between pro and anti-inﬂammatory action of these substances (Elenkov and Chrousos,
2002). In turn, cytokines act directly on pituitary cells as well as indirectly by con-
trolling the release of hypothalamic factors (Miller et al., 2002; Murali et al., 2006;
Zunszain et al., 2011).
The HPA axis and the locus coeruleus-CNS network are not independent of one an-
other because activation of one system tends to activate the other. For example,
CRH activates the Locus Coeruleus in addition to its primary function of stimulating
ACTH release (Curtis et al., 1999; Jedema and Grace, 2004; Valentino et al., 1983).
HPA and the sympathetic nervous system are stimulated in stress conditions and
a population of CRH parvocellular neurons project to extra-hypothalamic sites, in-
cluding limbic nuclei, which are important for emotional responses, as well as the
brainstem.
Corticosteroid hormones secreted as a consequence of stress also regulate the expres-
sion of an important inhibitory neurotransmitter, the gamma-amino-butyrric acid
(GABA) (Orchinik et al., 2001). Changes in GABA receptors have also been demon-
strated following administration of exogenous corticosteroids.
Acute and chronic stress have been shown to alter the expression of GABA and a
reciprocal regulation of stress hormones and GABA receptors has been postulated
(Mody and Maguire, 2011).
An increasing amount of evidence show that the stress-induced release of corticoster-
oids, induces changes in glutamate neurotransmission in the hippocampus, prefrontal
cortex and amygdala. Glutamate is a major excitatory neurotransmitter in the cent-
ral nervous system and changes in glutamate transmission can have an important
inﬂuence on cognitive processes and emotions (Graybeal et al., 2012; Popoli et al.,
2011).
Corticosteroid hormones produced by adrenal glands and also exogenous corticoster-
oids might therefore have an impact on animal brains through very complex inter-
connections consisting of both direct actions on receptors and neurotransmitters and
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feedback systems.
Because the production of corticosteroids, stimulated by ACTH, are secreted in a
pulsatile fashion with peaks that occur after 15-30 minutes of an ACTH pulse with
variations during the day that follow a circadian rhythm, assessment of corticosteroid
levels and interpretation of their action is complex (Kolezvská et al., 2003; Leal and
Moreira, 1997; Miller and Gronﬁer, 2006). This is complicated further by the ﬁnding
that there are refractory periods when the HPA is not sensitive to activation by mild
stressors(Young et al., 2004).
For example, Windle et al. showed that exposure to noise stress in female rats evoked
a signiﬁcantly smaller response when stress exposure coincided with a non secretory
phase of pulse (Windle et al., 1998).
Corticosteroids exert negative feedback control over ACTH secretion with both a rapid
and a delayed feedback action. The rapid feedback inhibits the release and synthesis
of ACTH in the hypothalamus immediately after a rise in circulating corticosteroids,
while the delayed feedback acts via epigenomic action on glucocorticoid receptors in
the brain. The epigenomic action of corticosteroids alters transcription of target genes
and leads to a change in protein synthesis. Corticosteroids act on the hypothalamus
in particular, with a negative feedback action that prevents a continued activation of
the HPA axis (Gómez et al., 1998; Herman et al., 2012), but also the hippocampus.
CRH is activated after exposure to stress, but it also acts as a neurotransmitter in
numerous brain regions.
Several studies have demonstrated that peptide hormones like CRH have functional
targets in the brain that are unrelated to the neuroendocrine HPA circuit. How-
ever, both classes of function of CRH are activated by factors that disturb organism
homeostasis (Amodio and Harmon-Jones, 2011; Claes, 2004; Kovács, 2013; Majzoub,
2006).
1.3.1 Stress does not have the same consequences in all indi-
viduals
Despite the description of a general adaptation syndrome, it is important to recog-
nise that stressful events and, as a consequence, the action of stress hormones exert
their eﬀect on individuals who are diﬀerent from each other. Every individual can
encounter stressful experiences but not every individual experiences the same con-
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sequences. There are individuals that are more resilient to stress and environmental,
genetic, epigenetic and neural mechanisms that underlie resilience are involved in
the individual diﬀerences in stress responses (Hughes, 2012). Resilience seems to
be mediated by adaptive changes in several neural circuits involving numerous neur-
otransmitter and molecular pathways (Degnan and Fox, 2007; Feder et al., 2009).
Environmental inﬂuences during the developmental period aﬀect the neural and hor-
monal pathways controlling emotional responses and behaviour. The developmental
period is therefore crucial because, as a consequence of external stimulation, the neur-
oendocrine system and the cascade of hormonal and neurotransmitter responses are
shaped and the tone of the stress processing system is adjusted. In primate and
rodent models it has been shown that early life stress provoked by deprivation of ma-
ternal care and early physical interactions with peers are important risk factors for
aggressive behaviour in adulthood (Veenema, 2009). Genes and environment control
of neuroendocrine mechanisms are therefore part of the basis of individual vulnerab-
ility to stress.
1.3.2 Stressors: what are they?
Stress stimuli, also called stressors, can be physiological or psychological, the
former involving physical challenges, the latter a reaction to an aversive stimulus
without direct physical modiﬁcation of the animal's body.
Physiological stressors challenge body integrity and physiological balance, a balance
that has to be maintained around a relatively narrow range of parameters such as, for
example, a range of temperatures, a range of extracellular sodium concentrations or a
range of blood glucose levels. Any challenge to these balances is taken under homeo-
static control. Homeostasis is a condition of stability of an organism that should
be reached through the responses of the stress system to challenges (Cannon, 1929;
Chrousos and Gold, 1992).
Psychological stressors, are processed through higher order brain circuits and involve
learned, emotional and cognitive processes. Like physiological stressors, psychological
stimuli such as, for example, social conﬂicts, inappropriate handling, fearful stimuli,
perception of an inability to cope and many others also activate parvocellular neur-
osecretory motor neurons in PVN. Visceral responses to psychological stressors also
include cardiovascular, respiratory, gastrointestinal and thermoregulatory changes and
are stressor speciﬁc. Although it may seem that psychological and physical stressors
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activate diﬀerent pathways at a functional neuroanatomical level, stressors are often
compound-both psychological and physical (Kovács, 2013). For example, an analysis
of medical records of USA veterans returned from Iraq showed a signiﬁcantly higher
frequency of combination of physical problems and post traumatic stress disorders
compared with the frequency in which physical and psychological conditions were
present in isolation (Lew et al., 2009), while eustress seemed to be associated with
improvement of physical health (Edwards and Cooper, 1988).
1.3.3 Corticosteroids
Corticosteroids and cathecolamines are still recognised as the main players in stress
responses. Cathecolamines play important roles in modulating impulsivity, arousal
and attention; while corticosteroid eﬀects are more indirect. Corticosteroids eﬀects are
mediated by mineralcorticoid receptors (MRs) and glucocorticoid receptors (GRs) in
brain areas that are crucial for memory, learning and emotions. MRs have an aﬃnity
for corticosteroids that is 10-fold higher than GRs (De Kloet et al., 1998; Zimmer and
Spencer, 2014), which means corticosteroids preferentially bind to them ahead of the
GRs in the body. MRs are mainly expressed in the hippocampus, a brain region that
is crucial for memory processes. Under baseline conditions they are largely occupied,
but during stressful times they become saturated, so the occupation of GRs increases.
GRs are distributed in diﬀerent areas in the brain but are more abundant in hypo-
thalamic CRH neurons and the pituitary. When MRs are predominantly activated
hippocampal neurons receive excitatory activation, while additional activation of GRs
induces an impairment in hippocampal transmission. In summary, MRs are largely
saturated by basal level of hormones, but GRs are activated by high corticosteroid
levels such as in stressful conditions. This means that when corticosteroid levels are
low (and MRs are not suﬃciently activated) or too high (GRs become predominantly
activated), memory and learning may be impaired (Gómez et al., 1998; Prickaerts
and Steckler, 2005). When, for example, environmental stimuli induce fearful arousal,
high levels of circulating corticosteroids saturate GRs and cause related behavioural
responses. Such responses increase survival in the natural environment but chronic
activation of stress responses might lead to more problematic states in the short-term
such as anxiety, phobias and depression. Like endogenous corticosteroids, exogenous
corticosteroids bind to GRs and MRs although with diﬀerent potencies. Corticost-
eroid drugs are used for their glucocorticoid action and their mineralcoticoid action
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varies depending on the type of drug. Cortisol is the standard comparison for the
glucocorticoid and mineralcorticoid potencies and, for example, dexamethasone has
a glucocorticoid potency that is 25-80 times compared with cortisol but has no min-
eralcorticoid potency, while prednisolone has 4 times glucocorticoid potency and 0.8
times mineralcorticoid potency compared with cortisol (Rhen and Cidlowski, 2005).
The amygdala is a key structure in the fear system and corticosteroid levels aﬀect
the amygdala and a variety of other structures, inﬂuencing emotional processes. The
hippocampus, amygdala and prefrontal cortex are modiﬁed by stress and, as a con-
sequence, aﬀective states and behavioural responses can change (Pêgo et al., 2008).
The mediator of stress responses can have potentially protecting or damaging ef-
fects. Physiological stress responses are indispensable for dealing with life challenges
and should be followed by the organism returning to a state of stability, of homeo-
stasis. The involvement of the hippocampus can potentially be detrimental in many
ways. For example memory function can be impaired by high levels of cortisol in
aged human patients (Lupien et al., 2009) and both chronic stress and corticosterone
treatment have been shown to cause impairment of hippocampal-dependent memory
tasks in laboratory rats (Clark et al., 2000; Diamond and Rose, 1994; Endo et al.,
1996; McLay et al., 1998; Park et al., 2008). The onset of structural changes in the
hippocampus as a consequence of the action of stress hormones has been investig-
ated in many studies, with CA3 pyramidal cells in the dentate gyrus being shown
to be particularly vulnerable to stress. Neurogenesis and cell survival in the dentate
gyrus can be suppressed in stressful conditions (Gould and Tanapat, 1999) and the
dendrites of CA3 cells can show stress-induced modiﬁcations (Joëls, 2007; Stewart
et al., 2005). In summary, adrenal steroids seem to be important mediators of the
changes in hippocampal neurons during stress. There are also multiple interactions
with other neurochemical systems include serotonin, endogenous opioids, GABA re-
ceptors, the calcium channel currents and glutamate (McEwen and Magariños, 2001).
For example, it has been suggested that chronic restraint stress increases the release of
glutamate in rats (Magariños et al., 1997). Glutamate has a critical role in controlling
synaptic excitability and its dysfunction can cause behaviours of concern (Aida et al.,
2015).
Furthermore, chronic restraint stress can cause alterations in prefrontal cortical dend-
ritic morphology and these changes have been related to attention impairments. The
prefrontal cortex (PFC) is involved in extinction, a learning process that is very im-
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portant for adaptation, and chronic stress has been related to impairment of extinction
of a fear conditioned task in rats. The medial PFC is a target for corticosteroids in-
volved in stress response and stress can cause, as mentioned above, an increase in
glutamate, along with acethylcholine release. These neurochemical changes due to
chronic stress cause atypical changes in the dendrites of pyramidal neurons of PFC
and the consequences are functional changes and, eventually, behavioural changes.
For example, the retrieval of the memory of fear extinction was impaired in distressed
rats: i.e. the animals did not recall the extinction previously learned (Miracle et al.
2006). Chronic restraint stress was also reported to enhance amygdala-dependent
fear conditioning and unlearned fear (Conrad et al., 1999). The observed increase
in aggression between rats in the same cage as a consequence of chronic stress has
also been considered to be a sign of amygdala hyperactivity (Wood et al., 2003), and
chronic corticosterone treatment in mice produced anxiogenic eﬀects that could be
related to amygdala activity (Ardayﬁo and Kim, 2006; Makino et al., 1994).
It therefore appears that whilst corticosteroids are essential for protecting against ad-
verse events, their eﬀects can turn from adaptive to maladaptive in cases of imbalanced
actions that last for prolonged periods of time (De Kloet et al., 1999). Intensive, pro-
longed and repeated stimulation of the stress system can lead to the onset of anxiety,
with a range of maladaptive behaviours such as an increase in avoidance strategies,
aggression, displacement activities and stereotypies. The boundary between an ad-
aptive stress response and a maladaptive one is not easy to deﬁne when considering
dog behaviour, and some behaviours that owners perceive as problems might be just
normal coping strategies, part of the normal range of an animal's behaviour. The
attempt of an animal to perform adaptive behaviours in contexts where adaptation
is diﬃcult or impossible might lead to maladaptive, non functional behaviours (Mills,
2003). What often makes the diﬀerence between normal and problematic behaviours
is the intensity and duration of behaviours, often with the inclusion of signs of anxiety.
These signs overlap with more general signs of acute and chronic distress, with stress
and the stress response often at the heart of the issues. A qualitative, holistic eval-
uation of dog behaviour is probably more applicable and suﬃciently reliable, being
the evaluation of the whole animal a useful approach to detect signs of stress and
anxiety and infer emotional states (Mills et al., 2006; Wemelsfelder, 1997). Because
stress hormones aﬀect the animals' brain, emotion and cognition, being able to dis-
tinguish between normal and problematic behaviours is important in order to be able
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to recognize their eﬀects.
1.4 Behavioural And Psychological Side Eﬀects Of
Corticosteroids
Many studies have shown how endogenous and exogenous corticosteroids might af-
fect mammal brains in diﬀerent ways. They can modulate neuron excitability through
diﬀerent mechanisms and neurotransmitters, and can cause changes in the prefrontal
cortex and limbic system, structures that are profoundly interconnected. The pre-
frontal cortex has been described as an important area for cognition, while the limbic
system is deeply involved in emotions. The prefrontal cortex mediates the cognitive
regulation of emotion, the amygdala exerts emotional inﬂuences on cognitive pro-
cesses and the hippocampus is greatly involved in memory formation. It has been
shown that both acute stress and exogenous corticosteroid exposure might enhance
the memory of emotional experiences and impair memory abilities (Barsegyan et al.,
2010; Salzman and Fusi, 2010).
Explicit short term memory also called working memory, which is the ability to retain
information and then use it to guide future behaviours, is an important function of
the prefrontal cortex and in experimental treatment with the exogenous corticoster-
oid dexamethasone spatial working memory and cognitive ﬂexibility were impaired
in rats. Furthermore, memory retrieval was shown to be impaired by both stressful
events and administration of the endogenous corticosteroid corticosterone (Cerqueira
et al., 2005; Schutsky et al., 2011).
An increase in anxiogenic-like behaviour has also been observed in mice after chronic
administration of corticosterone (Ardayﬁo and Kim, 2006). Glucocorticoid adminis-
tration before an experiment involving fear conditioning in rats increased the acquis-
ition of the memory of the fearful event (Thompson et al., 2004), but rats chronically
treated with corticosteroids needed more time and trials to accomplish a maze learn-
ing task compared with controls. The authors concluded that chronic administration
of corticosteroids impairs learning and memory (Endo et al., 1996).
Ramos-Remus et al. investigated the eﬀects of prednisolone (a drug commonly used
for long term management of inﬂammatory conditions in veterinary practice) admin-
istration in rats using a water maze to assess disturbance in learning and memory,
and also investigated neural and glia cell changes. Rats treated with prednisolone
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showed a signiﬁcant delay in learning and memory retention of the maze task com-
pared with controls and the degeneration index of neural cells was signiﬁcantly higher
compared with control animals. They concluded that prednisolone produces learning
and memory impairment and changes in neurons and glia cells in cerebral regions
involved in learning and memory (Ramos-Remus et al., 2002). These results and the
use of exogenous corticosteroids for treating neural disorders seem to be in contrast
because corticosteroids are also used for their neuro-gliomodulation eﬀects (Gonzalez-
perez et al., 2010). Corticosteroids exert several important eﬀects by targeting glia
cells and the most abundant glia cells in the brain, astrocytes, play important roles in
neurotransmitter reuptake and release, modulation of synaptic transmission and hor-
monal signaling. Synthetic corticosteroids modulate neural cells and their actions on
glia and neurons have been shown to produce detrimental or positive eﬀects, so while
in rats in the study of Ramos-Remus et al. (Ramos-Remus et al., 2002), predniso-
lone appeared to induce degeneration of neural cells, the same corticosteroid drug did
prevent the reduction of brain-derived neurotropic factor (BDNF) and neural grown
factor (NGF) mRNA expression in the brain in experimental autoimmune encepha-
lomyelitis in mice, although in combination with another drug (Chen et al., 2009).
The diﬀerent eﬀects of exogenous corticosteroids on neural cells have not been com-
pletely clariﬁed, and appear to be mediated by dose, individual features , and brain
region phenomena (Numakawa et al., 2012). A reliable picture of possible behavioural
eﬀects of corticosteroids might be reached by merging the evidence of the available
and future studies that investigate corticosteroid eﬀects at diﬀerent levels, from cell
responses to the whole animal behaviour in diﬀerent contexts. Rats that received
corticosterone before social encounters were found to be more aggressive compared
with non-treated controls, with corticosteroids increasing aggression in social chal-
lenging situations, but not in normal conditions (Mikics et al., 2007, 2004). Such
experiments in laboratory animals provide evidence that not only stressful events but
also the administration of exogenous corticosteroids can inﬂuence emotion, cognition
and behaviour.
Corticosteroid drugs are widely used in veterinary medicine as in modern human
medicine. Although in human medicine the behavioural and psychological side eﬀects
of these drugs have been reported since they started being used, and these drugs have
been shown to induce clinically signiﬁcant and sometimes severe psychological, cog-
nitive, and behavioural disturbances (Brown et al., 1999; Kenna et al., 2011; Patten
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and Neutel, 2000), virtually no literature was available on these kinds of side eﬀects
in dogs before the publication of our studies from this thesis (Notari and Mills, 2011;
Notari et al., 2015). It is therefore important to appreciate what these eﬀects in hu-
mans might be and how the equivalent problem might manifest in companion dogs.
Descriptions of the psychiatric side eﬀects of corticosteroids in humans date back to
the 1950's, when these drugs started being prescribed on a regular basis. For example,
in 1951 Borman and Shmallenberg, in the Journal of American Medical Association,
reported a case of the suicide of a patient in treatment with corticosteroids (Borman
and Schmallenberg, 1951). From then on, several case reports concerning psychiatric
side eﬀects of corticosteroids have been published. Selwin Brody in 1952 described
several clinical cases, reporting psychiatric observations in patients that had received
treatment with corticosteroids. He described some emotional reactions to cortisone
and ACTH as euphoria, psychosis, ambivalent behaviours and depression (Brody,
1952).
Many other cases have been reported in the following decades and, because of the wide
scale use of this medication in human medicine, with its frequent prescription for long
term treatment, investigation of this topic has received a lot of attention (Kenna et
al., 2011; Judd, 2014). Individual cases or case-series reports have illustrated im-
pressive severe neuropsychiatric outcomes in adults, adolescents and children (Brown
and Chandler, 2001; Brown et al., 1999; Drozdowicz and Bostwick, 2015; Mian et
al., 2007; Warrington and Bostwick, 2006). It was reported that 6% of patients who
received corticosteroids had severe psychiatric side eﬀects and that corticosteroid dose
was a risk factor for these kinds of side eﬀects, with a reduction of the dose result-
ing in recovery from psychiatric symptoms (Dubovsky et al., 2012). The case-report
literature concerning psychiatric side eﬀects of corticosteroid drugs often lacks sci-
entiﬁc validation. In addition the implication of other inﬂuencing factors such as the
decrease in the quality of life due to pain and disease, the onset of other physical
side eﬀects of these drugs as increased appetite and change in body shape that might
have inﬂuenced both the individual and social life of patients (Bolton et al., 2010),
along with the bias inherent in patient or care-giver reports suggest caution when
considering this evidence (Stella et al., 2015). Nevertheless, as far as the development
of psychiatric symptoms is concerned, the extensive reports of these side eﬀects along
with a few controlled studies in human patients suggest that the issue is an important
one.
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An example of a more structured, cross sectional and longitudinal study concerning
psychological side eﬀects of corticosteroids in humans is the study of Keenan et al.
(Keenan et al., 1996). One of the investigated eﬀect of corticosteroid drugs in human
beings is their eﬀects on memory and it was shown that treated patients performed
worse in explicit memory tasks but not in implicit memory tasks, compared with con-
trols. Explicit memory is the conscious recall of information while implicit memory
is remembering without recall, a sort of unconscious memory like being able to per-
form previously learned task without the need to think about how to perform it, for
example riding a bike or dancing. The longitudinal part of this study was conducted
following the patients across 3 months of therapy and it was shown that both acute
and chronic administration of corticosteroids can negatively aﬀect memory (Keenan et
al., 1996). Other studies have suggested that the age of human patients appears to be
unrelated to the risk of psychiatric symptoms during corticosteroid treatment, while
a slightly higher prevalence may be found in women, but this kind of prevalence bias
might be related to the fact that many diseases that require corticosteroid treatments
are more frequent in female patients (Cerullo, 2006).
Some reports in human patients suggest that corticosteroids might play a role in the
onset or worsening of bipolar disorders, psychiatric disorders that cause exaggerated
and abnormal shifts in mood with important inﬂuence on the ability to carry out
normal daily tasks (Panwar and Lassi, 2011; Pies, 1981).
The diagnosis of what is called steroid psychosis is a challenging one for human
psychiatrists. Mood disorders are frequently described as the most evident aspect of
steroid psychosis along with corticosteroid-induced mania, but these disorders are not
easy to distinguish from primary disorders that might be worsened during corticost-
eroid treatment (Cerullo, 2006). So, investigation of the eﬀects in psychiatric patients
is inherently more challenging.
Cognitive impairment, in terms of memory impairment and even dementia, due to
corticosteroids has also been described (Martignoni et al., 1992; Varney, 1997). For
instance, Sacks and Shulman reported the case of an elderly patient who was treated
with prednisolone and developed a severe dementia, some of whose symptoms resolved
after discontinuation of the drugs, but signs of memory and attention deﬁcits were
still present six months after the discontinuation of the therapy (Sacks and Shulman,
2005). But cognitive and attentional eﬀects are not limited to the elderly; Wolkow-
itz et al. describe the case of a 10 year old child who received diﬀerent kinds of
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corticosteroids including prednisolone (oral administration, 60 mg/day), methylpred-
nisolone (endovenous administration 80-120 mg/day) and dexamethasone in addition
to inhaled medications to treat asthma and, after the beginning of the corticosteroid
treatment, he started to show signs of depression, irritability, memory and attention
problems and also avoidance of social contact (Wolkowitz et al., 2007). After dis-
continuation of the corticosteroid therapy these psychiatric signs gradually improved
but brain Magnetic Resonance Imaging performed after 3 years revealed that the pa-
tient's hippocampal volume was 19.5% smaller than that of the young patient's twin.
This might suggest a signiﬁcant developmental impact on the immature individual,
consistent with that reported in laboratory animals (Edwards and Burnham, 2001).
A survey conducted in 2012, quantiﬁed the impact of corticosteroid psychiatric side ef-
fects in humans by analysing the UK electronic medical database called The Health
Improvement Network (THIN). That has the longitudinal medical records includ-
ing all prescriptions of patients included in the database, from 1990 to 2008. The
authors identiﬁed prescriptions for oral corticosteroids and compared the incidence
of neuropsychiatric disorders in patients exposed and non-exposed to corticosteroid
therapies. They assessed hazard ratios associated with the ﬁrst prescription issued for
corticosteroid drugs and performed a sensitive analysis that excluded prescriptions for
psychotropic drugs, used as a deﬁnition of previous neuropsychiatric disorders. They
also selected a mix of ﬁrst and later exposure to corticosteroids in order to be able to
understand whether previous exposure to corticosteroids was associated with a higher
risk of developing a psychiatric disorder. They found that, compared with a patient
population unexposed to corticosteroid therapies, exposed patients showed a ﬁve to
seven fold increased risk of suicide and an even greater risk for delirium, confusion,
disorientation and mania. An increased risk was also found for depression and panic
disorder in exposed patients.
Furthermore, high doses of corticosteroids and a prior history of neuropsychiatric
disorder were associated with higher risk of negative psychiatric outcomes. On the
contrary, a prior history of corticosteroid treatments was associated with a lower risk.
This latter outcome might be explained by the decreased probability of receiving a
second prescription for corticosteroids in patients that had psychiatric adverse events
the ﬁrst time (Fardet et al., 2012).
In patients with a history of multiple treatment courses with corticosteroids larger
doses of corticosteroids and a previous history of neuropsychiatric disorder associated
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with corticosteroid therapy was associated with the risk of having the same disorder
in subsequent corticosteroid treatments. Only 1.3% of severe psychiatric symptoms
were reported in patients with daily doses of prednisone equivalents lower than 40 mg,
while 18.4% of severe psychiatric symptoms were reported in patients that received
more than 80 mg of prednisone equivalent every day. The overall risk of developing
neuropsychiatric adverse events in patients exposed to corticosteroid treatments was
15.7 in every 100 patients and was 22.2 percent in patients on their ﬁrst treatment
with corticosteroids.
1.5 Conclusion
Given these ﬁndings and the general recognition that stress is an important risk
factor for behaviour problems in dogs, together with the fact that corticosteroids
are widely used in veterinary practice, it is important to consider that exogenous
corticosteroids might aﬀect the cognition and behaviour of companion dogs. This
research represents the ﬁrst attempt to discover what kinds of changes can be expected
in such dogs when these drugs are prescribed.
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In this chapter a ﬁrst exploratory survey about possible behavioural ef-
fects of corticosteroid drugs in dogs is described. This survey was informed
by the available literature about behavioural and psychological side eﬀects
of corticosteroid drugs in other species, including human beings. The main
goal was to generate items for future use in a controlled structured ques-
tionnaire. The perceptions of behavioural changes in dogs during corticos-
teroid therapy were investigated through semi-structured open interviews
of the owners of 31 dogs of diﬀerent breeds, genders, and ages and eleven
owners reported behavioural changes in their dog behaviours.
2.1 Introduction
In chapter 1 it has been suggested how, in other species, corticosteroids might
have remarkable behavioural side eﬀects. In veterinary medicine, although the phys-
ical side eﬀects of corticosteroids have been widely described, reports of psychological
or behavioural side eﬀects are anecdotal (Dodman and Shuster, 1998), and so far there
are no literature data about the incidence of these kinds of problems in pet animals.
In 2008 Klinck et al. investigated about possible association between pruritic skin dis-
ease and aggression, fear or anxiety-related behaviours in dogs (Klinck et al., 2008).
The results of their survey showed a signiﬁcantly increased reactivity to noises and
thunderstorms in dogs treated with corticosteroids, without any signiﬁcant eﬀect re-
lated with pruritic skin diseases. This survey probably represents the ﬁrst report
about possible behavioural eﬀects of corticosteroids in dogs and it is therefore par-
ticularly interesting from our point of view because it shows that, at least in the
owners' opinion, one of the main sign of dermatological conditions and probably the
most evident, pruritus, was not considered as signiﬁcantly associated with behavioural
changes, while treatment with corticosteroids seemed to inﬂuence dog behaviour. One
of the most widespread use of corticosteroids in veterinary medicine is in dermatology,
where these drugs are used for their immunosuppressive and anti-inﬂammatory prop-
erties in the treatment of a variety of skin conditions, as for example atopic dermatitis
(Olivry et al., 2010). Systemic corticosteroids were shown to be prescribed in 20%
of skin cases in primary veterinary care practice (Hill et al., 2006). Corticosteroids
are widely used in veterinary medicine for a number of conditions, not just in derma-
tology, and they are among the most prescribed drugs for pet animals (Sousa, 2009;
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McDonald and Langston, 1995). According to O'Neill et al., the use of corticosteroid
therapies in veterinary practice is quite widespread, with 14.55% of dog consultations
in primary care practice receiving systemic corticosteroid prescriptions (O'Neill et al.,
2012). Corticosteroids are potent anti-inﬂammatory and immunosuppressive agents
and the majority of therapeutic applications for these drugs fall into these classiﬁc-
ations. Corticosteroids are also prescribed for treating neoplastic diseases, allergic
reactions and are also employed in some emergency protocols (Ferguson et al., 2009).
For the purpose of this study, treatments for life-threatening or very severe conditions
were not considered because the drug eﬀect in those cases would more probably be
overcome by the eﬀect of the distress due to pain.
Due to the presence of corticosteroid receptors in almost all cells, both the desired and
undesired eﬀects of corticosteroid therapy are manifold, making the need for prudent
use particularly important (Behrend and Kemppainen, 1997) and veterinarians are
becoming more and more cautious in prescribing these drugs as they become more
and more aware of the possible drawbacks of corticosteroid therapies (Ferguson et al.,
2009; Levine et al., 2008; Torres et al., 2005). However, behavioural side eﬀects, even
when mentioned, are not supported by evidence (Dodman and Shuster, 1998; Pageat,
1998).
Corticosteroid drugs can have both mineralocorticoid and glucocorticoid receptor
activity, but are mainly employed for their glucocorticoid eﬀects (De Kloet et al.,
1999); exogenous corticosteroids can lead to medical complications in dogs, either
directly or indirectly by causing, for example, immunosuppression or masking signs
that might be important for the diagnosis or monitoring of a disease. The eﬀects of
corticosteroids on the brain are complex but result in a cascade of neurotransmitters
involved in a range of cognitive processes and behavioural responses (Wolkowitz et
al., 2009, see also Chapter 1).
Considering the wide use of corticosteroids in veterinary medicine, it is perhaps sur-
prising that there is this lack of data and awareness relating to potential behavioural
side eﬀects, especially since the role of stress hormones in the onset of behaviour prob-
lems is widely recognised in the veterinary literature (Overall, 1997; Pageat, 1998).
Such information would not only be beneﬁcial to practicing veterinarians, but data
about the incidence of behavioural side eﬀects in dogs might also be useful for owners,
in order to prevent them inadvertently increasing personal risk to themselves or others
when their dogs are under treatment with these drugs.
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In order to systematically, investigate this issue, perhaps the ﬁrst question that needs
to be answered is: what kind of behaviours, if any, might owner's observe as a con-
sequence of the administration of exogenous corticosteroids? Using a similar approach
to that used in the investigation of behavioural changes associated with chronic pain
in dogs (Wiseman et al., 2001), it was hypothesized that owners, through direct ob-
servations of their dogs' behaviour during corticosteroid therapy, might provide useful
information in order to set a starting point for the development of the present research
project.
In this chapter, the ﬁrst stage of our investigation into the behavioural side eﬀects
of exogenous corticosteroids in dogs is reported, in which we aimed to establish the
possible behavioural side eﬀects using a systematic owner interview procedure.
2.2 Materials and Methods
Subjects were a self-selected convenience sample of dog owners recruited from cli-
ents of veterinary clinics in the north of Italy. Inclusion criteria were that dogs had
received therapy with systemic corticosteroids for at least two weeks in the last six
months. Semi-structured interviews were conducted, in which owners were asked if
they had noticed any change in their dogs' behaviour during the time they were giving
corticosteroids. At the beginning of the interview; owners were free to answer without
any prompts, then they were prompted with questions about areas of behaviour in
which, on the basis of the literature, changes might be expected. Table 2.1 lists the
investigated domains. The interviews terminated when data redundancy occurred.
The point of data redundancy was determined as the point at which owner interviews
failed to generate new information for 10 successive interviews (Sandelowski, 1995;
Strauss and Corbin, 1998).
Using this method, the owners of 31 mixed-breed dogs were recruited, 19 male dogs
and 12 females of diﬀerent ages (range of ages from 1 to 13) were included in this pre-
liminary survey. Eighteen dogs had been oral administered methylprednisolone (dose
range 0.2-1mg/kg), eight dogs received oral prednisolone (dose range 0.2-1mg/kg), ﬁve
dogs received dexamethasone via intramuscular injection (dose range 0.01-0.3mg/kg).
Further details concerning individual subjects and the dosing procedure used are
given in Table 2.1. Nine dogs were also receiving antibiotic therapy. Twenty four
dogs suﬀered from a dermatological condition, ﬁve dogs suﬀered from arthritis, one
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dog suﬀered from myasthenia gravis and one suﬀered from recurrent otitis (Table 2.2).
QUESTION INVESTIGATED DOMAINS QUESTION EXAMPLES
1 General question Did you notice any change in your
dog's behaviour during corticost-
eroid therapy?
Can you describe this change?
2 Dog personality How would you describe your
dog's personality? Is this changed
in any way during corticosteroid
therapy?
Can you describe this change?
3 Behaviour with family
members
Have you noticed any change to-
wards family members when the
dog was under corticosteroid ther-
apy?
Can you describe this change?
4 Behaviour with strangers
at home and outside
Have you noticed any change
towards strangers or guests at
home or people outside, when the
dog was under corticosteroid ther-
apy?
Can you describe this change?
5 Behaviour when left alone Have you noticed any change in
your dog's behaviour when he/she
was left alone at home, during cor-
ticosteroid therapy?
Can you describe this change?
Table 2.1: Continued on next page
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QUESTION INVESTIGATED DOMAINS QUESTION EXAMPLES
6 Behaviour during walks Have you noticed any change in
your dog's behaviour during walks
when the dog was under corticos-
teroid therapy?
Can you describe this change?
7 Fears and avoidance
behaviours
Have you noticed any change as
far as fearfulness or avoidance of
people, animals or situations when
the dog was under corticosteroid
therapy?
Can you describe this change?
8 Barking Have you noticed any change in
the intensity of barking in general,
when the dog was under corticos-
teroid therapy? Can you describe
this change?
9 Eating Have you noticed any change in
behaviour around food when the
dog was under corticosteroid ther-
apy?
Can you describe this change?
10 Drinking Have you noticed any change
related drinking when the dog
was under corticosteroid therapy?
Can you describe this change?
11 Sleeping Have you noticed any change in
the way your dog sleeps when the
dog was under corticosteroid ther-
apy?
Can you describe this change?
Table 2.1: Continued on next page
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QUESTION INVESTIGATED DOMAINS QUESTION EXAMPLES
12 Behaviour with other
animals
Have you noticed any change in
behaviour towards other dogs or
other animals when the dog was
under corticosteroids?
Can you describe this change?
13 Behaviour problems Have you noticed any behaviour
problem that was not present be-
fore, when the dog was under cor-
ticosteroid therapy?
Can you describe this change?
Table 2.1: Areas of dog behaviour that were investigated through open questions.
Questions focused on diﬀerences on and oﬀ corticosteroid therapy.
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Dog Age Gender Medical Corticosteroid SD W/MD Concomitant
Breed/Type (years) Condition mg/kg mg/kg Drug Therapies
1 Charplanina 5 M Dermatological Methylprednisolone 0.6 0.3 Antibiotics
Sheep Dog
2 Crossbreed 3 F Dermatological Methylprednisolone 0.5 0.25
3 Crossbreed 8 M Arthritis Dexamethasone 0.15 0.07
4 Jack Russel Terrier 2 F Dermatological Methylprednisolone 0.5 0.25
5 Pomeranian 4 M Dermatological Methylprednisolone 0.6 0.3 Antibiotics
6 Fox Terrier 6 M Dermatological Prednisolone 0.5 0.25 Antibiotics
7 WHWT 9 FS Dermatological Prednisolone 0.6 0.3
8 Crossbreed 3 FS Dermatological Methylprednisolone 0.5 0.25 Antibiotics
9 Crossbreed 7 M Dermatological Methylprednisolone 1.0 0.5 Antibiotics
10 Beagle 5 M Dermatological Prednisolone 0.3 0.3
11 German Shepherd 2 M Dermatological Methylprednisolone 0.4 0.2
12 Italian Hound 7 FS Dermatological Methylprednisolone 0.6 0.3 Antibiotics
13 Crossbreed 3 M Dermatological Methylprednisolone 0.5 0.25
Table 2.2: Continued on next page33
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Dog Age Gender Medical Corticosteroid SD W/MD Concomitant
Breed/Type (years) Condition mg/kg mg/kg Drug Therapies
14 Golden Retriever 8 FS Dermatological Prednisolone 0.4 0.2 Antibiotics
15 WHWT 13 FS Dermatological Methylprednisolone 0.5 0.25
16 Boxer 1 M Dermatological Methylprednisolone 1.0 0.5
17 Crossbreed 6 M Dermatological Prednisolone 0.5 0.25
18 Miniature Schnauzer 11 F Arthritis Dexamethasone 0.3 0.15 Antibiotics
19 Yorkshire Terrier 12 M Recurrent otitis Prednisolone 0.4 0.2
20 Dachshund 3 M Dermatological Methylprednisolone 0.4 0.2 Antibiotics
21 German Shepherd 2 F Dermatological Methylprednisolone 0.5 0.25
22 Bull Terrier 2 F Dermatological Methylprednisolone 0.6 0.3
23 Crossbreed 7 M Dermatological Methylprednisolone 0.5 0.25
24 Lagotto Romagnolo 6 M Myastenia gravis Prednisolone 0.5 0.25
25 Golden Retriever 4 M Dermatological Methylprednisolone 0.6 0.3 Antibiotics
26 Bernese Mountain 8 F Arthritis Dexamethasone 0.2 0.1
27 German Shepherd 9 M Arthritis Dexamethasone 0.1 0.05
Table 2.2: Continued on next page34
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Dog Age Gender Medical Corticosteroid SD W/MD Concomitant
Breed/Type (years) Condition mg/kg mg/kg Drug Therapies
28 Boxer 9 F Arthritis Dexamethasone 0.06 0.03
29 Crossbreed 5 M Dermatological Methylprednisolone 0.5 0.25
30 Maremmano Abruzzese 4 M Dermatological Prednisolone 0.4 0.2
31 Bergamasco Shepherd 8 M Dermatological Methylprednisolone 0.8 0.4
WHWT = West Highland White Terrier; M = male; F = Female; FS = Spayed Female; SD = Starting dose of corticosteroids;
WD/MD = Weaning Dose/Maintenance Dose of Corticosteroid.
Table 2.2: Breed, gender and reproductive status, age, disease, type and doses of administered corticosteroids of the 31
dogs included in the study.
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2.3 Results
Eleven owners reported behavioural changes in their dog's behaviour, nine dogs
were reported to show more than one behavioural change. Of these nine dogs, two were
also receiving treatment with antibiotics (amoxicillin and clavulanic acid). Six dogs
reportedly showed nervousness/restlessness, three an increase in startle responses,
three food guarding, two a decrease in their activity level, three an increase of avoid-
ance responses, 4 irritable aggression and 2 increased barking. These interpretations
were deduced and summarized from the owners' descriptions and were represented
by the onset of certain behaviours or by an increase in frequency and/or intensity of
them. The results are summarized in Table 2.3.
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Dog Breed Age Gender Medical Corticosteroid Concomitant Reported
Condition Drug Therapies Behavioural Changes
1 Charplanina 5 M Dermatological Methylprednisolone Antibiotics* Food guarding;
Sheep Dog irritable aggression
3 Crossbreed 8 M Arthritic Dexamethasone none Nervousness; increased
startle response
7 WHWT 9 F Dermatological Prednisolone none Nervousness and decreased
activity level
10 Beagle 5 M Dermatological Prednisolone none Nervousness; food guarding
12 Italian Hound 7 F Dermatological Methylprednisolone none Nervousness; onset/increased
avoidance behaviours
15 WHWT 13 F Dermatological Methylprednisolone none Avoidance behaviours
16 Boxer 1 M Dermatological Methylprednisolone none Decreased activity level
20 Dachshund 3 M Dermatological Methylprednisolone none Increased startle response;
increased barking
25 Golden 4 M Dermatological Methylprednisolone Antibiotics* Food guarding;
Retriever irritable aggression
Table 2.3: Continued on next page
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Dog Breed Age Gender Medical Corticosteroid Concomitant Reported
Condition Drug Therapies Behavioural Changes
29 Crossbreed 5 M Dermatological Methylprednisolone none Nervousness;
increased startle response;
increased barking
30 Maremmano 4 M Dermatological Prednisolone none Nervousness;
Abruzzese/ irritable aggression
Shepherd Dog
*Amoxicillin and Clavulanic Acid
Table 2.3: Breed, age, gender, medical condition, concomitant therapies and behavioural changes reported in 11 dogs
with identiﬁed changes during corticosteroid therapies. Dog number corresponds to number in Table 2.2.
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Brief case reports on positive cases are given below.
The owner of Dog 1 reported that after a few days of corticosteroid therapy the dog
became more aggressive in the presence of food and more aggressive in general when
disturbed or approached. The owner of Dog 3 described him as a very sweet and calm
dog before the therapy, while after the second injection of dexamethasone (day 3 of
therapy) he became restless, very nervous and tended to be startled by even minimal
sound. The owner reported that his dog was almost impossible to keep calm, but
that after a few days following the interruption of corticosteroid treatment the dog
gradually returned to his usual behaviour and reactivity level.
The owner of Dog 7 also reported that after a few days of therapy the dog was more
prone to startling at every sound and stimulus but was less active, in general, during
the day, while appearing restless in the evening.
Dog 10 received 5 mg of prednisone (0.3 mg/kg) for 2 months and the owner described
that after a few days he started to show aggression in the presence of food and became
very diﬃcult to manage because he had become very nervous, restless and showed
increased attention-seeking by barking and jumping on people. When the therapy
was discontinued the dog gradually became more calm and manageable.
The owners of Dogs 12 and 15 both described that their dogs tended to stay isolated
from social contexts, in particular when people spoke with loud voices. Dog 12, had
been rescued when she was 2 years old and the owner described the dog as fearful
and tending to avoid people when ﬁrst obtained, although this resolved with time.
After corticosteroid treatment the owner reported that she seemed to have returned to
showing the behaviour she had expressed at the time she was adopted, several years
before. Both these dogs reportedly returned to their more usual behaviour when
therapy was discontinued.
Dog 16 received 1 mg/kg of methylprednisolone on the ﬁrst day of therapy. Almost
immediately the owner noticed that he became very calm. The owner reported that
like many boxers, this dog used to be very lively and jump on people all the time.
Under corticosteroid therapy he seemed almost sedated. The dose was reduced by a
half (0.5 mg/kg) in the second day of therapy and the dog appeared less sedated but
still very calm until the end of the entire period of corticosteroid therapy, when he
gradually returned to his previous behaviour.
Dog 20 reportedly became more reactive and started to bark very frequently and
intensely at even minor stimuli a few days after the beginning of corticosteroid therapy.
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During the second week the owner interrupted the therapy and the dog apparently
became gradually calmer and returned to his previous behaviour. The signs of the
dog's dermatological condition which preceded and followed the corticosteroid therapy
and the behaviour change, had not been solved at the time of interview.
The owner of Dog 25 reported that during the ﬁrst week of corticosteroid therapy the
dog started to growl at anyone who came close to his food bowl and also bit a family
person who tried to pet him while he was lying on his bed. The dog had started to
suﬀer from the dermatological problem some days before the onset of the therapy,
but did not apparently show any sign of aggression until the initiation of the therapy.
When corticosteroids were discontinued the dog stopped growling in similar contexts.
The owners of Dog 29 reported that after a few days of treatment the dog started
to become nervous and agitated, and to bark incessantly at almost any stimulus, to
the point that they could not leave him in the garden anymore. The dog also started
to react fearfully towards people during walks and to bark at them. Although the
dermatological problem was not resolved, they decided to interrupt the therapy in the
third week of treatment and the dog gradually returned to his previous behaviour.
The owner of Dog 30 reported that, after a few days of therapy, he started to become
nervous and showed aggression towards both a stranger and a family member for
no apparent reason beyond coming close to him. These episodes happened during
the second week of therapy while the dog was taking half of the starting dose of
methylprednisolone. The owner decided to interrupt the therapy and to treat the dog
just with antibiotics. After the interruption of corticosteroid therapy the dog seemed
to return to its previous behaviour but the dermatological condition worsened. After
one month the veterinary surgeon suggested starting corticosteroids again, at the dose
of 0.3 mg/kg of prednisolone. After a few days the dog began to become nervous again
and bit the owner on his arm when he tried to hold him.
2.4 Discussion
The sample used in this ﬁrst stage of the research might have been biased towards
positive reports due to the possible perception that corticosteroid drugs are danger-
ous, a perception that seems to be quite common among human patients (Charman
et al., 2000; Janson and Becker, 1998). However, our ﬁndings suggested that the
alterations in behavioural repertoire in dogs during corticosteroid therapy deserved
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further attention with more rigorous quantitative methodologies, providing valuable
information that we could use to proceed towards the next phase of our investigation.
The method of collecting data through the reports of carers, in a similar manner to
that used here, has been employed in several studies, both in humans and in non-
human animals (Hall et al., 2003; Wells and Hepper, 2000). It has been argued that
since owners spend considerable time in contact with their animals, they are in the
best position to provide interpretive information on the overall patterns of behaviour
of their own dogs (Wemelsfelder, 1997; Wiseman et al., 2001). The results are con-
sistent with the predictions that might be made on the basis of the scientiﬁc literature
described in Chapter 1, which would suggest a general increased reactivity to stimuli,
especially potentially aversive ones (De Kloet et al., 1999; Korte, 2001). Nonetheless,
it must be recognised that other factors in the study population might be important
for the apparent onset of behavioural changes. For example, the stress and discom-
fort associated with conditions such as pruritus and pain, that necessitate the use of
corticosteroid therapies, might alter the behaviour of the animals (Seksel and Linde-
man, 2001). If a subject is stressed either physiologically or psychologically, ACTH
production is enhanced, regardless of the levels of circulating cortisol, and so it might
be expected that the behaviour of dogs who already have some form of behavioural
disturbance, may be exacerbated by treatment, rather than the problem behaviour
caused by it (McEwen, 2000). As mentioned in the Introduction, the survey conduc-
ted by Klinck et al. showed that the negative behavioural side eﬀects in dogs suﬀering
from dermatological conditions were signiﬁcantly related to corticosteroid therapies
and not to the level of pruritus, as reported by owners, and this therefore supports
our hypothesis (Klinck et al., 2008).
In this preliminary study, the main goal was to ﬁnd items for future investigation
through a controlled survey and therefore owners were prompted to use their own
words to describe their dogs' behaviours in an open and articulate way. Among the
positive cases, most owners spontaneously reported several important behavioural
changes after the ﬁrst general questions (Table 2.1 Q1 and Q2). These questions
could easily be included in routine follow-up monitoring in practice and may help
alert practitioners to potential risks they need to be aware of, especially given that,
in several cases, treatment was associated with aggression and an actual bite in two
incidences.
Most of the dogs involved in the study suﬀered from dermatological problems and were
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treated with oral corticosteroids, methylprednisolone and prednisolone, with similar
dose ranges and therapeutic schedules. These started with a higher dose in the ﬁrst
week of therapy and continued with half the dose for another week and, ﬁnally, with
the same half dose every two days for variable periods of time. It is worth noting
that the reported behaviour changes seemed to appear quite early during corticoster-
oid treatments and this seems to be consistent with data reported in human studies
(Warrington and Bostwick, 2006). Two owners (Dogs 20 and 29) explicitly reported
a stronger association with corticosteroid treatment rather than the clinical condition
for which the medication was prescribed, and this might be important since the latter
could be a confounding factor in many case reports. Nonetheless it must be acknow-
ledged at this time, that owners may easily perceive relationships when none actually
exist, especially since some may perceive corticosteroids as dangerous drugs (Cullen
et al., 2006).
The co-administration of other therapies further complicates the interpretation of the
results. It has been showed that some antibiotics can aﬀect behaviour, for example
penicillin and its analogues have been associated with sedation and anxiety(Pies,
1999; Turjanski, 2005), while quinolones, widely used in dogs and cats might cause,
in rare cases, restlessness and irritability or, on the contrary, lethargy (Sternbach and
State, 2009; Turjanski, 2005). Many other drugs that are often used in dogs, like
antiparasitic products both for topical or oral use can have eﬀects on dogs' behaviour
(De Souza Spinosa et al., 2000; Flório et al., 1989). For example it was shown that
amitraz, often used topically in dogs, can have central depressant eﬀects (Flório et
al., 1989).
Another example about an antiparasitic drug commonly used in dogs is ivermectin, an
agonist for the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that
can be administered orally, topically or by injection and can have serious nervous side
eﬀects such as depression, coma and even death. Collie dogs are particularly sensitive
to this drug and minimal doses can cause severe neurological side eﬀects (Edwards,
2003), but other more subtle behavioural side eﬀects were observed in mice that
became signiﬁcantly more active in an open ﬁeld exploration test during ivermectin
treatment than before treatment, and also showed a greater acoustic startle amplitude
compared with non treated mice (Davis et al., 1999). It is reasonable to suggest that
exogenous corticosteroid dosage might inﬂuence the onset of behavioural side eﬀects
and, in our sample, dose ranges varied and questions were directed generally to ob-
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tain information about changes in behaviour on and oﬀ therapy, without any speciﬁc
investigation about dose related eﬀects. Dose and type of corticosteroid employed
should be more thoroughly considered in future studies, along with other elements
related to the pharmacokinetics of these drugs; for example unbound serum predniso-
lone levels are higher during periods of hypoalbuminemia (Wolkowitz et al., 1990).
Investigating the eﬀect of dose of corticosteroid is a particularly challenging issue
because they are often prescribed in dogs with changing titrations and are adjusted
according to desired eﬀect. A more speciﬁc investigation at diﬀerent dosages would
be useful in order to be able discern any possible correlation, as has been reported in
humans, between dose and behavioural disturbances, although even the human data
are not consistent (Felder-Puig et al., 2007; Hall et al., 2003).
Other factors to consider include genetic inﬂuences on negative feedback mechanisms
that are involved in stress response (Gómez et al., 1998), and the rhythmicity of HPA
activity. Cortisol is secreted in a pulsatory fashion; circadian patterns, similar to the
ones that have been demonstrated in humans, are diﬃcult to verify in dogs probably
because of the very diﬀerent housing and management conditions of individual dogs
and groups of dogs (in shelters, laboratories, in breeder kennels in households and
so on), but it seems reasonable to suggest that there are patterns of diurnal activity,
depending on dog management conditions (Kolezvská et al., 2003). Feeding appears
to be one of the most important regulatory elements for the synchronization of HPA
activity (Leal and Moreira, 1997). Exogenous corticosteroid might therefore interfere
with the normal physiology of HPA axis depending on the management of dogs and
we cannot exclude that some eﬀects were inﬂuenced by external factors such as the
time of feeding or the housing conditions. The eﬀects might also be indirect; for
example, the appetite stimulant eﬀects of corticosteroids are widely recognised, and
if a dog is hungrier, it may be more prone to guard food and associated aggression.
Other indirect relationships might also exist with some of the other reported signs.
The above issues suggest caution in the interpretation of the results of this ﬁrst sur-
vey but the results encouraged further investigation given both the strong theoretical
basis for corticosteroids increasing vigilance and biasing sensitivity towards aversion.
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2.5 Conclusion
In this chapter, semi-structured interviews provided useful preliminary informa-
tion about behavioural eﬀects of corticosteroid drugs in dogs, and areas of future
investigation were identiﬁed. The outcomes of the interviews reported here have been
used in the next phase of this research, to investigate more rigorously the possible
relationship between these signs and corticosteroid drug use in dogs.
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In this chapter the information gathered in the preliminary survey was
used to build a more structured questionnaire to survey a larger number
of respondents. In order to have controls, dog owners with dogs receiving
treatment with a range of corticosteroid preparations and dog owners with
dogs receiving treatment with other drugs, were asked to complete the
questionnaire. Dogs under corticosteroid treatment were reported to show
changes in their behaviours that were consistent with the ﬁndings of the
preliminary study reported in Chapter 2.
3.1 Introduction
In the ﬁrst phase of our research we wanted to explore what dog owners might
have noticed when their dogs were receiving treatment with corticosteroid drugs.
From the literature, we already knew that in other species a number of behaviours
related to avoidance, fear and negative emotion in general have been shown to appear
or increase when animals and humans are treated with corticosteroids (Kajiyama et
al., 2010; Korte, 2001). Cognitive changes such as memory impairment have also
been described in laboratory animals, suggesting that corticosteroids might cause
changes related with both emotion and cognition (Henckens et al., 2012; Kim and
Haller, 2007). Because corticosteroids might mimic the eﬀects of organisms' stress
responses, it is not surprising that treatment side eﬀects such as increased avoidance,
fear and aggression seem to be more evident in already distressed individuals (Brown
and Chandler, 2001; Panwar and Lassi, 2011; Wolkowitz et al., 1990). One of the
main challenges, when investigating the eﬀects of drugs on behaviour, is to identify
to what extent treatment contributes to the onset or worsening of signs of negative
aﬀective states in subjects that are also suﬀering physical discomfort, that increases
distress per se (Blackburn-Munro and Blackburn-Munro, 2003). This survey aimed
to investigate the eﬀects of corticosteroid therapies on dog behaviour through the
analysis of questionnaires completed by dog owners which included the use of other
drugs used for similar conditions for comparative purposes.
The preliminary survey established the primary areas likely to be of importance (see
previous chapter), and informed the design of the present study questionnaire, which
also allowed the introduction of a number of additional controls to reduce some of the
risks associated with responder bias.
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3.2 Materials and Methods
The introductory part of the questionnaire gathered demographic data relating to
both the owner and their dog, information about the drugs being given to the dog
at the time of survey (such as type of drug, time of administration and doses) and
information about the type of condition/disease for which it was being used.
The respondents were asked to mention all drugs taken in the same period for the same
or other concomitant conditions. Twelfe double items of the questionnaire were related
to the animal's behaviour (Appendix A). This was completed by dog owners with dogs
receiving or having recently received drug treatment, preferably for dermatological or
orthopaedic conditions. This part of the questionnaire was informed by the results of
the previous survey, described in Chapter 2. Seven of the 12 items were selected on
the basis of the results of the previous survey (Chapter 2), with ﬁve further questions
relating to other behavioural changes not identiﬁed in the previous survey selected
among the behaviours that most frequently cause complaints by dog owners (Adams
and Clark, 1989; Beaver, 1994). These were inserted partly as ﬁllers and to aid
validation of target eﬀects. Items in questionnaires are listed to achieve information
about a particular topic and inserting questions that hide the real intent of the
questions is likely to improve the reliability of the results (Domino and Domino, 2006).
The questionnaire was published via the Internet in both English and Italian, with a
paper version also distributed to Italian veterinary clinic clients. Questionnaires were
back translated by independent mother tongue translators to assess the consistency
of the two versions. The items were scored on a seven point scale with two scores for
each question posed: one score for the respondent's perception when the animal was
receiving pharmacological treatment for the condition and one for when the animal
was not receiving pharmacological treatment (Figure 3.1).
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Figure 3.1: Example of question and scoring system used in owner questionnaire:
Q1 Play Behaviour.
Questions are illustrated in Table 3.1 and Items 1 (Play behaviour), 5 (Attention
seeking), 7 (Obedience), 8 (Guarding behaviour) and 12 (Mounting behaviour) were
added as additional ﬁllers.
QUESTIONS DETAILS OF QUESTIONS
Q1 Some dogs are very motivated to play with people, other
dogs or toys. On a scale from 1 to 7 where 1 is not very
playful and 7 is very playful how would you rate your
dog's behaviour?
Q2* Thinking about your dog's temperament, how would
you deﬁne its nervousness/restlessness on a scale from
1 to 7 where 1 is very nervous and restless and 7 is
very calm?
Table 3.1: Continued on next page
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QUESTIONS DETAILS OF QUESTIONS
Q3* Thinking about your dog's general responses, for ex-
ample, in the presence of unknown people or of new,
unknown stimuli (sounds, loud voices, unknown con-
texts, unknown animals or children...), on a scale from
1 to 7 where 1 is extremely fearful and insecure and 7
is very conﬁdent , how would you rate your dog?
Q4 Thinking about your dog's behaviour when there is food
around, on a scale from 1 to 7 where 1 is not at all
aggressive and 7 is very aggressive in the presence of
food, how would you rate your dog?
Q5 Some dogs tend to be very insistent and seek physical
contact with owners by jumping up, snapping, scratch-
ing with a front paw, whining or barking: on a scale
from 1 to 7 where 1 is no attention seeking behaviours
and 7 is frequent and intense attention seeking beha-
viours, how would you rate your dog?
Q6 Some dogs bark at any time, night and day, some others
bark only in exceptional occasions. On a scale from 1 to
7 where 1 is rare barking and 7 is frequent and intense
barking, how would you rate your dog's behaviour?
Q7 Some dogs are very obedient, for example they come
when called and go to bed when asked, while some oth-
ers are less easily controlled. On a scale from 1 to 7
where 1 is not at all obedient and 7 is very obedient,
how would you rate your dog's behaviour?
Table 3.1: Continued on next page
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QUESTIONS DETAILS OF QUESTIONS
Q8 Some dogs are very predisposed to guarding behaviour
and tend to threaten people by barking and growling,
some others are friendly with everyone and don't show
any guarding behaviour. On a scale from 1 to 7 where 1
is no guarding behaviour and 7 is intense & frequent
guarding behaviour, how would you deﬁne your dog's
behaviour?
Q9 Some dogs tend to startle very easy, for example when
they hear a sound or are suddenly touched. In these
cases they can react by ﬂeeing, getting jumpy or showing
aggression. On a scale from 1 to 7 where 1 is low/rare
startle response and 7 is an excessive and very frequent
startle response, how would you deﬁne your dog's be-
haviour?
Q10 Some dogs tend to react aggressively if someone tries to
touch them or come close while they are resting. These
dogs can become aggressive whenever the owner tries to
brush them, medicate them or even simply tries to pet
them. On a scale from 1 to 7 where 1 is never aggress-
ive when disturbed/restrained and 7 is very aggressive
when disturbed/restrained, how would you deﬁne your
dog's behaviour?
Table 3.1: Continued on next page
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QUESTIONS DETAILS OF QUESTIONS
Q11 Some dogs have a marked tendency to avoid people or
situations that are unknown or unfamiliar, for example
they tend to leave the room when unknown guests arrive
or when people scream or there are loud noises. On a
scale from 1 to 7 where 1 is no tendency to hide or
avoid people or situations and 7 is High tendency to
hide or avoid people or situations, how would you rate
your dog's behaviour?
Q12 Some dogs can show a tendency to mount people (chil-
dren and adults) or other dogs, often of the same sex.
On a scale from 1 to 7 where 1 is no tendency to mount
and 7 is high tendency to mount how would you rate
your dog's behaviour?
* reversed scale
Table 3.1: Owner questionnaire. Verbatim of questions. Scale 1-7 illustrate the level
of expression of the investigated behaviour.
3.2.1 Data analysis
Summary descriptive statistics was calculate initially. A Spearman's correlation
test was used in a ﬁrst analysis to identify possible correlations between changes in
the investigated behaviours and use of corticosteroid drugs. For the purpose of this
ﬁrst analysis the sample was divided into two main groups, one group was composed
of dogs that used corticosteroids, alone or with other drugs, and the other group was
composed of dogs that assumed other drugs.
Responses were then collated and analysed using a repeated measures multivariate
GLM . In this analysis, treatment related eﬀects on behaviour when on and oﬀ drug
were considered as dependent measures; type of treatment (divided into 3 categories:
corticosteroids, corticosteroids and other drugs, only drugs other than corticosteroids),
duration of treatment (divided into 5 categories: 1 week, 1-2 weeks, 2-3 weeks, 2-4
weeks, more than 4 weeks), the reason for treatment (divided into 3 categories: derma-
tological conditions, orthopedic conditions and others) were considered independent
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factors. This ﬁrst multivariate analysis was made to test drug eﬀects within-subjects,
and since only treatment type was found to be a signiﬁcant factor and there was great
variation in the baseline value of subjects, a univariate GLM was then used to ex-
amine the diﬀerence between behaviour when on and oﬀ treatment versus treatment
type, with post hoc pairwise comparisons corrected for multiple testing by means of
Bonferroni correction. Data were analyzed using SPSS 21.
3.3 Results
By the close of the survey in February 2011, 98 questionnaires had been completed
correctly by dog owners and were considered suitable for analysis. Dogs were from
a variety of breeds and genders, and aged between 1-14 years. Figure 3.2-3.4 shows
breed, age, gender and reproductive state distributions of dogs (see Appendix D for
description of breed groups).
Figure 3.2: Breed distribution of dogs, according to the classiﬁcation of the
Fédération Cynologique Internationale (FCI): details in Appendix F).
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Figure 3.3: Age distribution of dogs divided into three main categories.
Male = non neutered males; Female = non neutered females.
Figure 3.4: Gender distribution of dogs with the indication of their reproductive
state.
Reasons for treatment were dermatological conditions (n = 55), orthopedic condi-
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tions (n = 36) and other kinds of condition that included respiratory, gastrointestinal
ad immune diseases that were grouped together because of the very small number
of subjects in each cathegory (n = 7). Treatment duration varied from one week of
treatment to long term maintenance treatment. Of the sample of 98 dogs, 44 re-
ceived corticosteroids and 54 received only other medications, mainly antibiotics (n =
20) and non-steroidal anti-inﬂammatory drugs (n = 28), with a small proportion on
other drugs (n = 6) that included immunosuppressive drugs, antacid and antiemetic
drugs. Of the 44 dogs that received corticosteroids, 23 also received other drugs,
mainly antibiotics. The 44 dogs receiving treatment with corticosteroids were subject
to a variety of corticosteroid preparations, but mainly prednisone/prednisolone (n =
32) and methylprednisolone (n = 7). Two dogs received betamethasone and three
dogs received dexamethasone. Corticosteroid drug doses were between 0.1-1.2 mg/kg
for prednisone and prednisolone, between 0.5-1.5 mg/kg for methylprednisolone, 0.05
mg/kg for betamethasone and 0.1 mg/kg for dexamethasone.
A Pearson correlation test revealed a signiﬁcant correlation between corticosteroid
treatment and diﬀerences in eight of the investigated behaviours, as reported by own-
ers, (see Table 3.2).
Response Items Pearson Correlation Signiﬁcance (2-tailed)
Play** - 0.325 0.001
Nervousness** - 0.292 0.004
Fear** - 0.433 0.000
Food Aggression** 0.316 0.002
Attention Seeking 0.013 0.898
Barking** 0.302 0.003
Obedience - 0.105 0.306
Guarding 0.001 0.993
Startle Reactions** 0.297 0.003
Irritable Aggression** 0.283 0.005
Avoidance* 0.236 0.019
Mounting 0.081 0.429
Signiﬁcant items are in bold. ** = p < 0.01; * = p < 0.05*
Table 3.2: Correlations between the diﬀerences in behaviours on and oﬀ treatment
and corticosteroid treatment as reported by owners (n. 98 dogs).
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Data were not normally distributed, but still suitable for analysis of variance (Ballinger,
2004; Taylor, 2011).
The repeated measures multivariate GLM analysis showed that the only signiﬁcant
factor related to a change in the behaviour of dogs was the treatment used. The
treatment administered had a statistically signiﬁcant eﬀect on the response to eight
items. Five behaviours, Play (F = 6.525, Nervousness (F = 6.130), Fear (F = 13.112),
Startle Reactions (F = 5.705), Irritable Aggression (F = 5.080)  signiﬁcantly changed
with p < 0.01; three behaviours, Food Aggression (F = 4.793), Barking (F = 4.330),
Avoidance (F = 4.463)  signiﬁcantly changed with p < 0.05.
Post-hoc pairwise comparisons showed that treatment with corticosteroids (44 dogs)
produced signiﬁcant changes in behaviour for the items Play (p < 0.01), Nervous-
ness(p < 0.01), Fear(p < 0.01), Food Aggression (p < 0.05), Barking (p < 0.05)
Startle Reactions (p < 0.01), Irritable Aggression (p < 0.01) and Avoidance (p <
0.05). By contrast, treatments without corticosteroids (54 dogs), produced no signi-
ﬁcant changes (p > 0.05) in response to any item but playfulness (p < 0.01), which
showed a change in the opposite direction with dogs becoming more playful when
treated with other drugs (Table 3.3).
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CG GROUP OG GROUP
RESPONSE ITEM Oﬀ On Oﬀ On
Play behaviour Mean 4.80 4.05** 3.80 4.63**
(± SD) (1.82) (1.71) (1.90) (1.85)
Nervousness Mean 4.57 3.75** 4.69 5.02
(± SD) (1.56) (1.92) (1.78) (1.55)
Fear Mean 4.89 3.95** 4.54 4.94
(± SD) (1.48) (1.72) (1.61) (1.37)
Food Aggression Mean 2.00 2.57* 2.20 2.07
(± SD) (1.45) (2.11) (1.56) (1.37)
Attention Seeking Mean 3.91 4.14 3.93 4.15
(± SD) (1.70) (1.84) (1.86) (1.77)
Barking Mean 2.73 3.43* 2.74 2.67
(± SD) (1.69) (2.05) (1.75) (1.78)
Obedience Mean 5.18 4.91 5.07 5.04
(± SD) (1.48) (1.60) (1.33) (1.29)
Guarding Mean 3.39 3.50 3.20 3.31
(± SD) (1.87) (2.05) (2.10) (1.92)
Startle reactions Mean 2.84 3.77** 3.19 3.06
(± SD) (1.68) (2.07) (1.83) (1.62)
Irritable Aggression Mean 1.93 2.43** 2.07 1.96
(± SD) (1.47) (1.83) (1.46) (1.30)
Avoidance Mean 2.27 2.73* 2.29 2.11
(± SD) (1.80) (2.05) (1.48) (1.42)
Mounting Mean 1.80 1.75 2.02 1.80
(± SD) (1.29) (1.48) (1.56) (1.19)
* = p < 0.05; ** = p < 0.01 (Signiﬁcant diﬀerences within groups)
CG = Corticosteroid Group; OG = Other Group
Table 3.3: Reported changes in behaviour score on and oﬀ diﬀerent treatments.
Scale 1-7 represent the expression of the behaviour. Questions about nervousness
and fear had reversed scales.
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3.4 Discussion
The results reported here are highly consistent with those reported in the previ-
ous chapter, using a diﬀerent methodology. All the behaviours that were reported
to change under the inﬂuence of corticosteroid drugs in the preliminary survey were
found to change signiﬁcantly in the present study, adding weight to the reliability
of these reported eﬀects. In addition, one further item, not previously reported, but
also possibly inﬂuenced by negative aﬀect i.e. a change in play behaviour, was also
found to be reportedly reduced under corticosteroid treatment. The robustness of
these ﬁndings is further enhanced by the ﬁnding that the other four items (attention
seeking, obedience, guarding and mounting) introduced as ﬁllers did not show signi-
ﬁcant changes associated with the use of corticosteroid therapies.
The additional discovery of an eﬀect on play is important as play is considered to be a
useful indicator of animal welfare, with animals not playing if they are in a distressed
state (Boissy et al., 2007; Held and pinka, 2011; Oliveira et al., 2010). The ﬁnding
is all the more interesting as corticosteroids are widely used to relieve pain and irrit-
ation in veterinary practice, and it might be predicted that their use would increase
playfulness as a result. However, these results suggest that their eﬀects on aﬀective
state can outweigh these beneﬁcial eﬀects and that their value in this context might
be largely related to increasing arousal rather than a positive aﬀective state, as might
be often assumed. The question about play behaviour was inserted as a ﬁller but it
worth notice that in the preliminary survey (see Chapter 2) two owners reported a
decrease in their dogs' activity levels and this might have included a decrease in play
behaviour although it was not speciﬁcally mentioned.
The eﬀect of corticosteroids on increasing nervousness was identiﬁed in the survey
illustrated in Chapter 2, with six owners (out of a sample of 31) describing that their
dogs tended to be more agitated and restless. In the current study, dogs receiving
corticosteroids were also reported to be signiﬁcantly more nervous and restless, more
fearful/less conﬁdent, and more prone to startle when on treatment and such a re-
sponse was not revealed in relation to other medications. Agitation and restlessness
have been described frequently in humans treated with corticosteroids (Benyamin et
al., 2008; Warrington and Bostwick, 2006). Endogenous corticosteroids are important
factors in a range of stress responses and are involved in the onset of avoidance beha-
viours, probably by inducing chemical changes that predispose the subject to the onset
of reactions related to fear and anxiety (Korte, 2001; Rodrigues et al., 2009; Steimer,
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2002). We hypothesize that, from a biological perspective, this central response is
possibly a more reliable consequence than the behavioural output, and may oﬀer a
better explanation of the impact of corticosteroids on aﬀective state. Although a rise
in endogenous corticosteroids is often attributed to the presence of aversive stimuli, it
is well recognized that a rise also occurs at other times which might be associated with
positive aﬀect, e.g. during sexual arousal (De Kloet et al., 1999; McEwen, 2007). This
has led some to speculate that corticosteroid levels are simply a reﬂection of arousal.
However, an interpretation based on increased cognitive sensitivity to aversion may be
more useful, since even at times of intense positive stimulation, this bias is adaptive,
because these are also occasions when the animal may be more vulnerable to predat-
ors due to its focused attention on positive salient stimuli. Therefore, the release of
corticosteroids at this time not only facilitates the necessary increased arousal, but
also serves to reduce the risk of harm, by simultaneously predisposing the animal to
threat vigilance. In this context it is worth noting that the startle response (which
was reportedly increased in this study) has been used as a speciﬁc response modulated
by negative aﬀective states both in laboratory animals and human beings (Angrilli
et al., 1996; Dreissen et al., 2012; Gresack and Risbrough, 2011; Lang et al., 1990).
Further empirical investigation of this hypothesis is possible since it has been found
that animals in negative aﬀective states are also more likely to respond negatively to
ambiguous stimuli (Burman et al., 2011; McNaughton and Corr, 2004; Mendl et al.,
2010; Paul et al., 2005).
The tendency to behave aggressively in the presence of food is consistent with this
hypothesis but also with other known eﬀects of corticosteroids. Many dogs receiv-
ing exogenous corticosteroids may have an increased appetite, eat and drink more
(Sousa, 2009; McDonald and Langston, 1995). This could result in an increased per-
ceived value of food, and tendency to defend it from possible competitors as a result.
The concomitant generation of a negative aﬀective state will also increase the risk
of an aggressive response in the presence of ambiguous and potentially threatening
stimuli.
Dogs under corticosteroid treatment were also reported to be signiﬁcantly more prone
to react aggressively when disturbed. In the preliminary survey described in Chapter
2, four owners described their dogs, during treatment with corticosteroids, showing
the tendency to react aggressively when petted or just approached.
The way dogs respond to a social approach depends on several diﬀerent elements, and
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aggression at this time may be viewed as a response style associated with a wider
range of stress-related responses. Studies in both humans and laboratory animals
have shown that corticosteroids play an important role in the onset of aggressive re-
sponses (De Kloet et al., 1996; Kim and Haller, 2007).
Subjects under corticosteroid treatment were also perceived to be signiﬁcantly more
prone to avoiding people or situations. The inﬂuence of corticosteroids on avoidance
behaviour and learning has been reported in both laboratory animal studies and hu-
man case reports (Cottrell and Nakajima, 1977; De Kloet et al., 1999; Medina et al.,
2007). This result is again consistent with the tendency for dogs under treatment
with corticosteroids to be in a general negative aﬀective state.
Owners also reported that dogs under corticosteroid treatment barked signiﬁcantly
more than when they were not receiving therapy, although no speciﬁc context or situ-
ation was deﬁned for this behaviour. Vocalizations are part of dog communicative
behaviour but can also be indicators of emotional arousal, either positive or negative
and the further interpretation of this behaviour would need a description of the vo-
calization features, of the visual signals given by the dogs along with an evaluation
of the context of the displayed behaviour. Nevertheless, it was reported that an in-
creased tendency to bark can be observed in dogs that are fearful or distressed and
intense, frequent barking is perceived as a problem by dog owners (Beerda et al., 2000;
Landsberg and Akermann, 2003), and so owners should be warned of this potential
side eﬀect too.
No eﬀect of corticosteroid administration on the ﬁllers relating to obedience, attention
seeking, guarding or sexual behaviour was found. Filler items are often used in the
design of questionnaires in psychology to prevent bias (Domino and Domino, 2006).
The ﬁllers used here were chosen following consideration of the behaviours that most
frequently cause complaints by dog owners and which are part of the behavioural
repertoire of most pet dogs (Adams and Clark, 1989; Beaver, 1994; Lindell, 2009;
Wells and Hepper, 2000). These behaviours were not mentioned by dog owners in the
previous survey and so the lack of perceived signiﬁcant changes in the present survey
supports the speciﬁcity of the reporting by owners in the current study. Overall, these
results provide further evidence that in dogs, as in other species, corticosteroid drugs
can bias cognition and change behaviour, but further empirical studies are needed in
order to conﬁrm these ﬁndings. Nonetheless in the absence of evidence to the con-
trary, the precautionary principle should be followed, with advice given on these
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potential side eﬀects for best practice.
Except in the management of acute episodes, corticosteroid drug treatments in dogs
are typically given for one or more weeks depending on the type and severity of dis-
ease, and the dose is gradually reduced; some treatments require a prolonged or even
lifelong treatment (Sousa, 2009; O'Neill et al., 2012). The decision to consider the
length of the drug therapy was partly related to the need to have reliable data and to
exclude cases of single administration, for example for dealing with acute allergic reac-
tions. However, in the clinical reports of the psychiatric side eﬀects of glucocorticoid
drugs in humans, it seems that these can be both dose-dependent and time dependent
(Bender et al., 1991; Brown et al., 1999). The issues of dose-related and time-related
eﬀects were not the speciﬁc focus of this investigation, and although neither factor
was found to be signiﬁcant in the initial statistical analysis, their potential relevance
should not be dismissed on the basis of this study. Further investigation using mul-
tiple observations at diﬀerent times on individual dogs are necessary, in order to build
chronological data for analysis. The possible inﬂuence of diﬀerent types of corticost-
eroid drugs could not be investigated because about 90% of the corticosteroid drugs
were very similar molecules (prednisone, prednisolone and methylprednisolone), but
this aspect might be worth investigation in future studies.
All dogs involved in the survey were in treatment for diﬀerent conditions and the
eﬀects of disease on behaviour have been widely reported and studied (Larson and
Dunn, 2001), for example, the behavioural eﬀects of cytokines involved in the immune
response, such as decreased exploratory behaviour and increased avoidance (Anisman
and Merali, 1999). Problematic behaviour was considered in the preliminary survey
in Chapter 2, where case studies were reported, with two dog owners reporting an
association with corticosteroid treatment rather than the clinical condition for which
the medication was prescribed. The treatments in these two dogs were discontinued
because of the onset of behavioural problems after a few days of corticosteroid therapy
and both dogs, although still in bad physical condition, reportedly stopped showing
the unwanted behaviours as a result. It is worth noting that in the present survey
diﬀerent groups were deﬁned on the basis of the treatment used but only the corticos-
teroid group showed signiﬁcant behavioural changes.
Owner reports of individual dog behaviours might be biased by pre-existing personal
opinion, expectation, cultural attitudes and beliefs. Corticosteroids are often por-
trayed in popular media as dangerous drugs and owners' evaluations might therefore
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be inﬂuenced by such a perception rather than by direct observation of their dogs'
behaviour (Cullen et al., 2006). This sort of bias is probably the main risk of sur-
veys based on the opinions of dog owners, but there is also an important potential
advantage associated with gathering information about dogs' behaviour from owners
associated with their experience in a range of contexts (Wemelsfelder, 1997; Wiseman
et al., 2001). The direct testing of dogs may be more reliable in terms of collection
of data but has the limitation of context speciﬁcity. However, given the results es-
tablished so far, the next logical step is to see if the perceptions reported here are
replicated in a more objective and controlled behavioural test setting.
3.5 Conclusion
The results presented in this chapter, are consistent with previous ﬁndings and
contribute additional evidence to suggest that exogenous corticosteroid treatment can
inﬂuence the onset of avoidance responses and aggressive responses in dogs. This can
be explained by a tendency for these drugs to bias sensitivity towards aversion in dogs
that is also associated with an increase in vigilance.
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In this chapter, a phase of this research that involved behavioural test-
ing of dogs on corticosteroid therapies is described. This phase is intended
to provide dog-based objective data about the eﬀects of corticosteroid
drugs on dog behaviour through the direct testing of dogs in treatment
with these drugs. A control group of dogs was also tested using the same
methodology. Dogs in treatment with corticosteroid drugs were less ex-
plorative and eat less pieces of food compared with the control group.
4.1 Introduction
After having investigated the possible behavioural side eﬀects of corticosteroid
drugs in dogs indirectly through owners' opinions, the following step was to carry out
a behavioural test in order to have more objective data recorded directly from the
dogs themselves that could support our hypothesis that corticosteroid drugs in dogs
can bias sensitivity towards aversion. Directly testing dogs gives the possibility to
measure their behaviour in a more objective way, compared with the subjective eval-
uations of dogs' owners although , with the survery approach, the owners' responses
might provide information about complex behaviours in diﬀerent contexts (Svartberg,
2005), and main limit of directly testing dogs is the narrow range of investigated con-
texts. Testing dogs also implies ethical issues, for example dogs might be scared by
social and environmental stimuli used to elicit their behavioural responses and test
experience might cause the onset of negative associations that might last and possibly
elicit future avoidance responses. These issues had to be addressed ﬁrst in the phase
of test design and then during the development of test attempts in order to select
appropriate setting and stimuli (see Appendix C).
From the results of the previous surveys, reported in Chapters 2 and 3, we knew that
dogs on corticosteroid drugs might become less playful, more nervous, more fearful,
more aggressive in the presence of food, bark more, have an increased tendency to
startle, be more irritable and increase their tendency to avoid unusual situations. Our
hypothesis was that these changes in behaviour were related with increased negative
aﬀective states and arousal. Setting an experimental condition that would enable us
to detect the presence or increase of a negative aﬀective state in dogs, but without
endangering their welfare, was the major challenge.
Behavioural tests intended to demonstrate changes in behaviour that reﬂect diﬀer-
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ences in aﬀective state as a consequence of exposure to pharmacological treatments
have been largely developed and used in laboratory animals (Ardayﬁo and Kim, 2006;
Handley and Mithani, 1984; Kajiyama et al., 2010). For example the reactions of
male rats to spatial novelties in relation with diﬀerent levels of corticosterone were
investigate in an open ﬁeld test, which is an arena with walls to prevent escape. This
interesting experiment investigated the U-shaped eﬀects of corticosteroids, where very
low levels and very high levels of these hormones seem to have similar eﬀects on re-
activity. They found that adrenalectomized rats increased their reactivity to novel
objects in the arena but also high doses of corticosterone produced similar patterns
of behaviour (Oitzl et al., 1994). While the majority of studies about drugs that can
aﬀect behaviour in dogs have been conducted in owned dogs and are based on owners'
opinions (King et al., 2000; Landsberg et al., 2008), more recently, behavioural tests
have been used with laboratory dogs to demonstrate the eﬀects of nutraceuticals on
dog behaviour (Araujo et al., 2010; DePorter et al., 2012).
For instance, testing an increase or decrease of speciﬁc behaviours thought to be asso-
ciated with the experience of negative emotions when exposed to aversive stimuli (e.g.
fear of thunderstorms) was investigated by DePorter et al. with the purpose of testing
the eﬃcacy of a nutraceutical compound on thunderstorm phobia in dogs (De Porter
et al., 2012). This latter study was a blinded and placebo study and dogs were tested
in an open ﬁeld test. Activity levels were the primary outcome measure of negative
emotions, with reduced inactivity during the administration of artiﬁcially reproduced
thunder sounds taken to indicate a reduction in fear and anxiety. Inactivity dura-
tion, inactivity frequency, distance travelled and time spend close to the exit of the
arena during the administration of the adversive sound were considered as related to
freezing responses and attempt to escape and used as parameters to measure anxiety.
They found that dogs in treatment were less inactive during the thunderstorm phase
but no other signiﬁcant diﬀerences were detected. A diﬀerent study on laboratory
dogs investigated the eﬀects of Anxitane R©, another nutraceutical compound based
on the amino acid L-Theanine (N-ethyl-L-glutamine), an analogue of L-Glutamine
and L-Glutamate (Nathan et al., 2009), on the apparent fear of unfamiliar humans
(Araujo et al., 2010). In this study, dogs that were characterized as being anxious
were observed to show less interaction with an unknown human compared to the in-
teraction level of control dogs and this parameter was used to test the eﬀect of the
nutraceutical. They found that dogs fearful of unfamiliar humans, when in treatment,
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increased the frequency and duration of interactions as well as the time spent near the
human in the test environment (Araujo et al., 2010). The interpretation of aﬀective
state using levels of activity as parameters might have limitations and in the study
of DePorter et al. (2012) dogs neither signiﬁcantly increased their distance travelled
nor signiﬁcantly decreased the time spent close to the exit of the arena, suggesting
that increased activity might have been related with increased sympathetic activity,
a stress response (Katz et al., 1981). In the same way, in the study of Araujo et al.,
(Araujo et al., 2010), behaviours generated by an approach-avoidance conﬂict might
have inﬂuenced the amount of time spent near the human (Roth and Cohen, 1986).
Both in humans and laboratory animals, behavioural inhibition can be associated
with elevated corticosteroid levels (Cavigelli et al., 2007) while behavioural responses
to novel, surprising stimuli and resilience have been related with the presence of pos-
itive emotional states (Cavigelli et al., 2007; Degnan and Fox, 2007; Turner et al.,
1996). As mentioned above, behavioural inhibition or increased activities should be
cautiously evaluated because high levels of arousal and increased activity intended as
increased tendency to explore in a positive way might be diﬃcult to distinguish.
The behavioural test presented here was designed to challenge dogs with a surpris-
ing stimulus that was also intended to be slightly aversive in the context of the test
setting in order to directly observe unambiguous behavioural changes in dogs under
treatment compared to a control group of dogs. The ﬁndings of the previous stages
of this research provided the rational to design the behavioural test described in this
chapter. The aim was to see if dogs on corticosteroid therapies were more avoidant
and less explorative, as shown by the increase of negative motivated behaviour il-
lustrated in the previous surveys. With this test we wanted to directly investigate
possible changes in the behaviour of dogs in treatment with corticosteroid drugs and
all the treated dogs were patients of veterinarians that were not directly involved in
this research.
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4.2 Materials and Methods
4.2.1 Subjects
Eleven dogs receiving (or due to receive) corticosteroid treatment and 11 control
dogs were recruited and successfully completed two sessions of the behavioural test.
Treatment dogs were recruited from the patients of veterinary practices in the North of
Italy. Veterinarians were asked to propose dog owners that had received prescriptions
of oral corticosteroid drugs for dermatological problems to participate in the research.
Criteria for inclusion were that dogs had not been prescribed any other medication; the
prescription dose range was within 0.4-0.5 mg/kg of prednisone or methylprednisolone
every day. Control dogs were recruited from among the healthy patients of veterinary
practices and clients of dog trainers.
Control dogs were tested twice in the same environment as the dogs on corticosteroids,
with the same time interval between the two tests. Details of all subjects are given in
Table 4.1.
Dog Breed/type GENDER AGE TREATMENT(*)
1 Collie M (n) 9 0.5/kg prednisone
2 Dachshund M 4 0.4/kg prednisone
3 Labrador M 5 0.4/kg methylprednisolone
4 Golden retriever F (n) 10 0.5/kg prednisone
5 Crossbreed F (n) 4 0.4/kg prednisone
6 Cocker M 9 0.4/kg methylprednisolone
7 Pitbull M (n) 7 0.4/kg prednisone
8 Jack Russell M 3 0.5/kg prednisone
9 Crossbreed M 1 0.4/kg prednisone
10 Golden retriever F 2 0.5/kg prednisone
11 Crossbreed M 4 0.4/kg prednisone
12 Crossbreed M (n) 9 No treatment
Table 4.1: Continued on next page
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Dog Breed/type GENDER AGE TREATMENT(*)
13 Crossbreed F (n) 2 No treatment
14 Crossbreed M 2 No treatment
15 Pitbull M (n) 2 No treatment
16 Shiba Inu M 1 No treatment
17 German shepherd F 1 No treatment
18 Crossbreed F (n) 7 No treatment
19 Cocker Spaniel M 6 No treatment
20 Border collie M 5 No treatment
21 German shepherd M 4 No treatment
22 Crossbreed F (n) 1 No treatment
* = no dogs were receiving treatment in the ﬁrst test trial, treatment refers to
medication in use during the second test trial.
M = male dog; F = female dog, (n) = neutered.
Table 4.1: Dogs involved in the study.
The ﬁrst behavioural test for treatment dogs occurred just before they started
therapy, with a second taking place 6-7 days into the therapy, often just before the
dose of corticosteroid started being reduced with a view to its withdrawal.
4.2.2 Test procedure
The tests were conducted in three diﬀerent locations in order to accommodate the
travel restrictions of clients, but the set-up was the same at each of these: a room of
suﬃcient size to accommodate the experimental apparatus, with a chair for the owner
at the opposite end of the room. The apparatus composed of a screen covered with
a blanket that hid a loudspeaker system connected to a computer. Five pots were
placed in front of the screen, 35 cm from the loudspeakers. The pots were placed in
a way that enabled the researcher to put small pieces of food into them at the same
time (Figure 4.1). For each dog, the kind of treat used during testing was indicated
by the owner as being the dog's favourite. The same kind of treat was used in both
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test trials for that subject. Two video cameras (Canon Legria HF R506) were used
to record the dog's behaviour during testing for later behavioural coding. The video
cameras were mounted on a tripod, one to one side of the room and the other at the
back of the room. The part of the room within 150 cm of the screen was considered
to be the test area and when dogs were within this area with evident interest in
exploring it, the screen or the pots, their behaviour was considered as exploring the
test area. Exploring the test area included:
1. Sniﬃng: The dog overtly approached the ﬂoor, the bowls or the screen and
appeared to inhale through its nose;
2. Exploring: Remaining in the test area watching towards the ﬂoor, the screen or
the bowls;
3. Investigating the pots: approaching the pots with nose within 1 cm of pot and
nose or muzzle inside pot.
Behaviours such as staying far from the screen, either close to the owner or at the op-
posite end of the room to the experimental apparatus, were considered as behaviours
associated with not exploring the test area.
Dogs were brought into the test environment on a leash by their owners. In each
test trial the owner was invited to calmly restrain the dog on the leash, sit and wear a
pair of sunglasses to restrict eye contact between dog and their owner. The researcher
showed the dog a few pieces of food and then put one small piece of food in each pot.
After this, the researcher sat on a chair in a corner of the room, showing no overt
interest in the procedure. The owner was instructed to unleash the dog and then
behave in a neutral way, pretending to read a book provided by the researcher and
completely ignoring the dog until a signal signifying the end of the test was given.
The dog was left free to investigate the test area and take the treats from two pots.
As soon as it started to approach the third pot, playback of a three second growl was
started. Three types of dog growl recordings were used: small dog, medium dog and
large dog growls, and these were allocated on the basis of the size of the dogs being
tested (i.e. small test dog = small dog growl) in order to minimize the scaring eﬀect of
the growl. The growls were chosen because they had been recorded in the context of
food guarding and used in a previous study (Faragó et al., 2010). The dog's behaviour
was then observed for two minutes. At the end of the test, the owner was asked to
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call the dog and put it on its leash. This behavioural test procedure is illustrated in
Figure 4.2.
V1 and V2 = Video cameras; TA = Test Area; S = Screen; B = pots disposition;
L = Loudspeaker; OW = Owner position; R = Researcher position during the test.
Figure 4.1: Test setting.
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A = the dog is shown the food; B = a piece of food is placed into each pot; C = the owner
unleashes the dog; D = the owner is instructed to behave in a neutral way; E = the dog explores
the pots; F= the dog reacts to the growl.
Figure 4.2: Behavioural test procedure.
4.2.3 Behavioural Observation
The video recordings of tests were analyzed using Solomon Coder
(http://solomoncoder.com/). We considered the following behaviours for analysis:
• Latency
Time from release to the approach to the ﬁrst pot (nose within 1cm of pot)
(Latency 1);
Time from the growl/startle reaction to further investigation of pots (Latency
2).
• Durations
Time spent investigating the test area (TTA);
Time spent investigating the pots (TTP);
Time spent investigating the test area before the growl (Expl1);
Time spent investigating the test area after the growl (Expl2).
• Startle reaction scores
Grade 1. The dog responds with minimal, momentary re-orientation of head;
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Grade 2. The dog responds with re-orientation of head, steps back;
Grade 3. The dog responds with re-orientation of head, steps back and takes
a few seconds before coming back to the pot or leaves the test area and does
not return within 2 minutes;
• Food eaten
The number of food pieces eaten by each dog in each test trial.
4.2.4 Data Analysis and Statistics
The ﬁrst observer transcribed the video recordings of both test trials (n = 22) and
scored them using the ethogram on two separate occasions to assess intra-observer
reliability. The recordings from ten of the dogs (ﬁve treatment dogs and ﬁve control
dogs) were randomly selected for their behaviour to be assessed by a second observer
who was blind to the treatment allocation in order to evaluate inter-observer vari-
ability. Spearman's correlation coeﬃcient was used to measure pairwise correlation
among raters.
Data from the video analysis regarding Latency 1, Latency 2, TTP, TTA, Expl1 and
Expl2 were analyzed using SPSS 21. Data were not normally distributed and there-
fore an extension of the Generalized Linear Model (GZLM), Generalized Estimating
Equations (GEE) was used in order to evaluate the results that accommodated cor-
related within-subjects data and allowed comparisons between subjects.
Startle reactions were evaluated for their severity according to the above descriptions.
Eating of food was evaluated by counting the number of food pieces eaten by each
dog during each test trial. Comparison between the control and treatment dogs for
these two metrics was evaluated using Mann-Whitney U test at a given time point
(e.g. either ﬁrst or second test), with Wilcoxon's Matched Pairs Signed-Ranks Test
used to compare within groups between tests (ﬁrst versus second test).
4.3 Results
The behavioural testing of dogs (11 sample dogs and 11 control dogs) ended in
October 2013.
Spearman's coeﬃcient of correlation revealed statistically signiﬁcant positive correl-
ations between intra-observer (n = 22) and inter-observer (n = 10) measurements.
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Intra-observer correlations were positive with r = 0.994 and p < 0.01. Inter-observer
correlations were positive with r = 0.996 and p < 0.01 for all items.
GEE revealed no signiﬁcant diﬀerences in Latency1, Latency 2, TTA, TTP, EXPL1
and EXPL2 between groups in the ﬁrst test trial, before the treatment dogs had
been placed on corticosteroids. In the second test trial, the total time spent invest-
igating the test area (TTA) was signiﬁcantly lower in the group of dogs treated with
corticosteroids (unstandardized coeﬃcient - B = 25.309; χ2(1) = 6.157; p < 0.05)
compared with the control group of dogs.
In the second test trial, the exploration time after the growl of dogs (EXPL2) in the
treatment group was signiﬁcantly lower (B = 26.18; χ2(1) = 6.600; p<0.05) compared
with the same behaviour in the control group of dogs. Latency times (L1 and L2),
time spent investigating the area before the growl (EXPL1) and the time spent in-
vestigating the pots (TTP) were not signiﬁcantly diﬀerent between the two groups (p
> 0.05) [Latency 1: B = -3.573 , χ2(1) = 0.588 , p = 0.443; Latency 2: B = -9.709 ,
χ2(1) = 0.477 , p = 0.490; EXPL1: B = -0.545 ,χ2(1) = 0.310 , p = 0.577; TTP: B
= 5.991 ,χ2(1) = 2.583 , p = 0.108].
Startle reactions in the ﬁrst test trial were present in six dogs from the treatment
group and nine dogs from the control group. Three dogs from the test group were
graded at level 1 (S1) and four at level 2 (S2). Eight dogs from the control group
were scored at level 1 (S1) and one at level 3 (S3).
In the second test trial seven dogs from the treatment group and nine dogs from the
control group produced startle reactions (see Table 4.2). No signiﬁcant diﬀerences
between groups were found as far as startle reactions were concerned (p > 0.05).
In the ﬁrst test trial, seven dogs from the treatment group ate all ﬁve food treats, two
dogs did not eat any food and two dogs ate three pieces. In the ﬁrst test trial, eight
dogs from the control group ate all the food, two dogs did not eat any food and one
dog ate three pieces.
In the second test trial, ﬁve dogs from the treatment group ate all the food, two dogs
ate four pieces, two dogs ate three pieces and two dogs did not eat any food. In the
second test trial, all dogs from the control group ate all the food. A Mann-Whitney
U test revealed a signiﬁcant diﬀerence between groups as far as number of pieces of
food eaten was concerned (z = -2.765; p = 0.028) with control dogs eating more than
treatment dogs.
Wilcoxon's Matched Pairs Signed-Ranks Test revealed no signiﬁcant diﬀerences within
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groups in the two test trials (p > 0.05) for either startle or food consumption.
Dog Trial 1 Startle Trial 2 Startle Trial 1 Trial 2
score score Food eaten Food eaten
1*   5 5
2* S1 S2 5 5
3*   5 5
4*   5 4
5* S2 S3 3 3
6*  S2 5 0
7* S2 S1 0 4
8* S2 S2 0 0
9* S1 S1 3 3
10* S2 S2 5 5
11*   5 5
12 S1 S1 5 5
13   5 5
14 S1 S1 5 5
15 S1 S1 5 5
16 S1 S2 0 5
17 S1 S1 5 5
18 S3 S3 3 5
19   5 5
20 S1 S1 5 5
Table 4.2: Continued on next page
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Dog Trial 1 Startle Trial 2 Startle Trial 1 Trial 2
score score Food eaten Food eaten
21 S1 S1 0 5
22 S1 S1 5 5
* = dogs receiving treatment with corticosteroids in the second test trial;
Trial 1 Food = pieces of food eaten in trial 1; Trial 2 Food = pieces of food eaten in trial 2;
S1 = The dog responds with minimal, momentary re-orientation of head; S2 = The dog
responds with re-orientation of head, steps back; S3 = The dog responds with
re-orientation of head, steps back and it takes a few secondsbefore coming back to the pot
or never comes back.
Table 4.2: Startle reactions and pieces of food eaten by dogs in the two test trials.
4.4 Discussion
The results reported here from both studies are consistent with the preliminary
ﬁndings described in Chapter 2 and the results of the survey reported in Chapter 3.
Behavioural tests were included alongside the survey in order to provide, for the ﬁrst
time, objective and directly observed behavioural evidence of the eﬀect of corticos-
teroid therapy on dog behaviour. Because our initial ﬁndings were interpreted to
indicate that dogs on corticosteroid therapy were more avoidant, the test was de-
signed to stimulate exploration of the test area with minimal challenges. We designed
the test in a way that would have minimized the threat for the animal and asked the
owner to be present in order to provide a safe point of reference for the dog. The
owners were informed that they could interrupt the test in any moment if they felt
that their dog was too distressed and this was a further guarantee of preservation of
the animal's welfare. The introduction of a surprising, potentially negative stimulus
in the form of the growl, had the purpose of testing both reactivity and avoidance
tendency. Decreases in exploratory behaviour have also been associated with negative
aﬀective states (Cavigelli et al., 2007; van Dijken, 1992; Rygula et al., 2013), and this
is likely to be the product of a negative cognitive bias associated with negative aﬀect:
when in a negative aﬀective state the desire to seek new information is reduced and
so the animal might avoid rather than explore open areas and novel stimuli (Burman
et al., 2011; Harding et al., 2004). In the behavioural tests, types of corticosteroids
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and drug doses were very similar within the treatment group. Cytokines involved in
the immune response might explain behavioural eﬀects (Anisman and Merali, 1999),
such as decreased exploratory behaviour and increased avoidance reported by owners
in the survey, but this would not explain the results obtained in the behavioural tests.
Some dogs suﬀered from allergic dermatological conditions, that have been shown to
induce the production of cytokines in diﬀerent species including dogs (Gonzales et al.,
2013), when they were tested oﬀ treatment and no signiﬁcant diﬀerences were found
between treatment and control group dogs at this time; rather a signiﬁcant decrease in
exploratory behaviour between groups was observed only when treatment dogs were
on corticosteroids.
Unlike the dogs receiving corticosteroid treatment, control dogs did not show a signi-
ﬁcant change in their exploratory behaviour, when receiving treatment. Comparisons
between groups showed that the exploratory behaviour was lower when dogs were on
corticosteroids. In laboratory animals, the administration of corticosteroids after a
training session seemed to inﬂuence contextual fear memories and hippocampal long
term potentiation (LTP), suggesting that they may enhance contextual fear memory
consolidation via enhancing hippocampal LTP (Abrari et al., 2009). The interac-
tion between corticosteroids, memory and emotional arousal has been investigated in
many studies (Roozendaal et al., 2006), showing that glucocorticoids interact with
the noradrenergic system in brainstem noradrenergic cell groups that project to the
basolateral amygdala. This may provide the neurological mechanism for the changes
seen in the dogs on corticosteroids during their second visit to the experimental set
up.
In the behavioural test, we found dogs on corticosteroids ate signiﬁcantly less food
compared with the control group, despite increased appetite being a well recognised
side-eﬀect of corticosteroid therapy (Sousa, 2009).
In the behavioural tests no signiﬁcant diﬀerences in startle reactions were found in
dogs treated with corticosteroids (p > 0.05). However, in the questionnaire study, dog
owners reported an increase in their dogs' startling tendency when on corticosteroids
and the startle response has been used as a speciﬁc response to assess a changed negat-
ive aﬀective state in both laboratory animals and human beings (Angrilli et al., 1996).
This apparent discrepancy can be explained because startle responses have diﬀerent
motor features according to whether they are triggered by emotional or voluntary
responses (Baschnagel et al., 2007; Cook et al., 1992; Davis et al., 1982; Dreissen et
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al., 2012; Koch, 1999; Lang et al., 1990), and it may be that the two contexts focus
on diﬀerent types of startle. The setting of the behavioural test involved two types
of salient stimuli, the food and the sound, in a framework that was supposed to be
neutral. However, the size of startle reﬂexes might have been inﬂuenced not only by
the underlying aﬀective state of dogs but also by other ongoing attentional processes
associated with the presence of food, which might diﬀer between the two groups. The
corticosteroids-related increase in appetite as previously discussed in chapter one and
three (Sousa, 2009; McDonald and Langston, 1995), might have attenuated the startle
response in the context of response to a growl while exploring food, since the animal
was focused on eating rather than on potential threats. By contrast the results about
startle reactions in the survey may reﬂect increases at other times, such as when the
animal is already anxious about a potential threat.
As discussed in chapter one and three, subjective evaluation of dog behaviour might
be biased but there is also an important potential advantage associated with gath-
ering information about dog behaviour from owners associated with their experience
in a range of contexts, since they know their own animals best (Wemelsfelder, 1997;
Wiseman et al., 2001). It is therefore important to support the ﬁndings from such
surveys by showing convergent validity with more objective measures, as reported
here. We decided to build a behavioural test in order to have more objective evidence
of behavioural side eﬀects of exogenous corticosteroids and, although the results of
behavioural tests might appear to have a small magnitude compared with what is
described in the literature for human patients, the decrease in exploratory behaviour
has been interpreted as a sign of negative internal states of dogs in treatment. The
study was designed in such a way that it did not endanger the dogs' welfare and there-
fore the presented stimuli were intended neither to scare nor to threaten the animals.
In a real situation, a negatively motivated animal, in the presence of stressors of
high magnitude (in general and compared with the ones proposed in the behavioural
test), might show a much more evident response such as aggression or overtly fearful
reaction. Direct testing of dogs in the behavioural test may be more reliable than
indirect owner-based behaviour assessments, but is more labour intensive, especially
when relying on clinical cases. This convergence, together with a consistency at the
theoretical level, indicate that these results are robust and the eﬀects reliable.
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4.5 Conclusion
In this chapter, the direct testing of dogs showed that dogs on cortiocosteroids were
less explorative compared with control dogs. Overall, these results indicated that in
pet dogs, corticosteroid treatment at therapeutic doses can bias cognition and change
behaviour. Therapeutic intervention with these drugs appears to increase sensitivity
towards aversion and these ﬁndings are consistent with the theoretical level and the
ﬁnding of the previous surveys presented in chapter two and three, indicating that
these results are robust and the eﬀects reliable.
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In this chapter the behaviour of 345 dogs, collected within the behavi-
oural clinic caseload of the author between February 2012 and November
2014, were analysed. The goal of this retrospective survey was to invest-
igate possible relationships between the aﬀective states associated with
the behavioural complaint of dogs and their previous history of treatment
with corticosteroids drugs. Results showed that a history of corticoster-
oid treatment was a signiﬁcant predictor of a range of behaviour problems
associated with negative aﬀective state.
5.1 Introduction
Throughout previous parts of this thesis, it has been highlighted how corticoster-
oid therapies might inﬂuence the behaviour of both humans and non-human animals.
The results so far are consistent with the psychiatric side eﬀects of corticosteroids
reported in the human literature, but have focused on mentally healthy individuals.
Although the results of the behavioural tests in the previous chapter might appear
to indicate a small eﬀect compared to what is described in the literature for human
patients, the decrease in exploratory behaviour is potentially a sign of a negative in-
ternal state in dogs receiving treatment. It should also be noted that the study was
designed in such a way so that it did not endanger the dogs' welfare and therefore
the stimuli used were intended neither to scare nor to threaten the animals, but to
be ambiguously negative. In a real-world situation a negatively biased animal, in
the presence of other stressors of higher magnitude or load might show a much more
problematic response such as aggression or an overtly fearful reaction. Given these
ﬁndings, it is worth asking the questions: What proportion of dogs presented for
diﬀerent behaviour problems have had a history of treatment with corticosteroids?
and Do corticosteroids appear to increase the risk of any complaints associated with
sensitivity to aversion, e.g. fears and anxieties?.
From the human psychiatric literature, we know that the negative psychological side
eﬀects of corticosteroid therapies can be more evident in patients that already have
some psychiatric disturbance (Fardet et al., 2012; Kenna et al., 2011; Sirois, 2003;
Ularntinon et al., 2010). But it is not known what proportion of dogs with behaviour
problems have taken corticosteroid drugs in the past. Such information will provide
a more complete picture of the importance of the possible behavioural side eﬀects of
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these drugs, in particular in dogs predisposed to behaviour disturbance.
A study in humans conducted in the UK in 2012, described in Chapter 1 (Fardet et
al., 2012), showed how psychiatric disturbances in human patients were signiﬁcantly
related to corticosteroid treatments. Data were extrapolated from The Health Im-
provement Network (THIN) database between 1990 and 2008. THIN contains data
about adult human patients registered with general practices. Patients with histories
of corticosteroid treatments were compared with patients who did not receive such
prescriptions. Human patients older than 18 years who had received at least one cor-
ticosteroid prescription were identiﬁed as exposed to corticosteroids (n. 372,696) and
they were compared with two groups of patients that did not receive corticosteroids.
The ﬁrst group of unexposed patients was a randomly selected sample of patients that
did not receive corticosteroid prescriptions (n. 1,224,984), the second group of unex-
posed patients did not receive corticosteroid prescription too, but had been diagnosed
with the same medical diseases as the exposed patients (n. 229,766). They selected
up to four unexposed individuals from each unexposed group to compare with an
individual of the exposed group. They found that patients with a history of corticos-
teroid prescription had an increased risk of suicidal behaviours and neuropsychiatric
disorders, mainly depression, mania and panic disorders. The distinction between
corticosteroid eﬀects and the severity of diseases is one of the main bias to overcome
and in this study it was found that patients with asthma, polymyalgia rheumatica and
giant cell arteritis who received corticosteroid treatments were at lower risk to develop
neuropsychiatric disorders compared with patients with other diseases. The authors'
hypothesis for the lower incidence of neuropsychiatric disorders in asthma patients was
that they might have been chronically exposed to low doses of inhaled corticosteroids
in the past and this might have somehow protected them, but no other hypothesis was
proposed for the other two conditions. Randomized placebo controlled studies should
be performed in order to distinguish the impact of the type and severity of a disease
from the eﬀects of corticosteroid treatment in the onset of neuropsychiatric disorders,
but the design of these studies would be ethically unacceptable (Fardet et al., 2012).
Gathering similar data in terms of diagnostic standardization and size from veterin-
ary clinics is logistically impossible, but the use of corticosteroid drugs in veterinary
practice has been investigated through a survey conducted of three UK veterinary
practices and a wide variation in prescribing patterns was detected. It was found that
14.55% of dog consultations resulted in systemic corticosteroid therapy (O'Neill et al.,
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2012). Despite this considerable percentage of prescriptions and considering the large
amount of literature in other species that indicates the possible inﬂuence of corticost-
eroid drugs on behaviour, no retrospective analysis has ever been done to investigate
possible relationships between corticosteroid therapies and behavioural problems in
dogs. The retrospective analysis of cases presented in this chapter, for the ﬁrst time,
investigates the possible implications of history of treatment with corticosteroids in
a population of dog behaviour patients. The data were collected from February 2012
to November 2014. A sample of 345 dogs between 1 and 10 years of age, presented
for behavioural problems, was selected from the database of the author's professional
caseload and analyzed. The goals were to gather information about the proportion
of dogs with behaviour problems who had a history of corticosteroid therapies and
to investigate possible relationships with behaviour problems and the aﬀective states
associated with these problems. The relationship between history of corticosteroid
therapy and the prescription of psychoactive drugs was also investigated, because this
might be related to the severity of behaviour problems (Dodman et al., 1996; King et
al., 2000; Marder, 1991; Pineda et al., 2014).
5.2 Material and Methods
5.2.1 Sample
The ﬁles of 345 dogs aged between 1 and 10 years that had presented for be-
havioural problems were selected from among the dog caseload of the author's own
veterinary behavioural clinic based in the north of Italy. This age range was selected
to decrease the probability that reported behaviour problems were due to manage-
ment problems in puppies or health conditions due to aging in older dogs. The data
were collected from February 2012 to November 2014.
5.2.2 Investigated items
Each case ﬁle was analyzed and the following items of data were extracted for the
purpose of this investigation:
1. Age of dog;
2. Gender and reproductive status of dog;
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3. Breed type divided into the number of Federation Cinologique International
Group (FCI: see Appendix F) for all the recognized breeds. Pitbull type dogs
were coded as Pitbull, with crossbreed dogs coded as crossbreed;
4. Treatment and medical history of dogs treated with corticosteroid drugs;
5. Treatment and medical history of dogs treated with other drugs;
6. Presence of aggression towards people;
7. Types of bites (severe or not severe);
8. Behaviour problems other than aggression;
9. Prescription of psychoactive drugs to address the behavioural complaint;
10. Aﬀective state (see below for details about deﬁnition of positive or negative
aﬀective state).
The source of the above information was both the Dog Behavioural History Form (See
Appendix D) that was completed for every dog at the time of the ﬁrst consultation,
and the therapist's own diagnostic and therapeutic notes.
For history of treatment with corticosteroids only systemic treatments that lasted
more than one week were taken into consideration, in order to avoid single treatments
for emergency interventions, since the eﬀects of longer term administration were the
focus of interest. Data about treatment with corticosteroid drugs was extrapolated
from the Dog Behavioural History Form completed during behavioural consultation
in the section concerning the medical history of patient. The exact administered dose
was not always recalled by owners and an inclusion requirement for those subjects
recorded as received treatment with corticosteroids was that the owner could recall
the name of the product, the reason why it was prescribed and the length of the
therapy in terms of more than a week or less than a week. As far as the item history
of treatment with other drugs (Item 5) was concerned, reported treatments were
considered as for treatment with corticosteroids.
As far as the item types of bites, bites that required medical intervention were con-
sidered as severe bites. Negative and positive aﬀective states (Item 10) were coded
(see below) on the basis of the responses of the owners to questions included in the
Dog Behavioural History Form (Appendix D) speciﬁcally in the section entitled Your
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dog's personality in conjunction with the evaluation of the veterinary behaviourist
who held the consultation. As far as the information extracted from the Dog Behavi-
oural History Form was concerned, owners had to answer yes or no to the following
questions:
1. Do you consider your dog as aggressive in most situations?
2. Do you think that your dog is often or always nervous or fearful in the presence
of unknown situations or stimuli (sounds, new stimuli, unknown people or dogs)?
3. Do you consider your dog largely enthusiastic and excited?
4. Do you think that your dog is sociable in general?
5. Do you consider your dog conﬁdent?
To be coded as having a positive aﬀective state, the owner had to answer No to
questions one and two and Yes to at least two of the last three questions. To be
coded as having a negative aﬀective states the owner had to answer Yes to at least
one of the ﬁrst two questions. The ﬁnal deﬁnition of aﬀective state as positive or
negative in connection with the type of behaviour problem was established through
the behavioural consultation and based on the description of the problem behaviour
and its context as well as the direct observation of the dog's behaviour in the clinical
context by the behaviour clinician.
Positive aﬀective state was attributed to dogs with problem behaviours that were
most likely to be related to positive emotions but perceived as problematic and/or
exaggerated by their owners, for example:
• Excessive play behaviour;
• Excessive activity such as running, digging, stealing objects;
• Excessive attention seeking behaviours, such as jumping on people, barking for
attention.
Negative aﬀective state was attributed to dogs presenting with behaviours that
were more likely to be related to negative emotions such as fear, anxiety and frustra-
tion. For example:
• Fear, phobia and anxiety;
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• Avoidant or assertive displays of aggressive behaviours;
• Repetitive conﬂict behaviours.
5.2.3 Statistics
Analysis was performed using SPSS 21, with summary descriptive statistics cal-
culated initially.
Possible relationships between dogs that received treatment with corticosteroids versus
dogs that received a treatment with other drugs diﬀerent from corticosteroids and:
• Positive or negative aﬀective states;
• Aggression towards people;
• Other complained about behaviours diﬀerent from aggression;
• Occurrence of severe bites;
• Prescription of psychoactive drugs
were assessed using a Pearson's Chi Squared test.
Regression analysis was then performed in order to hierarchically evaluate the best
predictors of the investigated items (p < 0.05).
5.3 Results
From the initial sample of 345 dogs selected from the author's caseload database
containing completely ﬁlled Dog Behavioural Forms, 2 dogs were excluded because
of incomplete reports about medical history and treatment and a ﬁnal sample of 343
was used for analysis.
Gender and reproductive state of dogs are shown in Table 5.1.
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Frequency n.(%)
Gender and Total No cortico On cortico
reproductive state group group
entire male 177 (51.6) 147 (51) 30 (54.5)
entire female 56 (16.3) 49 (17) 7 (12.7)
castrated male 35 (10.2) 29 (10.1) 6 (10.9)
spayed female 75 (21.9) 63 (21.9) 12 (21.8)
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.1: Gender and reproductive state distribution within the sample of 343 dogs.
Within the sample of 343 dogs, the age distribution of dogs is shown in Table 5.2.
Frequency n.(%)
Age Total No cortico On cortico
group group
1-2 years 195 (56.9) 179 (62.2) 16 (29.1)
3-4 years 87 (25.4) 70 (24.3) 17 (30.9)
5-6 years 34 (9.3) 24 (8.3) 8 (14.5)
7-8 years 26 (7.6) 14 (4.9) 12 (21.8)
8-9 years 3 (0.9) 1 (0.3) 2 (3.6)
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.2: Age distribution within the sample of 343 dogs.
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Breed distribution within the sample of 343 dogs is shown in Table 5.3:
Frequency n. (%)
Breed/type Total No cortico On cortico
group group group
FCI Group 1 45 (13.1) 34 (11.8) 11 (20.0)
Sheepdogs and
Cattledogs
FCI Group 2 43 (12.5) 32 (11.1) 11 (20.0)
Pinscher and Schnauzer/
Molossoid and Swiss
Mountain and Cattledogs
FCI Group 3 23 (6.7) 17 (5.9) 6 (10.9)
Terrier
FCI Group 4 8 (2.3) 6 (2.1) 2 (3.6)
Dachshunds
FCI Group 5 10 (2.9) 10 (3.5) 0
Spitz and primitive types
FCI Group 6 8 (2.3) 8 (2.8) 0
Scent hounds and related
breeds
FCI Group 7 9 (2.6) 8 (2.8) 1 (1.8)
Pointing Dogs
FCI Group 8 18 (5.2) 13 (4.5) 5 (9.1)
Retrievers/Flushing
Dogs/Water Dogs
FCI Group 9 29 (8.5) 25 (8.7) 4 (7.3)
Companion and Toy Dogs
FCI Group 10 7 (2.0) 7 (2.4) 0
Sighthounds
Crossbreed 126 (36.7) 113 (39.2) 13 (23.6)
Table 5.3: Continued on next page
86
Chapter 5. Corticosteroid Drugs And Dog Behaviour:
What Clinical Experience Can Tell Us
Frequency n. (%)
Breed/type Total No cortico On cortico
group group group
Pitbull 17 (5.0) 15 (5.2) 2 (3.6)
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.3: Breed distribution within the sample of 343 dogs. (For description of FCI
groups see also Appendix F).
Within the sample of 343 dogs, 209 (73.8%) had a history of treatment with
drugs other than corticosteroids and 55 (16.0%) had a history of treatment with
corticosteroid drugs. Forty-eight of the 55 dogs that had a history of treatment with
corticosteroids also had a history of treatment with other drugs. In Table 5.4, the
types of drug treatments other than corticosteroid in the two groups of dogs with and
without a history of treatment with corticosteroid drugs are shown.
Drug therapies have been divided into four main categories:
• Antibiotics and antifungal drugs;
• Antacid drugs;
• Non Steroidal Anti-inﬂammatory drugs (NSAIDs);
• Other drugs.
Frequency n.(%)
TYPE OF DRUG No cortico On cortico
group (n.209) group (n.55)
antibiotics and antifungal drugs 162 (78.3) 32 (66.7)
antacid drugs 18 (8.7) 12 (25.0)
NSAIDS 17 (8.2) 3 (6.3)
Others 10 (4.8) 1 (2.1)
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.4: Types of drug treatments diﬀerent from corticosteroids in the two groups
of dogs.
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Reported medical problems were divided into 5 main groups:
• Dermatological;
• Orthopaedic;
• Gastroenteric;
• Respiratory;
• Others.
In Others were included urinary and reproductive problems, cardiovascular and
hematological diseases and neurological diseases.
Medical problems reported in dogs treated with corticosteroid drugs and dogs treated
with drugs other than corticosteroids are show in table 5.5.
Frequency n.(%)
Medical Problems No cortico On cortico
group group
Dermatological 53 (18.4) 36 (65.5)
Orthopaedic 15 (5.2) 12 (21.8)
Gastrointestinal 74 (25.7) 5 (9.1)
Respiratory 54 (18.8) 1 (1.8)
Others 33 (11.5) 1 (1.8)
No medical problems with 79 (27.2) 0
more than 1 week therapy
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.5: Medical problems in dogs a history of treatment with corticosteroids. The
sum of percentages is not 100% because of multiple medical problems.
Within the sample of 343 dogs the main behavioural complaints are listed in Table
5.6. Speciﬁc conditions had to be pooled into broader categories as described below.
All forms of aggressive behaviour towards people with the exception of that associated
with play, were pooled.
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Aggression towards people included both aggression towards family members and ag-
gression towards strangers.
Aggression towards other dogs included both aggression between dogs living together
in the same family and dogs that were aggressive towards unfamiliar dogs.
Predation (predatory aggression) was complained about for just one dog and it was
referred for severe predatory behaviour towards cats.
Separation problems refers to all problem behaviours that happened in the absence
of owners/when the dog was left alone that were associated with distress.
House-soiling problems includes both urine marking and forms of inappropriate elim-
ination and housetraining problems.
Phobias refers to fear of speciﬁc situations (e.g. thunderstorm, wind, unknown envir-
onments), social fear (fear of people, fear of other dogs) and fear of sounds.
Repetitive behaviours includes compulsive licking, tail chasing and tail biting.
Excessive barking refers to problematic barking in diﬀerent situations.
Hyperactivity includes excessive play and play biting, excessive attention seeking be-
haviours, jumping on people, destructiveness and excessive excitement in diﬀerent
situations.
Other behaviour problems includes cases involving a tendency to run away from the
property, digging and decreased activity levels.
Aggression towards people was the most common complaint relating to 43.1% of dogs
(148). Multiple behaviour problems were presented in 66.5% of the total sample of
dogs (228). Within the sample of dogs in treatment with corticosteroids, 51% presen-
ted multiple behaviour problems (28). Results are shown in Table 5.6.
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Behaviour Total frequency n. (%)
Aggression towards people 148 (43.1)
Aggression towards other dogs 59 (17.2)
Predation 1 (0.3)
Separation problems 47 (13.7)
Housesoiling problems 22 (6.4)
Phobias 91 (26.2)
Repetitive behaviours 11 (3.2)
Excessive barking 43 (12.5)
Hyperactivity 90 (25.9)
Other 37 (10.7)
Table 5.6: Categories of presenting complaint; the sum of percentages is not 100%
because of multiple behaviour problems.
Psychoactive drugs were prescribed to 31.2% of the sample (107 dogs). Among
the 55 dogs with a history of corticosteroid treatments psychoactive drugs were pre-
scribed in the 43.6% of cases (24 dogs). Among the 290 dogs without any history
of corticosteroid drugs psychoactive drugs were prescribed in the 28.4% of cases (83
dogs).
The distribution of drugs used is shown in Table 5.7.
Frequency n.(%)
Prescribed drug Total No cortico On cortico
group group
Fluoxetine 69 (20.1) 50 (17.4) 19 (34.5)
Fluvoxamine 9 (2.6) 9 (3.1) 
Paroxetine 11 (3.2) 10 (3.5) 1 (1.8)
Selegiline 9 (2.6) 8 (2.8) 1 (1.8)
Clomipramine 8 (2.3) 5 (1.7) 3 (5.5)
Carbamazepine 1 (0.3) 1 (0.3) 
No cortico group= dogs that did not have an history of treatment with corticosteroid drugs.
On cortico group = dogs had a history of treatment with corticosteroid drugs.
Table 5.7: Psychoactive drugs prescribed within the whole sample (n = 343 dogs).
The possible relationships between corticosteroid therapies, behaviour problems,
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aﬀective states, incidence of severe bites and prescription of psychoactive drugs are
shown in Table 5.8. These relationships were also investigated taking into account
only dogs that had a history of medical problems that required more than one week
of therapy (n = 264) using Chi Square Tests.
Within this sample (n = 264), dogs with a history of corticosteroids were signiﬁcantly
more likely to be in negative aﬀective states (X(1) = 10.970, p < 0.001), to present
aggression towards people (X(1) = 5.527, p = 0.0014) to be prescribed psychoactive
drugs with (X(1) = 3.588, p = 0.043), but signiﬁcantly less likely to present problems
coded as hyperactivity (X(1) = 9.099, p < 0.001). See also table E.22 in Appendix
E.
n.(%)
Patient Factors No Cortico On Cortico Pearson Chi p
group group Square X(1) value
Positive aﬀective state 51 (17.7) 0
Negative aﬀective state 237 (82.3) 55 (100.0) 11.441 < 0.001
Aggression towards 117 (40.6) 31 (56.4) 4.663 0.023
people
Hyperactivity 85 (29.5) 4 (7.3) 11.889 < 0.001
Aggression towards 50 (17.4) 9 (16.4) 0.032 0.518
other dogs
Separation problems 38 (13.2) 9 (16.4) 0.330 0.392
Phobias 77 (26.7) 13 (23.6) 0.229 0.384
Excessive barking 38 (13.2) 5 (9.1) 0.709 0.276
History of severe bites 64 (22.2) 16 (29.1) 1.218 0.175
Psychoactive drug 83 (28.8) 24 (43.6) 4.724 0.024
prescription
No cortico group = group of dogs without a history of corticosteroid treatment;
On cortico group = group of dogs with a history of corticosteroid treatment.
Table 5.8: Relationship between history of treatment with corticosteroids and
negative aﬀective state, reported behaviour problems, occurrence of sever bites and
the prescription of psychoactive drugs in the whole sample (n. 343).
The predictive value of age, gender and type of medical problems in the onset of
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positive or negative aﬀective states was investigated in the group of dogs without a
history of corticosteroid drugs but with a history of medical problems (n = 209) by
means of binary logistic regression using forward analysis. Age was found to be the
only predictor, with dogs between one and two year of age 3.167 times more likely to
be in positive aﬀective states than other ages (B = 1.153; p < 0.01; exp(B) = 3.167;
C.I: 95% [1.44 - 6.96]). The percent of cases for which aﬀective state was correctly
predicted was 82.8.
The role of corticosteroid treatment history, medical condition, age and gender of
dogs on the main eﬀects of aggression towards people, hyperactivity and prescription
of psychoactive drugs were investigated by means of binary logistic regression using
forward analysis .
The best predictor for aggression towards people was gender, with males 3.49 times
more likely to be aggressive compared with gender other than male (B = 1,250; Exp(B)
= 3.489; p < 0.01; C.I. : 95% [2.10 - 5.79]) and castrated male dogs 2.8 times more
likely to show aggression compared with gender other than castrated male (B = 1.049;
Exp(B) = 2.828; p = 0.011; C.I. : 95% [1.27 - 6.28]). Age and gastrointestinal condi-
tions showed a signiﬁcant relationship with aggression towards people: dogs between
one and two years were less likely to be aggressive towards people (B = -0.752; Exp(B)
= 0.471; p < 0.01; C.I. : 95% [0.312 - 0.802]) as were dogs with history of gastrointest-
inal conditions (B = -0.809; Exp(B) = 0.445; p < 0.01; C.I. : 95% [0.250 - 0.792]).
The percent of cases for which the aggression towards people was correctly predicted
was 64.7.
Best predictors for hyperactivity were age and corticosteroid treatment: dogs between
one and two year of age were 4.27 times more prone to show hyperactivity compare
with other ages (B = 1.193; Exp(B) = 3.298; p < 0.01; C.I. : 95% [1.78 - 6.12]).
By contrast, dogs treated with corticosteroids were less prone to hyperactivity (B =
-1.455; Exp(B) = 0.233; p < 0.01; C.I. : 95% [0.08 - 0.68]). The percent of cases for
which hyperactivity was correctly predicted was 74.1.
Best predictor for the prescription of psychoactive drugs were gender and age: cas-
trated males were 2.49 times more likely to be prescribed psychoactive drugs compared
with gender other than castrated male (B = 0.911; Exp(B) = 2.486; p = 0.014; C.I.:
95% [1.20 - 5.14]). Dogs between one and two years of age were less likely to receive
prescriptions for psychoactive drugs compared with other ages (B = -0.730; Exp(B) =
0.482; p < 0.01; C.I. : 95% [0.30 - 0.77]). The percent of cases for which prescription
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of psychoactive drugs was correctly predicted was 70.6.
5.4 Discussion
The purpose of this ﬁnal study was to examine the evidence of the eﬀects of cor-
ticosteroids in a clinical context with a view to highlighting the importance of giving
correct behavioural advice to owners when corticosteroids have to be prescribed. This
work, on its own, is not suﬃcient to demonstrate causal links between corticosteroid
treatment and a particular behavioural problem.
Behavioural diagnoses are often diﬃcult to deﬁne and many dogs with behavioural
disturbances are diagnosed with multiple issues, many of which are linked to anxiety,
or a negative cognitive bias (Adams and Clark, 1989; Wells and Hepper, 2000).
Within the sample of 343 dogs referred for behaviour problems in this particular case-
load, 16% had a history of previous treatments with corticosteroids.
The main ﬁnding of this retrospective case study was that history of corticosteroid
treatment is signiﬁcantly related with negative aﬀective states and is a negative pre-
dictor for problems of hyperactivity.
Age was another signiﬁcant predictor for aﬀective states with dogs between one-two
year of age being more probably in positive aﬀective states than older dogs. Age was
also a signiﬁcant predictor for hyperactivity and younger dogs were more likely to be
presented for hyperactivity problems. Again, younger dogs were less likely to show
aggression towards people and to be the target for the prescription of psychoactive
drugs. On the contrary, male dogs were more likely to show aggression towards people
and this result is consistent with some of the literature data (Fatjo et al., 2007; Guy
et al., 2001; Overall and Love, 2011; Overall, 1997).
The history of medical problems was not a signiﬁcant predictor for behaviour prob-
lems with the exception of gastrointestinal problems that was linked with a lower
tendency to show aggression towards people.
These results must be cautiously considered, but they provide a useful contribution to
the picture of possible behavioural side eﬀects of corticosteroids and a starting point
for future investigation.
The small sample size and the diﬀerences in the two groups, with and without his-
tory of corticosteroid drug treatments, are obvious limitations, but it is worth noting
that medical history was not revealed to have a strong eﬀect in this study. Medical
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problems and ages in the two groups are very diﬀerent: in the group of dogs with a
history of corticosteroid treatment dermatological and orthopedic problems are over-
represented compared with the other group which is perhaps not surprising given
the indications for these drugs; gastrointestinal conditions are most numerous in the
group of dogs without a history of corticosteroid drugs and perhaps unsurprisingly
least numerous in the other group, since they would rarely be indicated for such prob-
lems. Most dogs in the no history of corticosteroid treatment group were less than
two years of age, while this age range was much less represented in the history of
corticosteroid treatment group. The eﬀects of medical histories cannot be reliably
evaluated here due to the low number of cases and although the eﬀect of pain and
discomfort on dog behaviour is an important issue (Barcelos et al., 2015; Camps et
al., 2015) and medical problems are important sources of distress (Mills et al., 2014;
Notari, 2009), no medical problem was a reliable predictor for negative aﬀective states.
As stated above, the main ﬁnding of this investigation was that dogs presented for
behaviour problems with a history of corticosteroids treatment appear to suﬀer more
from problems associated with negative aﬀect. The ﬁnding of a signiﬁcant relation-
ship between negative aﬀect and corticosteroid treatment suggests that exposure to
corticosteroids might increase dogs' sensitivity to environmental and social stressors
increasing the risk of problem behaviour as a consequence compared with dogs without
a history of corticosteroid treatment. Given that the sample of dogs with a history of
corticosteroid drugs was quite small (55 dogs), random eﬀects have a greater chance
of biasing the results, and so this study should not be considered deﬁnitive. Der-
matological conditions were over-represented in the group of dogs with a history of
corticosteroid drugs (65.5%), compared with the other group of dogs (18.4%) and,
even though dermatological condition was not found to be a predictor for aﬀective
state, a combined eﬀect of drugs and disease on negative aﬀective states cannot be
excluded. A matched control study would provide stronger evidence.
It has been shown that pruritus might be exacerbated by psychological disorders in
humans but also that pruritus can worsen behaviour (Shaw et al., 2007). The issue of
the inﬂuence of pruritus as a main sign of dermatological conditions was investigated
by Klink et al. and they that found no relationship between pruritus and aggression
or anxiety, but they did ﬁnd a signiﬁcant increase in reactivity to potentially fearful
stimuli in dogs treated with corticosteroid drugs (Klinck et al., 2008). This reported
increase in reactivity to negative stimuli seems to be consistent with our ﬁnding of an
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increase in negative aﬀective states due to corticosteroid treatment.
Corticosteroids and age were signiﬁcant predictors for problems of hyperactivity. Dogs
with a history of corticosteroid treatment were signiﬁcantly less likely to be hyper-
active, and, given the deﬁnition of hyperactivity used in this study, this result might
be consistent with the decreased tendency to play shown in the survey described in
Chapter 3. Furthermore, in the preliminary survey (Chapter 2) two owners of dogs
that received treatments with corticosteroids reported a decrease in their dogs' activ-
ity levels. The item Hyperactivity included a list of problematic behaviours like play
and play biting, excessive attention seeking behaviours, jumping on people, destruct-
iveness, excessive excitement in diﬀerent situations, all of which might be considered
to reﬂect positive aﬀect (reward seeking). The term did not imply a diagnosis of
pathological hyperactivity associated with impaired attention as in humans beings
(Blum et al., 2008; Wright et al., 2012).
In the caseload presented here, 16% of dogs had a history of treatment with corticost-
eroid drugs. A slightly lower percentage of corticosteroid prescriptions in pet dogs was
reported in general veterinary practice for diﬀerent diagnosis (14.55%) in the study
of O'Neil et al. (O'Neill et al., 2012). In dermatological conditions 20% of dogs have
been reported to receive a prescription of corticosteroid drugs (Hill et al., 2006) and
in our caseload the percentage of dogs with a history of dermatological conditions,
corticosteroid drug prescription was more common (40.4%). However, as there was
not a control group from general veterinary practice included in this study, it was
not possible to establish if dogs treated with corticosteroids were over represented
among subjects with behavioural problems, although these percentages indicate that
the issue is an important one.
The results concerning aﬀective states are consistent with previous ﬁndings and it is
now accepted that animals can feel a range of negative and positive emotions (Boissy
et al., 2007; Reimert et al., 2013). More and more attention has been given to the
issue of how aﬀective states of animals may inﬂuence behaviour and learning (Bento-
sela et al., 2009; Burman et al., 2011), but their assessment in animals is still diﬃcult
to deﬁne, mainly because they rise from subjective experience. In human beings this
assessment relies mostly on verbal communication while in animals it has to rely on
the observation of the individual, assuming that animal behaviour is the result of the
acquisition and assessment of environmental information and the elaboration of an
observable response. It has been shown that fearful and anxious animals tend to show
95
Chapter 5. Corticosteroid Drugs And Dog Behaviour:
What Clinical Experience Can Tell Us
behaviours that can be interpreted as motivated by a decrease in their anticipation
of positive events when presented with ambiguous stimuli. This kind of pessimistic
perspective has been called a negative cognitive bias or judgement bias (Paul et
al., 2005). Laboratory animals housed in deprived or unpredictable environments
showed a judgment bias and were less likely to anticipate a reward  and act con-
sequently  when presented with ambiguous stimuli (Boissy et al., 2007; Burman et
al., 2011; Mellor, 2012; Starling et al., 2013). It has also been shown that dogs with
separation anxiety expressed a pessimistic judgment bias that resolves with treatment
(Karagiannis et al., 2015; Mendl et al., 2010). In this retrospective study, no speciﬁc
behaviour problem was found to be linked with a history of corticosteroid drugs while
in the surveys carried out in the previous part of this research (see Chapter 2 and 3),
owners reported behavioural changes in speciﬁc areas of their dogs' behaviour.
Nevertheless these results deserve attention because a higher tendency to be in neg-
ative aﬀective states might be particularly important for individual dogs that already
have the tendency to show avoidance or aggressive behaviours.
Systemic corticosteroid prescription in pet dogs seems to be determined more by the
clinical experience and personal opinion of vets (O'Neill et al., 2012) and greater
recognition of the widespread risk of possible drawbacks from these drugs, including
the conditions identiﬁed in this research, might contribute to improved evidence-based
guidance for the therapeutic use of these drugs to minimize these risks (see the Check
list for veterinary practitioners in Appendix F).
5.5 Conclusion
The present chapter has been introduced in order to provide a clinical context to
the preceding studies and to emphasize the importance of considering the issue of
possible behavioural eﬀects of corticosteroid treatments.
The data from this work, along with the results of the surveys and the behavioural
tests, strongly suggest that advice should be given when these drugs are prescribed,
in particular when dogs show or have shown behaviour problems.
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Behavioural adverse reactions to corticosteroid treatment in dogs were apparent
in each of the studies in this thesis. Exploring the eﬀects on behaviour of important
players in stress responses such as corticosteroids was and is not an easy task even
in human medicine. In the human ﬁeld there are a large number of case reports and
studies reported on the possible psychiatric side eﬀects of these drugs, but no similar
data have been available in veterinary medicine, prior to the onset of this work.
The ﬁrst investigation, described in Chapter two, was an attempt to discover what
kind of behaviours might change under corticosteroid therapy in dogs, and owners re-
ported several changes that were consistent with the literature. The more structured
survey that was carried out building on the results of the ﬁrst preliminary investigation
(Chapter three), reported similar changes in the behaviour of dogs receiving corticos-
teroid therapy. In fact, the answers to the questionnaire were impressively consistent
with the answers given by owners in the preliminary study but the discovery of a
signiﬁcant reduction in play behaviour in dogs treated with corticosteroids suggested
that a more general increase in negative aﬀective bias might have been behind the
behaviour changes observed. The behavioural test results, presented in Chapter four,
showed that dogs in treatment with corticosteroids were less exploratory after the
growl: this behavioural inhibition was interpreted as a sign of increased sensitivity
to the mild anxiety provoking stimulus that was proposed. Finally, the behavioural
caseload in Chapter ﬁve showed that dogs with a history of corticosteroid drugs were
more likely to be in negative aﬀective states and less likely to be hyperactive for reas-
ons associated with positive aﬀective state compared with dogs that did not received
these drugs in the past.
An increased sensitivity to negative stimuli is likely to aﬀect the welfare of dogs and
might also explain why dogs on corticosteroids were reported to show more avoidance
behaviours and even aggression.
Both in humans and non-human animals, normal stress responses, when appropriate,
should increase adaptation and increase the chances of survival but extremely intense,
unpredictable repeated, chronic stress may become maladaptive and cause severe af-
fective problems. These problems have a common denominator: a negative aﬀective
state.
Changes in behaviour related to negative aﬀects reﬂect changes in the brain areas in-
volving emotion and cognition and there is evidence that not only stressful conditions
but also exogenous corticosteroids might damage brain structures that are crucial for
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memory and emotions. For example damage in the hippocampus has been demon-
strated in rodents and in primates (Sapolsky et al., 1990) and also hypothesized in
humans using MRI (Höschl and Hajek, 2001). The hippocampus is deeply involved
in short-term memory consolidation and HPA axis regulation and damage, such as
atrophy, might be induced by corticosteroid drugs (Brown et al., 1999; Höschl and
Hajek, 2001). Many factors have been recognized as a risk for increasing hippocam-
pal vulnerability to corticosteroids and it was described that both chronic stress and
prolonged exposure to corticosteroids can cause hippocampal dendridic retraction but
not irreversible cell death. This dendritic retraction might increase hippocampus vul-
nerability to metabolic changes or neurotoxins. Hippocampal dendridic retraction
has been related with spatial memory deﬁcits, contextual fear conditioning and also
depression-like behaviours (Qiao et.al, 2016; Conrad, 2008). This has been called the
glucocorticoid vulnerability hypothesis (Conrad, 2008). Brown et al. used MRI
to detect reduced amygdala volume in human patients treated with corticosteroids
(Brown et al., 2008). The right amygdala volume was inversely related to the length
of corticosteroid therapy. This study suggests that the amygdala, as well as the
hippocampus, is sensitive to corticosteroid eﬀects but, beyond this conclusion, the
interpretation of these results is not easy.
As already mentioned in the previous part of this thesis, the amygdala is a brain
structure deeply involved in emotion, particularly fear, and plays an important role
in stress responses. It has been shown that amygdala volume was smaller in humans
suﬀering from Post-Traumatic Stress Disorders compared with non-pathological con-
trols, and this was also associated with a smaller left hippocampal volume (Morey
et al., 2012). By contrast, Lupien et al. investigated hippocampus and amygdala
MRI images in children suﬀering from depression due to early separation from their
mothers (Maternal Distress Syndrome) and found larger amygdala volumes in aﬀected
children compared with non-aﬀected controls (Lupien et al., 2011). The diﬀerent ef-
fects of exogenous corticosteroids on neural cells have not been completely clariﬁed
and synthetic corticosteroids modulate neural cells and might produce detrimental or
positive eﬀects that appear to be mediated by dose, individual features, and brain
region phenomena (Numakawa et al., 2010; Ramos-Remus et al., 2002). Vyas et al.
described diﬀerent patterns of modiﬁcation of the volume of hippocampus and amy-
gdala in rats following chronic immobilization stress with dendritic atrophy in the
hippocampus but increased arborization in the neurons of basolateral complex of the
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amygdala (Vyas et al., 2002; see also Chapter 1). Investigating similar neuroana-
tomical changes in dogs is beyond the scope of this thesis, although neuroimaging is
increasingly used in dogs and studies that investigated dog brain areas related to the
perception of environmental and social stimuli have recently been carried out even
in conscious dogs (Andics et al., 2015; Berns et al., 2014). Neuroimaging studies
have been done to investigate the role of serotonin in impulsive aggression in dogs
(Peremans et al., 2003) and also to study the inﬂuence of ketamine on cerebral blood
perfusion and on serotonin receptors in the canine brain (Waelbers et al., 2015). The
eﬀects of aging on dog brain was also investigated through MRI in beagle dogs and
several areas of the brain, included hippocampus, were investigated and measured
(Kimotsuki et al., 2005), so there is no theoretical barrier to undertaking such work
in dogs. The use of advanced neuroimaging techniques to investigate brain area that
are crucial for cognition and emotion in dogs might provide important information
about the impact of corticosteroid drugs on brain structures such as amygdala and
hippocampus, as has already been done in human beings.
Merging the results of brain imaging examinations and behavioural tests might provide
a more complete picture of the eﬀects of corticosteroid drugs on dog brain and beha-
viour. Although these kinds of investigations are challenging from economic, practical
and potentially ethical perspectives, their outcomes are likely to provide important
information.
Behavioural tests remain an important tool to objectively assess behaviour and emo-
tional states and in future studies the use of a cognitive bias paradigm in order to
investigate the eﬀects of corticosteroid drugs in dogs might be a useful tool to evaluate
possible shifts in cognitive bias as illustrated by Karagiannis et al. (Karagiannis et al.,
2015). A negative bias is explained as a tendency to exhibit more intense behavioural
and physiological responses to negative stimuli and less intense responses to positive
stimuli, resulting in a more pessimistic appraisal of social and life situations. It has
been shown that corticosteroids and norepinephrine interactions have an important
role in the emergence of negative bias (Kukolja et al., 2008).
Future directions in this ﬁeld should consider some of the issues that have not been
addressed in this research work. One of the main questions that should be addressed
is the proportion of dog patients that show behavioural side eﬀects after administra-
tion of GCs drugs, in order to better quantify the risk.
Another important issue that needs to be further investigated is the relationship
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between the dose of GCs and the onset of behavioural changes. The corticosteroid
doses recorded throughout this research work were mostly around the low therapeutic
range of doses and our sample was targeted mainly towards patients with moderate
rather than severe medical conditions, in order to minimize the eﬀect of pain and
physical impairment. In human patients, investigations into eﬀects of corticosteroid
drugs have also been done in patients with severe disease such as nephrotic syndrome.
These studies have shown that high-dose corticosteroid treatment produces important
behavioural changes including aggression (Hall et al., 2003; Mishra et al., 2010).
The available literature data in human medicine report that the psychiatric symptoms
during corticosteroid therapy are dose dependent and often occur early in treatment.
It was also shown that these eﬀects are reversible with discontinuation of the therapy
(Brown and Chandler, 2001), and this is another issue that would be important to
investigate in dogs.
Because it was reported that in patients with a history of neuropsychiatric disorders
multiple treatment courses with corticosteroids was associated with the risk of having
the same disorders in subsequent corticosteroid treatments (Fardet et al., 2012), it
would also be worth investigating whether multiple treatment with corticosteroids in
dogs might be associated with the recurrence of behaviour problems.
Sensitivity to chemicals and drugs is related to individual features and individual
diﬀerences in endocrine reaction have been shown in genetically selected laboratory
animals (Liebsch et al., 1998). Genotype and early experiences have been shown
to inﬂuence stress-reaction patterns and also reaction to exogenous corticosteroids
(Mirescu et al., 2004). Corticosteroid sensitivity might depend on the diﬀerent dis-
tribution of GRs and MRs and the regulation of their action in the brain, which are
profoundly inﬂuenced by genetic factors (De Kloet and Derijk, 2004; De Kloet et al.,
1996). The issue of genetic inﬂuence on stress and corticosteroid sensitivity in dogs is
an important one and investigating diﬀerent changes in behaviour as a consequence
of corticosteroid therapies in diﬀerent breeds will also provide important information
about the impact of stress on dog behaviour.
Starting from this ﬁrst research the proposed check-sheet for veterinary practitioners
mentioned above (Appendix G) might be broadly distributed in order to produce a
large volume of data and provide more information about the impact on behaviour of
corticosteroid dosage, length of treatment, reason for treatment and individual treated
dog features including their gender, age and breed. Signiﬁcant results of such a survey
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will also be likely to facilitate the recruitment of a larger sample of dogs undergoing
treatment with corticosteroid drugs for behavioural tests because veterinarians might
be more aware of the importance of this issue and, as a consequence, more motivated
to recruit dogs. The behavioural tests described in this research might be replicated
with a larger sample and/or other behavioural tests might be introduced. As men-
tioned above a cognitive bias paradigm might be used to assess aﬀective states, as
already suggested by Burman (Burman, 2014), using test designs that have already
been used in other studies (see for example Karagiannis et al., 2015).
The behaviour of dogs is inﬂuenced by many diﬀerent factors and an important one
is the dog's perception of human behaviour; since it was shown that dogs can under-
stand human gestures and gaze (Cunningham and Ramos, 2014; Topál et al., 2014),
behavioural test involving responses to human communicative cues might be used as
a possible instrument to detect possible changes in social responses when dogs are in
treatment with corticosteroid drugs.
Throughout this research we have tried to systematically investigate an unexplored
ﬁeld that has multiple implications for dog behaviour and welfare as well as for dog-
human relationships. Companion dogs are more than just pets and many studies
have shown the importance of the dog-human bond in enhancing human well-being
(Hart, 1995; Siegel, 1990). Dog-owner relationships might have several dimensions:
a dog can be perceived as a relative, a friend or might represent a status symbol or
an extension of self (Dotson and Hyatt, 2008; Veevers, 2008). Negative changes in
companion dog behaviour will often have a deep impact on the life of its carers and
investigating behavioural responses to human cues in dogs treated with corticosteroids
might provide further tools to prevent detrimental eﬀects on dog-owner relationships
due to change in dogs' behaviour as a consequence of corticosteroid treatments used
as part of the normal healthcare of the individual.
Important advances in our knowledge have been made with practical implications
for better practice, alongside suggestions for future research directions. Behavioural
medicine is a ﬁeld that is becoming increasingly important within the veterinary pro-
fession and the results presented here provide a small, but signiﬁcant, piece in the
puzzle of understanding the link between corticosteroid drugs and dog behaviour:
other pieces should be added in the future.
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Press release  
  
Anglo-Italian research launched into drug side effects in dogs 
Researchers in Lincoln and Milan have launched a new study into the behavioural side effects of drugs in dogs.  Many drugs have been adapted for safe use in animals in so much as they do not cause overt harm, but some are known to have psychological side effects, which until now have been largely unexplored.  Dr Lorella Notari, a veterinary surgeon in Milan, Italy, who is working towards a PhD at the University of Lincoln, is leading a new research project which will examine the behavioural changes in dogs being treated with certain medications.  The researchers are particularly interested in the side effects of a group of commonly used anti-inflammatory drugs known as corticosteroid or ‘steroids’. These are often used in conditions like chronic skin problems or arthritis.  The researchers have found initial evidence to suggest they may directly affect a number of behaviours related to dogs’ perception of others and their environment.  The team are therefore following up this initial research by launching an online questionnaire aimed at collating reports from owners of dogs with these medical conditions.  Professor Daniel Mills, from the University of Lincoln’s Department of Biological Sciences, said: “The aim of the survey is to recruit a large number of pet owners whose dog is currently receiving treatment for some form of arthritis or skin problem. We need information from owners of dogs using different treatments in order to examine if one drug is associated with specific changes. By asking owners to report on a range of indirect behavioural responses that they observe when their dog is on treatment, we can then calculate the chance that a certain drug is associated with a higher risk of certain changes in behaviour and whether this fits with our predictions and initial evidence. Later we will test this association with carefully designed behaviour tests in volunteered subjects.”  Dog owners who would like to be involved in the research can visit http://www.dog-behaviour.org where the questionnaire is available in both English and Italian.    For general press enquiries contact:  Ian Richards: Media and PR officer (01522) 886042 irichards@lincoln.ac.uk  Visit our news web pages: www.lincoln.ac.uk/news/latestnews.htm   ENDS 
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Comunicato Stampa: 
Nuovo studio sugli effetti comportamentali dei farmaci sui cani 
É stato intrapreso un nuovo studio a Lincoln e Milano. Molti farmaci sono stati adattati per essere usati in sicurezza negli animali e non sono apparentemente rischiosi, ma alcuni possono avere degli effetti collaterali di tipo psicologico che finora non sono stati per nulla studiati. I ricercatori sono particolarmente interessati agli effetti collaterali di un gruppo di farmaci anti-infiammatori comunemente usati conosciuti come corticosteroidi o’steroidi’. Questi farmaci sono spesso usati nei problemi cutanei o nell’artrite e i ricercatori hanno rilevato delle prime evidenze che suggeriscono che questi farmaci potrebbero anche influenzare direttamente diversi comportamenti legati alla percezione degli altri e dell’ambiente circostante. Essi stanno dunque perseguendo questa linea di ricerca, con il lancio di un questionario online che ha lo scopo di raccogliere informazioni dai proprietari di cani che hanno questi problemi medici. Il Professor Mills dell’Università di Lincoln spiega: “lo scopo dello studio è di raccogliere un grande numero di proprietari di cani che stanno attualmente assumendo terapie per alcune forme di artrite, artrosi o problemi dermatologici; abbiamo bisogno di  informazioni  su cani che seguono diverse terapie per esaminare se un certo farmaco è associato con cambiamenti specifici. Chiedendo ai proprietari di riferire una serie di risposte comportamentali che possono osservare quando il loro cane è in terapia, possiamo calcolare la possibilità che un certo farmaco sia associato con un rischio più alto di mostrare certi cambiamenti comportamentali e se questi risultati sono compatibili con le nostre ipotesi e con le prime evidenze da noi trovate. In uno stadio successive testeremo questa associazione con test comportamentali appositamente studiati che verranno condotti con cani di proprietari che volontariamente si presteranno allo scopo”. Se desiderate partecipare, per favore andate all’indirizzo web  http://www.dog-behaviour.org Dove è disponibile il questionario sia in Italiano che in Inglese.   FINE    
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OWNERS’ QUESTIONNAIRE  This study is part of an International Research Project  and we are very grateful for your assistance in completing  it. Your personal details will remain confidential. The goal of this questionnaire is to collect data about the possible effects of the medication that you are giving to your dog,  that have not been reported before. These effects can be positive/favourable or negative/problematic  for your dog and its management. This survey is about your dog’s  behaviour during the period of  therapy. Your answers will be pooled with those of other dog owners and none of them will be directly attributed to you.    File n. Date……  Name …………………………….Tel……………………e-mail……………………………………….. 
Dog name…………………..Breed…………….Age………..M□ F□  Spayed/castrated□ 
 Disease ……………………………………………………………  Drug …………………………….  Dose (see note below)................................................................................................                        (Please, fill in the information about the drug including the instructions you have received from your vet: time of administration, change in dose in the following days or weeks etc. The dose can be expressed in milligrams or in tablets, specifying the dose for each tablet. For example if you give half a tablet you should specify the dose in milligrams in a tablet e.g 5 mg tablets half twice a day )  Other drugs taken in the same period (any treatment, in connection or not with the disease you mentioned above,  for example antiparasitic drugs or insulin if your dog is diabetic)?         
NO□ YES□  
Drug …………………………….  Dose ……………………………………...............................   Drug …………………………….  Dose ……………………………………...............................   WHEN YOU ANSWER THE FOLLOWING QUESTIONS, YOU ARE KINDLY REQUESTED TO THINK, AT FIRST, ABOUT THE BEHAVIOUR OF YOUR DOG BEFORE STARTING THE DRUG AND PUT AN X WHERE APPROPRIATE IN THE UPPER UNSHADED STRIP. THEN YOU SHOULD THINK ABOUT YOUR DOG’S BEHAVIOUR WHILE YOUR DOG IS TAKING THE DRUG AND PUT AN X WHERE APPROPRIATE IN THE DARKER, LOWER STRIP   Q1.  Play behaviour. Some dogs are very motivated to play with people, other dogs or toys. On a scale from 1 to 7 where 1 is ‘not very playful’  and 7 is ‘very playful’ how would you rate your dog’s behaviour?                      Not very playful                                                               Very playful                        Without drug       With drug                         1             2                3              4               5               6               7   Q2. Nervousness/restlessness. Thinking about your dog’s temperament, how would you define its nervousness/ restlessness on a scale from 1 to 7 where 1 is ‘very nervous and restless’ and 7 is ‘very calm’?            Very nervous/restless                                                                                       Very calm    Without drug       With drug                       1             2                3              4               5               6               7  
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Q3. Insecurity and fearfulness. Thinking about your dog’s general responses, for example, in the presence of unknown people or of new, unknown stimuli (sounds, loud voices, unknown contexts, unknown animals or children…), on a scale from 1 to 7 where 1 is  ‘extremely fearful and insecure’ and  7 is ‘ very confident’ , how would you rate your dog?             Fearful/insecure                                                                                             very confident    Without drug       With drug                       1             2                3              4               5               6               7    Q4.  Food related aggression. Thinking about your dog’s behaviour when there is food around,  on a scale from 1 to 7 where 1 is not at all aggressive and 7 is very aggressive in the presence of food, how would you rate your dog?       Not at all aggressive over food                                                                Very aggressive over food                   Without drug       With drug                       1             2                3              4               5               6               7    Q5.  Attention seeking behaviour. Some dogs tend to be very insistent and seek physical contact with owners by jumping up, snapping, scratching with a front paw, whining or barking: on a scale from 1 to 7 where 1 is ‘no attention seeking behaviours’  and 7 is ‘frequent and intense attention seeking behaviours’, how would you rate your dog?       No attention seeking                                                                               Frequent & intense attention seeking    Without drug       With drug                         1             2                3              4               5               6               7      Q6.  Barking. Some dogs bark at any time, night and day, some others bark only in exceptional occasions. On a scale from 1 to 7 where 1 is ‘rare barking’  and 7 is ‘frequent and intense barking’, how would you rate your dog’s behaviour?                Rare Barking                                                                                   Frequent and intense barking    Without drug       With drug                       1             2                3              4               5               6               7   Q7.  Obedience. Some dogs are very obedient, for example they come when called and go to bed when asked, while some others are less easily controlled. On a scale from 1 to 7 where 1 is ‘not at all obedient’  and 7 is ‘very obedient’, how would you rate your dog’s behaviour?            Not at all obedient                                                                                      Very obedient    Without drug       With drug                        1             2                3              4               5               6               7   
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Q8. Guarding behaviour.  Some dogs are very predisposed to guarding behaviour and tend to threaten people by barking and growling, some others are friendly with everyone and don’t show any guarding behaviour. On a scale from 1 to 7 where 1 is ‘no guarding behaviour’  and 7 is ‘intense & frequent guarding behaviour’, how would you define your dog’s behaviour?        No guarding behaviour                                                                            Intense/frequent  guarding    Without drug       With drug                        1             2                3              4               5               6               7   Q9.  Startle reactions. Some dogs tend to startle very easy, for example when they hear a sound or are suddenly touched. In these cases they can react by fleeing, getting jumpy or showing aggression. On a scale from 1 to 7 where 1 is ‘low/rare startle response’  and 7 is an ‘excessive and very frequent  startle response’, how would you define your dog’s behaviour?  Low/rare  startle responses                                                                  excessive/very frequent startle responses                       Without drug       With drug                        1             2                3              4               5               6               7    Q10. Irritable aggression.  Some dogs tend to react aggressively if someone tries to touch them or come close while they are resting. These dogs can become aggressive whenever the owner tries to brush them, medicate them or even simply tries to pet them. On a scale from 1 to 7 where 1 is ‘never aggressive when disturbed/restrained’  and 7 is ‘very aggressive when disturbed/restrained’, how would you define your dog’s behaviour?  Never aggressive when disturbed/restrained                                  Very aggressive  when disturbed/restrained                       Without drug       With drug                       1             2                3              4               5               6               7   Q11.  Tendency to avoid people or situations. Some dogs have a marked tendency to avoid people or situations that are unknown  or unfamiliar, for example they tend to leave the room when unknown guests arrive or when people scream or there are loud noises. On a scale from 1 to 7 where 1 is ‘no tendency to hide or avoid people or situations’  and 7 is ‘High tendency to hide or avoid  people or situations ’, how would you rate your dog’s behaviour? .            No tendency to hide/avoid                                                    High tendency to avoid                                         Without drug       With drug                        1             2                3              4               5              6               7   Q12.  Mounting behaviour. Some dogs can show a tendency to mount people (children and adults) or other dogs, often of the same sex. On a scale from 1 to 7 where 1 is ‘no tendency to mount’  and 7 is ‘high tendency to mount’ how would you rate your dog’s behaviour?           No tendency to mount                                                             High tendency to mount                        Without drug       With drug                      1             2                3              4               5               6               7   
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Did you identify other behaviours that your dog changed or started to show after the initiation of the drug?    (please provide details)…………………………………………………………………………………………………    THANK YOU FOR YOUR ASSISTANCE!  If you are willing to be contacted further about this research please provide your name and contact details below ( e-mail or residential address)  ................................................................................................................................................................................................   
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QUESTIONARIO      Questo questionario fa parte di un progetto di ricerca internazionale e la ringraziamo molto  per aver accetto di compilarlo. Le informazioni in esso contenute resteranno confidenziali. Lo scopo del questionario è raccogliere dei dati sui possibili effetti  della terapia che sta somministrando al suo cane. Questi effetti potrebbero essere positivi/favorevoli oppure negativi/problematici per il suo cane e per la sua gestione. Lo studio riguarda il comportamento del cane durante la terapia. Le sue risposte verranno raggruppate con quelle di altri proprietari e non potranno venire direttamente attribuite a lei, garantendole in questo modo l’anonimato .      Data……  Nome …………………………….Tel……………………e-mail……………………………………….. 
Nome del cane…………………..Razza/Tipo…………….Età………..M□ F□  Starilizzata/Castrato□ 
 Malattia/problema per il quale il cane assume il/i farmaci ……………………………………………………  Farmaco …………………………….  Dose* (vedere la nota sotto)……………………………………………..                            *(Per favore, compili le informazioni sul farmaco includendo le istruzioni che ha ricevuto dal suo veterinario: dosaggio, intervallo tra le somministrazioni, cambiamenti di dosaggio nei giorni o settimane seguenti etc. La dose può essere in milligrammi o in compresse, specificando però la dose in ogni compressa. Per esempio se date mezza compressa dovreste specificare la dose in milligrammi contenuta in una compressa; es. mezza compressa da 5 mg per 2 volte al giorno )     Altri farmaci assunti nello stesso periodo (qualsiasi terapia, che sia o meno connessa con la malattia/problema che avete citato sopra,  per esempio trattamenti antiparassitari o insulina se il vostro cane è diabetico)?             
NO□ SI□  
     Farmaco …………………………….  Dose ……………………………………...............................   Farmaco …………………………….  Dose ……………………………………...............................    
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 NEL RISPONDERE ALLE DOMANDE CHE SEGUONO, LA PREGHIAMO DI PENSARE, DAPPRIMA, AL COMPORTAMENTO DEL SUO CANE PRIMA DI INIZIARE LA TERAPIA E DI METTERE UNA X DOVE RITIENE OPPORTUNO NELLA STRISCIA BIANCA IN ALTO. POI DOVREBBE PENSARE AL COMPORTAMENTO DEL SUO CANE MENTRE STA PRENDENDO IL FARMACO E METTERE UNA  X DOVE RITIENE PIU’ APPROPRIATO, NELLA STRISCIA GRIGIA IN BASSO.   Q1.  Comportamento giocoso. Alcuni cani sono molto motivati a giocare con le persone, con altri cani o con i loro giocattoli, per esempio hanno sempre voglia di inseguire una pallina, al parco corrono e giocano volentieri con gli altri cani e passano molto tempo a mordicchiare e portare in giro i loco giochi, mentre altri sono disinteressati o quasi indifferenti se vengono invitati a giocare dal padrone o dagli altri cani e non sono interessati ai giocattoli.  In una scala da 1 a 7 dove 1 è ‘per nulla giocoso’ e 7 è ‘molto giocoso’ come classificherebbe il comportamento del suo cane?                   Per nulla giocoso                                                            Molto giocoso                        Senza farmaco       Con farmaco                       1             2                3              4               5               6               7   Q2. Nervosismo/agitazione. Ci sono cani che si eccitano facilmente, ansimano, saltano addosso, abbaiano alle persone e agli altri cani e non riescono a stare tranquilli nella maggior parte delle situazioni, sia in casa che durante le passeggiate. Altri invece si agitano molto raramente e sono tranquilli anche in situazioni nuove o in presenza di persone e cani sconosciuti. Pensando al temperamento del suo cane, come lo definirebbe dal punto di vista del nervosismo/ agitazione  in una scala da 1 a 7 dove 1è ‘molto nervoso e agitato’ e 7 è ‘molto calmo’?          Molto nervoso e agitato                                                                                      Molto calmo    Senza farmaco       Con farmaco                        1             2                3              4               5               6               7     Q3.  Insicurezza e paura. Pensando a come reagisce il suo cane in generale, per esempio, in presenza di persone sconosciute o di stimoli nuovi e sconosciuti (rumori, voci alte, posti che non conosce, animali che non conosce o bambini…), in una scala da 1 a 7 dove 1 è  ‘molto pauroso e insicuro’ e  7 è ‘ molto sicuro di sé’, come classificherebbe il suo cane?             Pauroso/insicuro                                                                                             molto sicuro di sé    Senza farmaco       Con farmaco                         1             2                3              4               5               6               7    
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Q4.  Aggressività in presenza di cibo. Alcuni cani ringhiano o addirittura tentano di pizzicare o mordere se qualcuno si avvicina alla loro ciotola del cibo, mentre altri sono completamente indifferenti e non hanno alcuna reazione neppure se la ciotola viene toccata o spostata. Pensando al comportamento del suo cane quando c’è del cibo, in una scala da 1 a 7 dove 1 è ‘per niente aggressivo’ e 7 è ‘molto aggressivo’ in presenza di cibo, come classificherebbe il suo cane?           Per nulla aggressivo sul cibo                                                                Molto aggressivo sul cibo                   farmaco       Con farmaco                       1             2                3              4               5               6               7     Q5.  Comportamenti di ricerca di attenzione. Alcuni cani tendono a essere molto insistenti e cercare il contatto fisico con i proprietari saltando addosso, pizzicando, grattando con la zampa, uggiolando o abbaiando: in una scala da 1 a 7 dove 1 è ‘nessun comportamento di ricerca di attenzione’ e 7 è ‘frequenti e intensi comportamenti di ricerca di attenzione’,  come classificherebbe il suo cane?  Nessuna ricerca di attenzione                                                            Frequente & intensa ricerca di attenzione    Senza farmaco       Con farmaco                        1             2                3              4               5               6               7       Q6.  Abbaiare. Alcuni cani abbaiano continuamente, giorno e notte, altri abbaiano solo in occasioni particolari. In una scala da 1 a 7 dove 1 è ‘abbaia raramente’ e 7 è ‘abbaio intenso e frequente’, come classificherebbe il comportamento del suo cane?           Abbaia raramente                                                                                  Abbaio intenso e frequente    Senza farmaco       Con farmaco                       1             2                3              4               5               6               7      Q7.  Obbedienza. Alcuni cani sono molto obbedienti, per esempio vengono prontamente se chiamati e vanno a cuccia quando viene loro chiesto, Mentre altri sono meno facilmente controllabili . In una scala da 1 a 7 dove 1 è ‘per nulla obbediente’ e 7 è ‘molto obbediente’, come classificherebbe il comportamento del suo cane?           Per nulla obbediente                                                                                  Molto obbediente  farmaco       Con farmaco                        1             2                3              4               5               6               7    
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Q8. Comportamento di guardia.  Alcuni cani sono molto predisposti a fare la guardia e tendono a minacciare le persone abbaiando e ringhiando, altri sono amichevoli con tutti e non mostrano alcuna tendenza a fare la guardia. In una scala da 1 a 7 dove 1 è ‘nessun comportamento di guardia e 7 è ‘intenso & frequente comportamento di guardia’,  come definirebbe il comportamento del suo cane?      Nessun comportamento di guardia                                                            Comportamento di guardia intenso/frequente      Senza farmaco       Con farmaco                        1             2                3              4               5               6               7  Q9.  Reazioni improvvise, di soprassalto. Alcuni cani  tendono  a trasalire molto facilmente,  per esempio quando sentono un rumore o vengono toccati inaspettatamente. In questi casi possono reagire scappando, innervosendosi, ringhiando o magari con un pizzico o un morso improvviso. In una scala da 1 a 7 dove 1 è ‘si allarma/trasale raramente’ quando viene sorpreso e 7 è ‘si allarma/trasale eccessivamente e frequentemente’, come definirebbe il comportamento del suo cane in presenza di cose che non conosce?     Si allarma/trasale raramente                                              si allarma/trasale eccessivamente/frequentemente                       Senza farmaco       Con farmaco                        1             2                3              4               5               6               7  Q10. Aggressività da irritazione.  Alcuni cani tendono a reagire con un ringhio o magari tentando di pizzicare o mordere se qualcuno tenta di toccarli o si avvicina mentre stanno riposando. Questi cani possono diventare aggressivi quando il padrone vuole spazzolarli,, medicarli o anche semplicemente accarezzarli.  In una scala da 1 a 7 dove 1 è ‘mai aggressivo quando disturbato/trattenuto/manipolato’ e 7 è ‘molto aggressivo quando disturbato/trattenuto/manipolato’, come valuterebbe l'irritabilità del suo cane?               Mai aggressivo se disturbato                                            Molto aggressivo se disturbato                       Senza farmaco       Con farmaco                        1             2                3              4               5               6               7  Q11.  Tendenza a evitare le persone o certe situazioni. Alcuni cani hanno una marcata tendenza a evitare persone o situazioni sconosciute o poco familiari, per esempio tendono a lasciare la stanza quando arrivano ospiti sconosciuti o quando le persone gridano o ci sono rumori forti. In una scala da 1 a 7 dove 1  è ‘nessuna tendenza a nascondersi o evitare persone o situazioni’ e 7 è ‘Spiccata tendenza a nascondersi o evitare persone o situazioni ’, Come classificherebbe il comportamento del suo cane?   Nessuna tendenza a nascondersi/evitare                                                  Spiccata tendenza a nascondersi/evitare                                         Senza farmaco       Con farmaco                        1             2                3              4               5              6               7  Q12.  Comportamento di monta. Alcuni cani mostrano una tendenza a montare le persone (Bambini e adulti) o altri cani, spesso dello stesso sesso. In una scala da 1 a 7 dove 1 è ‘nessuna tendenza a montare’ e 7 è ‘spiccata tendenza a montare’ come classificherebbe il comportamento del suo cane?               Nessuna tendenza a montare                                                            Spiccata tendenza a montare                        Senza farmaco       Con farmaco                       1             2                3              4               5               6               7   
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Ha identificato altri comportamenti che il suo cane ha modificato o ha iniziato a mostrare dopo l’inizio della terapia ?   (Per favore li descriva)……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………    GRAZIE PER IL SUO AIUTO!  Se ha piacere di essere contattato ancora riguardo a questa ricerca per favore scriva qui sotto dove vuole essere contattato (e-mail/ indirizzo/ numero di telefono)  ................................................................................................................................................................................................   
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OWNERS' DISCLAIMER
(Original Italian version)
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LIBERATORIA. 
Test  Comportamentale svolto il  
Test  1:  giorno ____________alle ore____________ 
Test  2:  giorno ____________  alle ore____________ 
 
Io sottoscritto/a __________________________________________dichiaro di avere ricevuto tutte le 
informazioni riguardo al test al quale viene  sottoposto oggi il mio cane di 
nome________________razza________________età_______sesso_____Sterilizzato    SI□   NO□   e di avere 
accettato di partecipare liberamente e senza compensi in danaro.  
 
Dichiaro inoltre di essere stato informato della possibilità di interrompere il test in qualsiasi momento, se lo 
ritenessi opportuno.  
Acconsento a che le registrazioni del test vengano impiegate a scopo di analisi e possano essere mostrate in 
seminari o convegni scientifici, avendo ricevuto la rassicurazione che tutte le informazioni riservate 
riguardanti la mia identificazione personale rimarranno riservate.  
In Fede 
 
 
 
 
 
 Dott. Lorella Notari Medico Veterinario Comportamentalista Dip. ECVBM-CA (Diploma Europeo in Medicina Comportamentale Veterinaria- Animali da Compagnia) Via Donatell0, 6  21100 Varese  Tel. +39 0332 286719 Cell. +39 335 5739223 lorellanotari@lorellanotari.it   
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OWNERS' DISCLAIMER
(Translation into English)
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CONSENT. 
Consent for behavioural tests on  
Test 1 :  _ date____________time____________ 
Test 2 :  _ date____________time____________ 
 
My name __________________________________________I declare I received the necessary information 
about the behavioural tests that will be undertaken by my dog  name________________breed/type 
__________________Age_________Gender________Spayed/castrated    YES□   NO□    
 
and I accept to partecipate under my own will and without any payment  .  
 
I declare I was informed that I can stop the test in any moment .  
I agree that the videorecordings of the tests will be used for behaviour analysis and that these recordings might 
be shown in scientific seminars and meetings. I have been informed that alla my personal details will remain 
confidential  .  
Signature 
 
 
 
 
 
 Dott. Lorella Notari Medico Veterinario Comportamentalista Dip. ECVBM-CA (Diploma Europeo in Medicina Comportamentale Veterinaria- Animali da Compagnia) Via Donatell0, 6  21100 Varese  Tel. +39 0332 286719 Cell. +39 335 5739223 lorellanotari@lorellanotari.it  
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PILOT STUDIES
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CORTICOSTEROIDS AND DOG BEHAVIOUR: PILOT STUDIES
Before reaching the ﬁnal version of our behavioural tests we made a few pilot
studies in order to evaluate both the feasibility of dog sample recruiting and the
reliability of the test design. Our goal was also to implement the test procedures.
The owners' questionnaire about possible eﬀects of corticosteroids on dog behaviour
(See Chapter 2 and 3) showed that dog in treatment with corticosteroid drugs tended
to startle more easily, to be more nervous and more avoidant. The ﬁrst pilot tests
were therefore designed to experimentally verify these results.
The ﬁrst pilots were designed with the goal of detecting dogs' reactions to acoustic
stimuli. Our ﬁrst attempts involved the use of a Prepulse Inhibition (PPI) test.
PPI is a neurological phenomenon in which a weaker prestimulus (prepulse) inhibits
the reaction to a subsequent strong startling stimulus (pulse). As acoustic stimuli we
used the same prepulse and pulse stimuli used for horses in a previous study (1). The
rational of this test was that dogs with more negative internal states might increase
their startle reactions in response to the pulse compared with when they were not on
corticosteroid therapy and compared with control dogs.
A simple apparatus was built, in order to be able to administer the stimuli (see ﬁgures
below).
1Van Der Laan, J. E. and Mills, D. S. (2011). Sensorimotor gating in equine stereotypy: prepulse
inhibition of the acoustic startle reﬂex. Proceedings of the 7th International Equitation Science
Conference. Academy Bartels - Hooge Mierde - The Netherlands
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(a) (b)
(c)
(a) Dog's view. The owner will sit on the chair. (b) Loudspeaker positions. The holes are at
diﬀerent levels for diﬀerent dog's sizes. (c) The dog is held by his/her owner through the screen
and the owner trys to keep the dog's head in the correct position by showing a titbit.
Figure C.1: PPI apparatus.
A few healthy dogs were used to test the apparatus but this test was discarded
because most dogs appeared distressed by the apparatus itself and the owner's at-
tempts to hold them in the right position for receiving the sound stimuli in most
cases seemed more salient than the administered stimuli itself. Because we expected
that the sample would not be easy to recruit and we had to be able to successfully
test dogs on corticosteroid without losing too many of them due to overly complicated
procedures we decided to change the test design.
A ﬁrst version of the test that we ﬁnally used was introduced. To test the tendency
of dogs to avoid a potentially mild aversive stimulus we designed a ﬁrst version of the
153
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test as in Figure C.2.
(a) Owner (b) Vases (c) Screen (d) Loudspeaker
Figure C.2: Test area with vases.
The test area was ﬁrstly set in a room of about 20 square meters, with ﬁve vase
arranged on the ﬂoor as in Figure C.1. A sound started from a loudspeaker positioned
behind a screen.
Practical problems arose in the ﬁrst test trials. The ﬁrst problem was to ﬁnd a
sound with the intrinsic intention of being mildly aversive to all dogs. The kind and
intensity of sounds were changed many times before reaching the decision to introduce
the growls that we used in the ﬁnal version of the tests.
The vase position was changed mainly in anticipation of having to make tests in
smaller environments such as veterinary practices. A single line of vases in front of
the screen that hid the loudspeakers took up less space and enabled us to put pieces
of food on both sides of the line at the same time.
The recruitment of dogs was a very challenging part of the study and diﬀerent methods
were considered including e-mails, social network advertising and the involvement of
training centers. The ﬁnal decision to limit the recruitment of sample dogs to dogs
that had just received a prescription for corticosteroid drugs led us to the decision to
contact veterinary clinics in the area.
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DOG BEHAVIOUR FORM
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SCHEDA INFORMATIVA PER IL
CANE
(Original Italian version)
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 Data consultazione… 
Caso n. 
 
INFORMAZIONI GENERALI 
 
Nome…………………..Indirizzo………………………………Città……………………CAP. 
Tel. Casa……… 
Cellulare…… 
e-mail………………… 
Veterinario curante/clinica…… ………………Tel………………………………………… 
 
Nome del cane… …….. 
Razza/tipo…… … …………….età… …..sesso…. 
È sterilizzato/a ?…………… 
Se si, quando è stato sterilizzato   Si□  No□    
 
LA STORIA 
 
Età di adozione?   …………………………. 
da dove proviene? …………………………. 
Sono suoi primi proprietari o è stato precedentemente in un’altra famiglia o in canile?  
……………………………………………… 
 
Adozione dal canile: notizie precedenti 
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LA DIETA 
 
Che tipo di alimentazione segue il suo cane ? Casalinga □   Idustriale  □  Mista  □ 
Quante volte al giorno?      …………………………. 
Quando? (ora e quando rispetto al pasto dei proprietari)  …………………………. 
Da qualche integratore? Se si, cosa?    …………………………. 
Mangia con entusiasmo o è schizzinoso?    …………………………. 
bocconcino-premio? Se sì, cosa? Decrivere    …………………………. 
 
ESERCIZIO, GIOCHI E INTERAZIONI CON GLI ALTRI CANI 
 
Tipo di movimento (es. solo in giardino, segue il proprietario che fa jogging, in campo di 
addestramento, agility o altri sport). Descrivere………………………………………….. 
Quante ore/minuti di movimento al giorno?……… …………… ….. 
da solo o con altri cani?…… …… 
al guinzaglio o libero?… …………………………………. 
Gli piace uscire in passeggiata?          Si□  No□   Dipende□ (descrivere) 
………………………………………………………………………………………… 
Ci sono interazioni/giochi con altri cani?  Si□  No□   Dipende□ (descrivere) 
…………………………………………………………………………………… 
Qual è il giocattolo preferito?  ……………………………………………………. 
Qual è il suo gioco preferito con le persone? ……………, ……………………… 
Dove tiene i giocattoli del cane?………………………………………………….. 
Il cane può accedere liberamente ai giocattoli?  Si□  No□   Dipende□ (descrivere) 
…………………………………………………………………………………… 
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SISTEMAZIONE IN CASA 
 
Dove dorme la notte?  Fuori casa □    In casa ma non in camera □ in camera □  altro ……… … 
Il cane ha una sua cuccia o brandina e lo usa per dormire di notte e riposare ? Si□  No□    
Se no, descrizione di dove dorme il cane di notte e dove riposa di giorno 
………………………………………………………………………………………… 
Dove sta il cane quando sono fuori casa?  In giardino □ In casa □  Altro…………….. 
È lasciato solo regolarmente? Se si, per quanto tempo?……… …………………… 
Ci sono problemi quando lo lasciano solo? Che cosa succede? (Descrizione). 
 
 
 
 
Lasciano giocattoli o qualche altra distrazione?   Si□  No□   Cosa? ………………… 
Ha accesso al giardino?      Si□  No□    
Quando ci sono, il cane tende a seguire per la casa?  Si□  No□     
 
LA STORIA DELLA SUA EDUCAZIONE/ADDESTRAMENTO 
 
Ha seguito qualche corso di educazione/addestramento? Si□  No□    
Che età aveva allora il cane? ….. 
Per quanto tempo? …. 
Era un corso singolo o c’erano altri cani?   Singolo □  Collettivo □    
Ci sono stati problemi?     Si□  No□   Quali? 
 
 
 
Come ha insegnato al cane a sporcare fuori casa? (Descrivere) 
 
 
 
Il cane tira al guinzaglio? Si□  No□   Dipende□ (descrivere)  
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 Torna al richiamo?   Si□  No□   Dipende□ (descrivere)  
 
 
 
Lascia oggetti che tiene in bocca quando richiesto? Si□  No□   Dipende□ (descrivere) 
 
 
 
Quali comandi conosce il cane /cosa sono in grado di chiedere al cane (es. vieni, seduto, resta…)?  
 
 
 
 
MEMBRI DELLA FAMIGLIA 
 
Quante persone vivono in casa? Ci sono bambini? Se si, quanti anni hanno? Descrizione dei 
componente della famiglia (età, sesso, grado di parentela) 
 
 
 
Tutti i membri della famiglia interagiscono con il cane? Descrizione (per esempio chi porta fuori il 
cane, chi gli da il cibo, chi lo spazzola etc.) 
 
 
 
Altri animali (Descrizione del tipo, età, sesso) ?
 
 
 
 
Quando sono stati adottati questi animali? Età di adozione/quando sono arrivati in famiglia
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OSPITI 
 
Quando arrivano ospiti/sconosciuti come si comporta?  Amichevole □  ha paura □ aggressivo □ 
altro □ (descrivere) 
 
 
 
 
Si comporta in modo diverso a seconda del tipo di ospite (per esempio, maschi, femmine, bambini). 
Descrivere  
 
 
 
 
SPAZZOLATURE E MANIPOLAZIONI  
 
Come si comporta quando viene spazzolato, per pulire le orecchie, per lavarlo? 
 
 
 
 
COMPORTAMENTO DAL VETERINARIO   
 
Come si comporta dal veterinario? (descrivere, per es. molto pauroso, aggressivo, deve sempre 
mettere la museruola) 
 
 
 
 
DESCRIZIONE DEL PROPRIETARIO DELLA PERSONALITA’ DEL CANE  
 
Aggressivo in molte/nella maggior parte delle situazioni?   Si □  No □. 
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Spesso nervoso o  spaventato (per rumori, cose nuove, estranei)?   Si □  No □ 
Prevalentemente vivace ed entusiasta?     Si □  No □. 
Socievole?         Si □  No □ 
Sicuro di sé?         Si □  No □. 
 
ANAMNESI CLINICA E VISITA CLINICA 
  
Il cane ha in questo momento problemi di salute ? Si□ No □   Quali?............................ 
 
Ha avuto problemi di salute in passato? Si□ No □    Quali problemi ha avuto? Elenco breve 
...................... 
…………….. 
…………….. 
Quali farmaci ha assunto per questi problemi?  
Nome del farmaco 1….. …..Dosaggio…… …. 
per quanto tempo?  
Meno di una settimana        □  
Più di una settimana      □   
Terapia ad vitam o per periodi molto lunghi   □ 
 
Nome del farmaco  2….. …..Dosaggio…… …. 
per quanto tempo?  
Meno di una settimana        □  
Più di una settimana      □   
Terapia ad vitam o per periodi molto lunghi              □ 
 
 
  
Appendix D
163
Visita clinica:  
 
Visita non svolta     □ 
Impossibile da visitare senza sedazione  □           
Visitato con museruola   □ 
Stato di Nutrizione (BCS)    1 □ 2  □  3  □  4  □  5 □  
Condizioni del mantello   Ottime □  Buone □    Scarse □ (descrivere)    Pessime □ 
(descrivere) 
Battito e respiro      Nella norma  □     Alterazioni  □ (descrivere)…………………………. 
Addome          Normale/palpabile  □     non palpabile  □     alterazioni (descrizione) 
Linfonodi        Normali    □          Alterazioni (descrizione)…………….. 
Temperatura rettale     (°) …… 
Orecchie – aspetto della pinna e del condotto uditivo esterno ………………… 
Orecchie temperatura    DX(°)….    SX(°) ….  
 
 
IL PROBLEMA PRINCIPALE 
 
Descrizione del comportamento 
 
 
 
Insorgenza del problema  
 
 
 
Il comportamento è rimasto lo stesso o è peggiorato nel tempo? 
 
 
 
Descrizione dell’ultimo episodio/incidente 
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Eventi precedenti e seguenti  
 
 
 
Dove è accaduto, quando è accaduto (giorno e ora) e chi era presente  
 
 
 
Contesti a rischio in casi di aggressività (es. passeggiata, arrivo di ospiti, presenza  
Di bambini, presenza di altri cani) . Elencare 
 
 
 
Il problema si presenta soprattutto se…  
 
 
 
Cronologia degli episodi/ incidenti avvenuti in passato. Descrizione 
 
 
 
Stato dell’animale (es. Calore, gravidanza, malattie) 
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ALTRI  PROBLEMI/COME SI COMPORTA: 
 
Con i bambini  
 
 
 
 
   
Con gli estranei 
 
 
 
Con i membri della famiglia  
 
 
 
Quando viene spazzolato o lavato  
 
 
 
 
Quando gli danno mangiare  
 
 
 
 
Con i gatti  
 
 
 
    
Quando ci sono rumori forti   
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Quando incontra altri cani   
 
 
 
 
CI SONO ALTRI PROBLEMI NON ANCORA DESCRITTI/RIPORTATI? 
 
 
 
 
PRESCRIZIONI 
 
 
 
 
ISTRUZIONI CONSEGNATE AL TERMINE DELLA VISITA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dott. Lorella Notari 
Medico Veterinario Comportamentalista 
Dip. ECAWBM-CA (Diploma Europeo in Medicina Comportamentale Veterinaria- Animali da 
Compagnia) 
Via Donatell0, 6  21100 Varese  Tel. +39 0332 286719 Cell. +39 335 5739223  
lorellanotari@etostudio.it 
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DOG BEHAVIOUR FORM
(English translation)
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Date of consultation… 
Case n. 
 
GENERAL IFORMATION 
 
Name…………………..Address………………………………City……………………CAP. 
Tel. Home……… 
Mobile…… 
e-mail………………… 
Veterinary surgeon/practice…… ………………Tel………………………………………… 
 
Dog name… …….. 
Breed/type…… … …………….age… …..gender…. 
Is the dog spayed/castrated ?  Si□  No□    
I yes when?  …………….    
 
DOG BACKGROUND 
 
Adoption age?      …………………………. 
Where does the dog come from?  …………………………. 
Are they the first owners or was the dog rehomed from another family or a rescue kennel?  
……………………………………………… 
 
In the case of adoption from a rescue kennel: information about previous dog’s life 
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THE DIET 
 
What kind of diet is the dog taking ? Home made □   Industrial food  □  A mix  □ 
How many times per day is the dog fed?   …………………………. 
When? (Time of the day)      …………………………. 
Any supplement? If yes, what?    …………………………. 
Is the food eaten with enthusiasm?      …………………………. 
Any titbit? If yes, what? Describe     …………………………. 
 
EXERCISE, PLAY AND INTERACTION WITH OTHER DOGS 
 
Type of exercise (for example only in the owner’s garden, jogging with the owner, walk in town or 
country, agility or other sports). Description………………………………………….. 
How many hours/minutes of exercise per day?……… …………… ….. 
Are there other dogs?…… …… 
On leash or also free from the leash?… …………………………………. 
Does he/she like to go out? Yes□  No□   Depends□ (describe) ………………… 
Are there interactions/play with other dogs? Yes□  No□   Depends□ (description) ………………… 
What is the dog’s favourite toy?  ……………………………………………………. 
What is the dog’s favourite game with people? ……………, ……………………… 
Where are the dog’s toy kept?………………………………………………….. 
Has the dog free access to his/her toys?  Yes□  No□   Depends□  
(description) ………………… 
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MANAGEMENT AT HOME 
 
Where does the dog sleep during the night?  Outdoor □    In the house but not in the bedroom □ in 
the bedroom □  other ……… … 
Does  the dog have  its own bed and use it for sleeping or resting ? Yes□  No□   If no, description of 
where the dog sleeps or rest at night or during the day ……………………… 
Where is the dog when the owners are away from home?  outdoor □ indoor □  Other…………….. 
Is the dog left alone regularly? If yes, how long?……… …………………… 
Are there problems when the dog is left alone? What happen? (Description). 
 
 
 
 
Do they leave toys or other distractions?      Yes□  No□    
What? ………………… 
Has the dog free access to the garden?      Yes□  No□    
When owners are at home, does the dog follow them all the time?  Yes□  No□     
 
HISTORY OF DOG TRAINING 
 
Did you follow training courses with your dog    Yes□  No□    
What age was the dog? ….. 
How long did you follow the course? …. 
Were there other dogs on the course?   Private/single courrse □  Collective □    
Problems during the training?     Yes□  No□   What problems? 
 
 
 
How was the dog housetrained? (description) 
 
 
 
 
Does the dog pull on the lead?   Yes□  No□   Depends□ (description) 
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Does the dog come when called?    Yes□  No□   Depends□ (description) 
 
 
 
Does the dog leave object when asked?  Yes□  No□   Depends□ (description) 
 
 
 
What words/commands can the dog  understand /what are the owners are able to ask the dog (for 
example come, sit, stay)?  
 
 
 
 
FAMILY MEMBERS 
 
How many people live in the house? Children? If yes, what age are they? Description of family 
members (age, gender, degree of  relationship) 
 
 
 
Do all the family members interact with the dog? Description of type of interactions (for example 
who walks the dog, who feeds the dog, who grooms the dog) 
 
 
 
Other pets (Species, type, age, gender) ?
 
 
 
 
Appendix D
172
When were these other pets  introduced? Age of adoption/when they arrived in the family
 
 
 
 
GUESTS 
 
How does the dog behave when guests arrive?  Friendly □  fearful □ aggressive □ other □ 
(description) 
 
 
 
 
Does the dog behave differently with different guests (for example male, female, children). 
Description  
 
 
 
 
GROOMING AND HANDLING 
 
How does the dog behave  when being groomed, ear cleaning, washing? 
 
 
 
 
BEHAVIOUR DURING VETERINARY VISITS 
 
How the dog behave with vets? (for example is very fearful, aggressive, there is a  need to wear a 
muzzle..) 
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HOW WOULD YOU DESCRIBE YOUR DOG PERSONALITY?  
 
Aggressive in most situations?     Yes □  No □. 
Do you think that your dog is often or always nervous or fearful in the presence of unknown 
situations or stimuli (sounds, new stimuli, unknown people or dogs)? 
        Yes □  No □ 
Do you consider your dog largely enthusiastic and excited? 
        Yes □  No □. 
Do you think that your dog is sociable in general?  Yes □  No □ 
Do you consider your dog confident?   Yes □  No □. 
 
CLINICAL HISTORY AND CLINICAL EXAMINATION 
  
Does the dog have health problems at the moment ? Yes□ No □   What?............................ 
 
Has the dog had any  health problems  in the past? Yes□ No □    What kind of problems? Brief list 
...................... 
…………….. 
…………….. 
What drugs did your dog take for these problems? List the most recent drug used 
Name of drug 1….. …..Dose…… …. 
How long did the dog take the drug?  
Less than a week        □  
More than a week     □   
Therapy ad vitam or for very long periods   □ 
 
Name of drug 2….. …..Dose…… …. 
How long did the dog take the drug?  
Less than a week        □  
More than a week     □   
Therapy ad vitam or for very long periods   □ 
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Clinical examination:  
 
No clinical examination    □ 
Impossible to examine     □           
Need a muzzle to be visited   □ 
Nutritional status (BCS)    1 □ 2  □  3  □  4  □  5 □  
Coat condition   very good □  good □    poor □ (description)    very poor □ (description) 
Hearth and respiratory rates      Normal  □     Alterations  □ 
(descriptions)…………………………. 
Abdomen         Normal/palpable  □     non palpable  □     Alterations (description) 
Lymphnodes        Normal    □          Alterations (description)…………….. 
Rectal temperature     (°) …… 
Ears – pinna and external duct aspect ………………… 
Ear temperature    DX(°)….    SX(°) ….  
 
 
MAIN BEHAVIOUR PROBLEM 
 
Description of the behaviour 
 
 
 
When did it start  
 
 
 
As the behaviour remained the same or deteriorated  over time? 
 
 
 
Description of the last episode 
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What happened before and after  (including what people/owner did before and after) 
 
 
 
Where did it happen, when (day and time) and who was present  
 
 
 
Risky contexts when aggression is involved (for example during walks, when guests arrive, in the 
presence of children, in the presence of other dogs…) . List these contexts 
 
 
 
The problem arises especially if…  
 
 
 
Chronology of past episodes and descriptions 
 
 
 
Physiological condition (for example heath, pregnancy, diseases) 
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OTHER BEHAVIOURS. HOW THE DOG BEHAVES: 
 
with children  
 
 
 
 
   
with strangers 
 
 
 
with family memebers  
 
 
 
when groomed or washed  
 
 
 
 
when it is fed  
 
 
 
 
with cats  
 
 
 
    
When there are loud noises    
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With other dogs   
 
 
 
 
ARE THERE OTHER PROBLEMS THAT HAVE NOT BEEN MENTIONED?  
 
 
 
 
PRESCRIPTIONS 
 
 
 
 
INSTRUCTIONS GIVEN AT THE END OF THE CONSULTATION 
 
 
 
 
 
 
 
 
 
Dott. Lorella Notari 
Medico Veterinario Comportamentalista 
Dip. ECAWBM-CA (Diploma Europeo in Medicina Comportamentale Veterinaria- Animali da 
Compagnia) 
Via Donatell0, 6  21100 Varese  Tel. +39 0332 286719 Cell. +39 335 5739223 
lorellanotari@etostudio.it 
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DESCRIPTIVE STATISTICS
CHAPTER 5. TABLES
• AGE ANDGENDERDISTRIBUTIONS IN THE DIFFERENTMED-
ICAL CONDITIONS
Dermatological Conditions
Age Frequency n. (%)
1-2 years 36 (40,4)
3-4 years 32 (36,0)
5-6 years 12 (13,5)
7-8 years 8 (9,0)
9-10 years 1 (1,1)
Table E.1: Age distribution of dogs with a history of dermatological condition.
Gender and Frequency
Reproductive State n. (%)
entire male 40 (44,9)
entire female 15 (16,9)
castrated male 16 (18,0)
spayed female 18 (20,2)
Table E.2: Gender and reproductive state distribution of dogs with a history of
dermatological conditions.
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Orthopaedic Condition
Age Frequency n. (%)
1-2 years 4 (14,8)
3-4 years 10 (37,0)
5-6 years 2 (7,4)
7-8 years 9 (33,3)
9-10 years 2 (7,4)
Table E.3: Age distribution of dogs with a history of orthopaedic condition.
Gender and Frequency
Reproductive State n. (%)
entire male 14 (51,9)
entire female 3 (11,1)
castrated male 2 (7,4)
spayed female 8 (29,6)
Table E.4: Gender and reproductive state distribution of dogs with a history of
orthopaedic conditions.
Gastrenterical Conditions
Age Frequency n. (%)
1-2 years 51 (64.6)
3-4 years 17 (21.5)
5-6 years 9 (11.4)
7-8 years 2 (2.5)
Table E.5: Age distribution of dogs with a history of gastrointestinal conditions.
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Gender and Frequency
Reproductive State n. (%)
entire male 38 (48.1)
entire female 11 (13.9)
castrated male 7 (8.9)
spayed female 23 (29.1)
Table E.6: Gender and reproductive state distribution of dogs with a history of
gastrointestinal conditions.
• AGE, GENDER AND AFFECTIVE STATES
Positive Aﬀective States
Positive aﬀect
Age Frequency n. (%)
1-2 years 40 (78.4)
3-4 years 8 (15.7)
5-6 years 3 (5.9)
7-8 years 0
9-10 years 0
Table E.7: Age distribution of dogs in positive aﬀective states.
Positive aﬀect
Gender and Frequency
Reproductive State n. (%)
entire male 22 (43.1)
entire female 15 (29.4)
castrated male 7 (13.7)
spayed female 7 (13.7)
Table E.8: Gender of dogs in positive aﬀective states.
182
Appendix E
Negative Aﬀective States
Negative aﬀect
Age Frequency n. (%)
1-2 years 155 (53.1)
3-4 years 79 (27.1)
5-6 years 29 (9.9)
7-8 years 26 (8.9)
9-10 years 3 (1.0)
Table E.9: Age distribution of dogs in negative aﬀective states.
Negative aﬀect
Gender Frequency n. (%)
entire male 155 (53.1)
entire female 41 (14.0)
castrated male 28 (9.6)
spayed female 68 (23.3)
Table E.10: Gender of dogs in negative aﬀective states.
• AGE, GENDER AND AGGRESSION TOWARDS PEOPLE
Agg.
Age Frequency n. (%)
1-2 years 69 (46,6)
3-4 years 45 (30,4)
5-6 years 21 (14,2)
7-8 years 12 (8,1)
9-10 years 1 (0,7)
Aggr.= aggression towards people.
Table E.11: Age distributions of dogs presented for aggression towards people.
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Agg.
Gender Frequency n. (%)
entire male 95 (64,2)
entire female 14 (9,5)
castrated male 19 (12,8)
spayed female 20 (13,5)
Aggr.= aggression towards people.
Table E.12: Gender of dogs presented for aggression towards people.
• AGE, GENDER AND HYPERACTIVITY
Hyperactivity
Age Frequency n. (%)
1-2 years 73 (82,0)
3-4 years 10 (11,2)
5-6 years 3 (3,4)
7-8 years 3 (3,4)
Table E.13: Age distributions of dogs presented for hyperactivity.
Hyperactivity
Gender Frequency n. (%)
entire male 41 (46,1)
entire female 18 (20,2)
castrated male 9 (10,1)
spayed female 21 (23,6)
Table E.14: Gender of dogs presented for hyperactivity.
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• AGE, GENDER AND PRESCRIPTION OF PSYCHOACTIVE
DRUGS
Psychoactive
Age Frequency n. (%)
1-2 years 46 (43,0)
3-4 years 32 (29.9)
5-6 years 15 (14.0)
7-8 years 13 (12.1)
9-10 years 1 (0.9)
Psychoact = psychoactive drug prescriptions.
Table E.15: Age distribution of dogs that received a prescription for psychoactive
drugs.
Psychoactive
Gender Frequency n. (%)
entire male 46 (43.0)
entire female 17 (15.9)
castrated male 19 (17.8)
spayed female 25 (23.4)
Psychoact = psychoactive drug prescriptions.
Table E.16: Gender of dogs that received a prescription for psychoactive drugs.
• MEDICAL CONDITIONS AND AFFECTIVE STATES
Positive aﬀect
Medical condition Frequency n. (%)
Dermatological problems 7 (13.7)
Orthopedic problems 1 (2.0)
Gastointestinal probems 17 (33.3)
Respiratory problems 9 (17.6)
Other medical problems 4 (7.8)
Table E.17: Medical conditions of dogs in positive aﬀective states.
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Negative aﬀect
Medical Condition Frequency n. (%)
Dermatological problems 82 (28.1)
Orthopedic problems 27 (7.9)
Gastointestinal probems 62 (21.2)
Respiratory problems 46 (15.8)
Other medical problems 30 10.3)
Table E.18: Medical conditions of dogs in negative aﬀective states.
• MEDICAL CONDITIONS AND AGGRESSION TOWARDS
PEOPLE
Agg.
Medical condition Frequency n. (%)
Dermatological problems 43 (29.1)
Orthopedic problems 15 (10.1)
Gastointestinal probems 22 (14.9)
Respiratory problems 26 (17.6)
Other medical problems 16 (10.8)
No history of medical problems 36 (24.3)
Aggr.= aggression towards people.
Table E.19: Medical conditions of dogs presented for aggression towards people.
• MEDICAL CONDITIONS AND HYPERACTIVITY
Hyperactivity
Medical condition Frequency n. (%)
Dermatological problems 16 (18.0)
Orthopedic problems 2 ( 2.2)
Gastointestinal probems 27 (30.3)
Respiratory problems 18 (20,2)
Other medical problems 0
No history of medical problems 30 (33,7)
Table E.20: Medical conditions of dogs presented for hyperactivity.
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• MEDICAL CONDITIONS AND PRESCRIPTION OF PSYCHO-
ACTIVE DRUGS
Psychoactive
Medical condition Frequency n. (%)
Dermatological problems 36 (33.6)
Orthopedic problems 9 (8.4)
Gastointestinal probems 22 (20.6)
Respiratory problems 17 (15.9)
Other medical problems 11 (10.3)
No history of medical problems 20 (18.7)
Table E.21: Medical conditions of dogs that received a prescription for psychoactive
drugs.
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History of
corticosteroid treatment
Patient Factors Positive Negative Pearson Chi p
n. (%) n. (%) Square X(1) value
Positive aﬀective state 0 (0.0) 36 (17.2)  
Negative aﬀective state 55 (100.0) 173 (82.8) 10.970 < 0.001
Aggression 31 (56.4) 81 (38.8) 5.527 0.014
towards people
Hyperactivity 4 (7.3) 55 (26.3) 9.099 < 0.001
Aggression towards
other dogs
9 (16.4) 41 (19.6) 0.300 0.370
Separation problems 9 (16.4) 30 (14.4) 0.140 0.425
Phobias 13(23.6) 56 (26.8) 0.225 0.387
Excessive barking 5 (9.1) 27 (12.9) 0.599 0.303
History of severe bites 16 (29.1) 47 (22.5) 1.045 0.198
Psychoactive drug 24 (43.6) 63 (30.1) 3.588 0.043
prescription
Table E.22: Relationship between history of treatment with corticosteroids and
negative aﬀective state, reported behaviour problems, occurrence of sever bites and
the prescription of psychoactive drugs in all dogs that had a history of medical
problems that required more than one week of therapy (n. 264).
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The Fédération Cynologique Internationale and breed groups.
The Fédération Cynologique Internationale (FCI) is the World Canine Organisation.
The FCI recognises 343 breeds. Each of them is the property of a speciﬁc coun-
try. The owner countries of the breeds write the standard of these breeds (detailed
description of the ideal type of the breed), in co-operation with the Standards and
Scientiﬁc Commissions of the FCI. The translation, updating and publication of the
standards are carried out by the FCI. These standards are the reference for the judges
at shows held in the FCI member countries, but also for the breeders in their attempt
to produce top-quality dogs.
Breed groups
FCI recognized breeds are divided into 10 groups. A brief description of these groups
and a brief list of the most popular breeds for each group are listed below.
• GROUP 1
Sheepdogs and Cattledogs (exept Swiss Cattledogs)
German Shepherd
Belgian Shepherd
Czechoslovakian Shepherd
Border Collie
Maremmano Abruzzese Shepherd
• GROUP 2
Pinscher and Schnauzer - Molossoid and Swiss Mountain and Cattledogs
Rottweiler
Boxer
Doberman
Cane Corso
British Bulldog
Great Dane
Schnauzer
• GROUP 3
Terrier
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American Staﬀordshire Terrier
Bull Terrier
West Highland White Terrier
Yorkshire Terrier
Fox Terrier
• GROUP 4
Dachshunds
• GROUP 5
Spitz and primitive types
Siberian Hysky
Akita Inu
Samoyed
Chow-Chow
Italian Spitz (Volpino Italiano)
• GROUP 6
Scent hounds and related breeds
Italian Scenthound
Beagle
Dalmatian
Basset Hound
• GROUP 7
Pointing Dogs
Pointer
Irish Setter
• GROUP 8
Retrievers  Flushing Dogs  Water Dogs
Labrador Retriever
Golden Retriever
Cocker Spaniel
Springer Spaniel
• GROUP 9
Companion and Toy Dogs
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Chihuahua
Shih Tzu
Cavalier King Charles
Pekinese
Poodles
Bolognese
• GROUP 10
Sighthounds
Greyhound
Galgo
Italian Greyhound (Piccolo Levriero Italiano)
193
Appendix G
194
CHECK SHEET FOR
VETERINARY PRACTITIONERS
195
DOG BEHAVIOUR CHECK LIST:  
IMPORTANT THINGS TO CHECK WHEN A DOG IS BEING PRESCRIBED 
CORTICOSTEROID DRUGS 
This check sheet is intended as an aid for practitioners, who may be unfamiliar with the 
behavioural side effects of corticosteroid drugs. The sheet focuses on the areas of 
behavioural change in the dog which have been found to be of significance  and relevance to 
human safety.  Please use this to help control preventable risk. 
Glucocorticoid drugs can change the behaviour of normal dogs and those with pre-existing 
behaviour problems. You should ask your clients a few simple questions before they start the 
corticosteroid treatment and provide at least the concise advice outlined below to help to 
prevent possible problems as necessary. In extreme cases you may wish to reconsider the 
benefits of corticosteroid therapy versus the risks, before the animal has received specialist 
behavioural support.  
Part 2 relates to a follow up session when potential changes in behaviour might have been 
noticed by owners during the treatment. This latter information might be very useful in the 
case of repeated courses of treatment in order to prevent the onset or worsening of 
management and behaviour problems in future.  
 
Case n.      Client name …………………. Tel/E-mail…………………………….. 
Dog name………….Age…... Gender M □ F □  Neutered □   Breed/type …….. 
Drug prescribed …………….Dose….. Reason for prescription…………………. 
 
PART 1. Prescription time.  Start of the therapy (day/month/year) ../../…. 
 
Question 1. Behaviour in the presence of food 
 
Did your dog ever growl or behave aggressively towards human beings in the presence of 
food?   
Yes  □    No □ 
 
Advice 
While your dog receives therapy with ……. .(name of the drug) he/she might be more 
motivated to defend food.  Regular rituals for feeding your dog will prevent unexpected 
aggressive reaction for example when someone comes close to his/her bowl or when the dog 
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is approached while he/she is chewing something. Give food in a quiet area of your house, 
take away the bowl when the dog has finished and is far removed from his/her feeding place. 
Supervise young children so that they will not have any opportunity to come close to the dog 
when there is food or chewing objects around. If you answered ‘Yes’ to this question, the 
above suggestions are important all the time and not just during corticosteroid therapy: 
consider seeking  professional behavioural advice to address this problem more fully. 
 
Question 2. Fears 
 
Is your dog fearful of people, sounds or particular stimuli?  
  
Yes  □   No □ 
 
Advice 
While your dog receives therapy with …………(name of the drug) he/she might increase fear  
related reactions. If your dog is shy with people he/she might be more motivated to avoid 
physical contacts and this might include a higher tendency to withdraw when approached or 
even try to snap or bite. If you notice that your dog tends to withdraw when approached ask 
people not to touch him/her and be particularly careful with children. In the same way, if your 
dog is sensitive to sounds, try to limit exposure to unusually noisy environments during the 
therapy. If your dog is fearful of thunderstorms this might worsen during the therapy: keep 
the dog in a quiet and protected place and avoid contact with children and strangers in these 
situations. If you dog shows severe signs of fear consider seeking  professional advice to 
address these problems more fully.   
 
Question 3. Irritability 
 
Does your dog growl when disturbed? For example when someone touches him/her while 
he/she is resting or playing?  
  
Yes  □   No □ 
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Advice 
While your dog receives therapy with …………(name of the drug) he/she might become 
more irritable.  
This tendency might also be related to physical discomfort and it is important to prevent 
unpredictable physical contacts. Always ask your dog to come towards you rather than go to 
his/her bed and pet him/her. Instruct all your family members to do the same. It is also 
important that children avoid hugging or holding  your dog while he/she is not well and 
receiving therapy with corticosteroid drugs. If your dog growled when touched in the past, 
prevent children and strangers from touching  him/her. If you dog has growled in the past 
when being groomed put on a muzzle before grooming. If you answered yes to Question 3, 
consider seeking  professional advice for a fuller resolution of this issue.  
 
Question 4. Barking 
 
Does your dog bark frequently and intensively?  
  
Yes  □   No □ 
 
Advice 
While your dog is  receiving therapy with …………(name of the drug) he/she might bark 
more.  
To prevent this problem try to individualise the contexts in which the dog tends to bark more 
and the motivation for barking. If barking is mainly motivated by alarm or territorial defense 
try to keep your dog far from your garden fence and in general try to protect him/her from 
any  triggering stimuli. This might prevent a worsening of this behaviour.  If barking is 
mainly motivated by attention seeking try not to reinforce this behaviour with your attention 
(this includes shouting at the dog in an attempt to tell him/her off) and increase positive 
reinforcements when the dog is calm. Excessive barking can be a sign of distress and 
professional advice might be indicated in severe cases.  
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PART 2. Follow up. End of the therapy (day/month/year) ../../…. 
 
A few possible changes in behaviour during glucocorticoid therapies might be reported by 
owners 
Some possible changes are listed below. Filling in this part of the checklist will be a useful 
tool for giving advice in case of repeated courses of therapy with corticosteroid drugs. 
 
During the therapy the dog was: 
 
• Less playful      □     More playful              □      Playful as usual   □ 
• More food protective □ Less food protective □       No change in food protection □ 
• More fearful      □ Less fearful  □       No changes in fearfulness □ 
• More irritable             □ Less irritable  □       No changes in irritability □ 
• Barked more               □ Barked less  □       No changes in barking  □ 
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Possible behavioral effects of exogenous corticosteroids
on dog behavior: a preliminary investigation
Lorella Notari, Daniel Mills
Animal Behaviour, Cognition and Welfare Group, Department of Biological Sciences, University of Lincoln,
Riseholme Park, United Kingdom.
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Abstract Glucocorticoids arewidely used in veterinarymedicine and their physical side effects arewell-
known; however, the effects on dog behavior linked to their role in the stress response and effects on
mood have not been reported in previously published data. In this article, retrospective owner reports
of the behavioral changes in dogs during corticosteroid therapy in a series of cases have been described
so as to generate items for future use in a controlled structured questionnaire. The perceptions of behav-
ioral changes in dogs during corticosteroid therapy were investigated through semi-structured open in-
terviews of the owners of 31 dogs of different breeds, genders, and ages. All dogs had received
corticosteroid therapies in the past 6 months. In all, 18 dogs had been administered methylprednisolone
(dose range, 0.2-1 mg/kg), 8 were administered prednisolone (dose range, 0.2-1 mg/kg), and 5 were ad-
ministered dexamethasone (dose range, 0.01-0.3). Methylprednisolone and prednisolone were used for
dermatological conditions, and dexamethasone was used for orthopedic conditions. Owners were asked
to describe their dog’s behaviors both on and off corticosteroid therapy. Interviews were ceased when
answers became repetitive with no new reported behavioral change (interview to redundancy). In all,
11 owners reported behavioral changes in their dogs; 9 dogs were reported to show more than one be-
havioral change. Six dogs reportedly showed nervousness and/or restlessness, 3 showed an increase in
startle responses, 3 showed food guarding, 2 showed a decrease in their activity level, 3 showed an in-
crease in avoidance responses, 4 showed irritable aggression, and 2 dogs increased barking. Semi-
structured interviews can be useful preliminary tools for the identification of areas of future investigation,
and the outcomes of the interviews reported in this article will be used in further quantitative research, to
investigate more rigorously the possible relationship between these signs and corticosteroid use in dogs.
 2011 Elsevier Inc. All rights reserved.
Introduction
Corticosteroids are widely used in veterinary medicine for
several conditions and they are among the most prescribed
drugs for pet animals (McDonald and Langston, 1995,
Sousa, 2009).
Corticosteroid drugs have both mineralocorticoid and
glucocorticoid activities, but are mainly used for their
glucocorticoid effects. It is well-known and also well
reported that exogenous corticosteroids can lead to medical
complications, either directly or indirectly, by causing, for
example, immunosuppression ormasking signs that might be
important for the diagnosis or monitoring of a disease;
however, they are also important components of stress
responses. Evidence from other species suggests that effects
on the brain are complex, involving multiple neurotransmit-
ters and a range of cognitive processes and behavioral
Address for reprint requests and correspondence: Lorella Notari, Ani-
mal Behaviour, Cognition and Welfare Group, Department of Biological
Sciences, University of Lincoln, Riseholme Park LN2 2LG, UK;
Tel: 1441522895356.
E-mail: lorellanotari@lorellanotari.it
1558-7878/$ - see front matter  2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.jveb.2011.02.004
Journal of Veterinary Behavior (2011) 6, 321-327
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responses (Wolkowitz, 1994). Although the physical side
effects of corticosteroids have been widely described in vet-
erinary medicine, reports of psychological or behavioral side
effects are anecdotal (Dodman and Schuster, 1998) and, so
far, no published data are available about the incidence of
these kinds of problems in pet animals. By contrast, in human
medicine and also in laboratory animals, the psychological
effects of exogenous corticosteroids have been described in
several studies. In the early 1950s, Brody (1952) suggested
that psychiatric reactions of patients under corticosteroid
treatment reflected an extreme version of a patient’s usual
stress reaction and recent studies report that exogenous cor-
ticosteroids can have side effects such as anxiety, depression,
and increased aggression (de Kloet et al., 1999; Brown and
Chandler, 2001; Hall et al., 2003). In several medical reports,
a serious reaction to exogenous corticosteroids called ‘‘ste-
roid psychosis’’ has been described. Steroid psychosis has
been defined as a condition characterized by a series of severe
symptoms, such as delirium, mania/hypomania, confusion,
insomnia, memory, and attention impairments, and the inci-
dence of such conditions seems to be related to corticosteroid
dose (Wolkowitz et al., 2009). Cerebral changes and anxiety
induced by prednisone have been described in rats
(Gonzalez-Perez et al., 2001) as has cognitive dysfunction,
with learning and memory impairment (Ramos-Remus
et al., 2002). Considering the wide use of corticosteroids in
veterinary medicine, it is perhaps surprising that there is
lack of data and awareness relating to potential behavioral
side effects, especially because the role of stress hormones
in the onset of behavior problems is widely recognized in
the veterinary literature (e.g., Overall, 1997; Pageat, 1998).
Data about the incidence of behavioral side effects in dogs
might be useful for owners to prevent them from inadver-
tently increasing personal risk to themselves or others
when their dogs are under treatment with these drugs. To in-
vestigate this issue, our approach has been to first investigate
which behaviors or changes in behavior, if any, are reported
by owners after the administration of exogenous corticoste-
roids to their dogs.
Using an approach similar to that used in the investiga-
tion of behavioral changes associated with chronic pain
in dogs (Wiseman et al., 2001), it was hypothesized that
owners, through direct observations of their dogs’ behavior
during corticosteroid therapy, might provide a useful start-
ing point for the development of further objective investiga-
tion. In this article, we report the first stage of an ongoing
investigation into the behavioral side effects of exogenous
corticosteroids in dogs. Our aim was to establish a list of
possible behavioral side effects using a systematic owner
interview procedure.
Materials and methods
Subjects used for this study included a self-selected con-
venience sample of dog owners who were recruited from
clients of veterinary clinics in the north of Italy. Inclusion
criteria were that dogs had received therapy with cortico-
steroids for a minimum of 2 weeks in the past 6 months
before the recruitment. Semi-structured interviews were
conducted, in which owners were asked whether they had
noticed any change in their dogs’ behavior during the time
they were given corticosteroids. At the beginning of the
interview, owners were free to answer without any prompts,
then they were prompted with questions about areas of
behavior in which, on the basis of the previously published
data, changes might be expected. Table 1 lists the investi-
gated domains. The interviews terminated when data redun-
dancy occurred. The point of data redundancy was
determined as the point at which owner interviews failed
to generate new information for 10 successive interviews
(Sandelowski, 1995; Strauss and Corbin, 1998).
The owners of 31 mixed-breed dogs (each owner had only
1 dog enrolled in the study), 19 male dogs and 12 females
of different ages (range of ages from 1 to 13 years), were
included in the case series. Of 31 dogs, 18 had been admin-
istered methylprednisolone (dose range, 0.2-1 mg/kg), 8 were
administered prednisolone (dose range, 0.2-1 mg/kg), and 5
dexamethasone (dose range, 0.01-0.3). Further details con-
cerning individual subjects and the dosing procedure used
are given in Table 2. Of these 31 dogs, 9 were also receiving
antibiotic therapy. In all, 24 dogs suffered from a dermatolog-
ical condition, 5 from arthritis, 1 from myasthenia gravis,
and 1 from recurrent otitis (Table 2).
Results
In all, 11 owners reported that they considered there were
behavioral changes in their dogs during corticosteroid
therapy. Nine owners reported that their dogs showed
more than one behavioral change, and of these 9 dogs, 2
were also receiving treatment with antibiotics (amoxicillin
and clavulanic acid). Six dogs reportedly showed nervous-
ness and/or restlessness, 3 an increase in startle responses, 3
food guarding, 2 a decrease in their activity level, 3 an
increase of avoidance responses, 4 irritable aggression, and
2 increased barking. These interpretations were deduced
and summarized from the owners’ descriptions and were
represented by the onset of certain behaviors or by an
increase in their frequency and/or intensity. The findings
are summarized in Table 3.
Brief case reports on cases showing behavioral changes
during treatment are given later in the text.
The owner of dog 1 reported that after a few days of
corticosteroid therapy the dog became more aggressive in
the presence of food and in general when disturbed or
approached. The owner of dog 3 described the dog as a very
sweet and calm dog before the therapy, whereas after the
second injection of dexamethasone (day 3 of therapy), the
dog became restless, very nervous, and tended to be startled
by even minimal sound. The owner reported that his dog
322 Journal of Veterinary Behavior, Vol 6, No 6, November/December 2011
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was almost impossible to keep calm, but that after a few
days following the interruption of corticosteroid treatment
the dog gradually returned to his usual behavior and
reactivity level.
The owner of dog 7 also reported that after a few days of
therapy the dog was more prone to startling at every sound
and stimulus but was less active, in general, during the day,
while appearing restless in the evening.
Dog 10 received 5 mg of prednisone (0.3 mg/kg) for 2
months and the owner described that after a few days of
therapy, the dog started to show aggression in the presence of
food and became very difficult to manage because he had
become very nervous, restless, and showed increased
attention-seeking by barking and jumping on people.
When the therapy was discontinued, the dog gradually
became more calm and manageable.
The owners of dogs 12 and 15 both described that their
dogs tended to stay isolated from social contexts, in
particular when people spoke loudly.
Dog 12 had been rescued when she was 2 years old and
the owner described the dog as fearful and tending to avoid
people when first obtained, although this resolved with
time. After corticosteroid treatment, the owner reported that
the dog seemed to have returned to showing the behavior
she had expressed at the time she was adopted, several
years before. Both these dogs (dogs 12 and 15) reportedly
returned to their more usual behavior when therapy was
discontinued.
Table 1 Areas of dog behavior that were investigated through open questions. Questions focused on differences on and off
corticosteroid therapy
Question Investigated domains Question examples
1 General question Did you notice any change in your dog’s behavior during
corticosteroid therapy? Can you describe this change?
2 Dog personality How would you describe your dog’s personality? Is this
changed in any way during corticosteroid therapy?
Can you describe this change?
3 Behavior with family members Have you noticed any change towards family members when
the dog was under corticosteroid therapy? Can you de
scribe this change?
4 Behavior with strangers at home and outside Have you noticed any change towards strangers or guests
at home or people outside, when the dog was under
corticosteroid therapy? Can you describe this change?
5 Behavior when left alone Have you noticed any change in your dog’s behavior when
he/she was left alone at home, during corticosteroid
therapy? Can you describe this change?
6 Behavior during walks Have you noticed any change in your dog’s behavior during
walks when the dog was under corticosteroid therapy?
Can you describe this change?
7 Fears and avoidance behaviors Have you noticed any change as far as fearfulness or
avoidance of people, animals or situations when the dog
was under corticosteroid therapy? Can you describe this
change?
8 Barking Have you noticed any change in the intensity of barking
in general, when the dog was under corticosteroid
therapy? Can you describe this change?
9 Eating Have you noticed any change in behavior around food when
the dog was under corticosteroid therapy? Can you
describe this change?
10 Drinking Have you noticed any change related drinking when the
dog was under corticosteroid therapy? Can you describe
this change?
11 Sleeping Have you noticed any change in the way your dog sleeps
when the dog was under corticosteroid therapy? Can you
describe this change?
12 Behavior with other animals Have you noticed any change in behavior towards
other dogs or other animals when the dog was under
corticosteroids? Can you describe this change?
13 Behavior problems Have you noticed any behavior problem that was not
present before, when the dog was under corticosteroid
therapy? Can you describe this change?
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Table 2 Breed, gender and reproductive status, age, disease, type, and doses of administered corticosteroids of the 31 dogs included in the study
Dog Dog breed/type
Age
(years) Gender
Medical
condition Corticosteroid SD mg/kg W/MD mg/kg
Concomitant
drug therapies
1 Charplanina sheep dog 5 M Dermatological Methylprednisolone 0.6 0.3 Antibiotics
2 Crossbreed 3 F Dermatological Methylprednisolone 0.5 0.25
3 Crossbreed 8 M Arthritis Dexamethazone 0.15 0.07
4 Jack russel terrier 2 F Dermatological Methylprednisolone 0.5 0.25
5 Pomeranian 4 M Dermatological Methylprednisolone 0.6 0.30 Antibiotics
6 Fox terrier 6 M Dermatological Prednisolone 0.5 0.25 Antibiotics
7 WHWT 9 FS Dermatological Prednisolone 0.6 0.3
8 Crossbreed 3 FS Dermatological Methylprednisolone 0.5 0.25 Antibiotics
9 crossbreed 7 M Dermatological Methylprednisolone 1.0 0.5 Antibiotics
10 Beagle 5 M Dermatological Prednisolone 0.3 0.3
11 German shepherd 2 M Dermatological Methylprednisolone 0.4 0.2
12 Italian Hound 7 FS Dermatological Methylprednisolone 0.6 0.3 Antibiotics
13 Crossbreed 3 M Dermatological Methylprednisolone 0.5 0.25
14 Golden retriever 8 FS Dermatological Prednisolone 0.4 0.2 Antibiotics
15 WHWT 13 FS Dermatological Methylprednisolone 0.5 0.25
16 Boxer 1 M Dermatological Methylprednisolone 1.0 0.5
17 Crossbreed 6 M Dermatological Prednisolone 0.5 0.25
18 Miniature schnautzer 11 F Arthritis Dexamethazone 0.3 0.15 Antibiotics
19 Yorkshire terrier 12 M Recurrent otitis Prednisolone 0.4 0.2
20 Dachshund 3 M Dermatological Methylprednisolone 0.4 0.2 Antibiotics
21 German shepherd 2 F Dermatological Methylprednisolone 0.5 0.25
22 Bull terrier 2 F Dermatological Methylprednisolone 0.6 0.3
23 Crossbreed 7 M Dermatological Methylprednisolone 0.5 0.25
24 Lagotto Romagnolo 6 M Myasthenia gravis Prednisolone 0.5 0.25
25 Golden Retriever 4 M Dermatological Methylprednisolone 0.6 0.3 Antibiotics
26 Bernese mountain dog 8 F Arthritis Dexamethazone 0.2 0.1
27 German shepherd 9 M Arthritis Dexamethazone 0.1 0.05
28 Boxer 9 F Arthritis Dexamethazone 0.06 0.03
29 Crossbreed 5 M Dermatological Methylprednisolone 0.5 0.25
30 Maremmano abruzzese shepherd 4 M Dermatological Prednisolone 0.4 0.2
31 Bergamasco shepherd 8 M Dermatological Methylprednisolone 0.8 0.4
WHWT, West Highland White Terrier; M, male; F, female; FS, spayed female; SD, starting dose of corticosteroids; WD/MD, weaning dose/maintenance dose of corticosteroids.
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Dog 16 received 1 mg of methylprednisolone on the first
day of therapy.Almost immediately the owner noticed that he
became very calm. The owner reported that this dog used to
be very lively and jumped on people all the time. Under
corticosteroid therapy he seemed to be almost sedated. The
dose was reduced to half (0.5 mg/kg) on the second day of
therapy and the dog appeared less sedated but still very calm
until the end of the entire period of corticosteroid therapy,
when he gradually returned to his previous behavior.
Dog 20 reportedly became more reactive and started to
bark very frequently and intensely at even minor stimuli a
few days after the beginning of corticosteroid therapy.
During the second week, the owner interrupted the therapy
and the dog apparently became gradually calmer and
returned to his previous behavior. The signs of the dog’s
dermatological condition which preceded and followed the
corticosteroid therapy and the behavior change had not
been resolved at the time of interview.
The owner of dog 25 reported that during the first week
of corticosteroid therapy, the dog started to growl at anyone
who came close to his food bowl and also bit a family
person who tried to pet the dog while he was lying on his
bed. The dog had started to suffer from the dermatological
problem some days before the onset of the therapy, but did
not apparently show any sign of aggression until the
initiation of the therapy. When corticosteroids were dis-
continued, the dog stopped growling in similar contexts.
The owner of dog 29 reported that after a few days of
treatment the dog started to become nervous and agitated,
and to bark incessantly at almost any stimulus, to the point
that they could not leave him in the garden anymore. The
dog also started to react fearfully toward people during
walks and to bark at them. Although the dermatological
problem was not resolved, they decided to interrupt the
therapy in the third week of treatment and the dog
gradually returned to his previous behavior.
The owner of dog 30 reported that, after a few days of
therapy, he started to become nervous and showed aggression
toward both strangers and family members for no apparent
reason beyond coming close to him. These episodes hap-
pened during the second week of therapy while the dog was
taking half of the starting dose of methylprednisolone. The
owner decided to interrupt the therapy and to treat the dog just
with antibiotics. After the interruption of corticosteroid
therapy, the dog seemed to return to its previous behavior
but the dermatological condition worsened. After 1 month,
the veterinary surgeon suggested starting corticosteroids
again, at the dose of 0.3 mg/kg of prednisolone. After a few
days, the dog began to become nervous again and bit the
owner on his arm when he tried to hold him.
Discussion
The findings of this descriptive analysis of a series of cases
in which dogs have been treated with corticosteroids seem
Ta
b
le
3
B
re
ed
,
ag
e,
g
en
d
er
,
m
ed
ic
al
co
n
d
it
io
n
,
co
n
co
m
it
an
t
th
er
ap
ie
s,
an
d
b
eh
av
io
ra
l
ch
an
g
es
re
p
o
rt
ed
in
1
1
d
o
g
s
w
it
h
id
en
ti
fi
ed
ch
an
g
es
d
u
ri
n
g
co
rt
ic
o
st
er
o
id
th
er
ap
ie
sa
D
o
g
D
o
g
b
re
ed
A
g
e
G
en
d
er
M
ed
ic
al
co
n
d
it
io
n
Co
rt
ic
o
st
er
o
id
Co
n
co
m
it
an
t
d
ru
g
th
er
ap
ie
s
R
ep
o
rt
ed
b
eh
av
io
ra
l
ch
an
g
es
1
Ch
ar
p
la
n
in
a
sh
ee
p
d
o
g
5
M
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
A
n
ti
b
io
ti
cs
(a
m
o
xi
ci
ll
in
an
d
cl
av
u
la
n
ic
ac
id
)
Fo
o
d
g
u
ar
d
in
g
;
ir
ri
ta
b
le
ag
g
re
ss
io
n
3
Cr
o
ss
b
re
ed
8
M
A
rt
h
ri
ti
c
D
ex
am
et
h
az
o
n
e
N
o
n
e
N
er
vo
u
sn
es
s;
in
cr
ea
se
d
st
ar
tl
e
re
sp
o
n
se
7
W
H
W
T
9
F
D
er
m
at
o
lo
g
ic
al
P
re
d
n
is
o
lo
n
e
N
o
n
e
N
er
vo
u
sn
es
s
an
d
d
ec
re
as
ed
ac
ti
vi
ty
le
ve
l
1
0
B
ea
g
le
5
M
D
er
m
at
o
lo
g
ic
al
P
re
d
n
is
o
lo
n
e
N
o
n
e
N
er
vo
u
sn
es
s;
fo
o
d
g
u
ar
d
in
g
1
2
It
al
ia
n
h
o
u
n
d
7
F
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
N
o
n
e
N
er
vo
u
sn
es
s;
o
n
se
t/
in
cr
ea
se
d
av
o
id
an
ce
b
eh
av
io
rs
1
5
W
H
W
T
1
3
F
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
N
o
n
e
A
vo
id
an
ce
b
eh
av
io
rs
1
6
B
o
xe
r
1
M
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
N
o
n
e
D
ec
re
as
ed
ac
ti
vi
ty
le
ve
l
2
0
D
ac
h
sh
u
n
d
3
M
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
N
o
n
e
In
cr
ea
se
d
st
ar
tl
e
re
sp
o
n
se
;
in
cr
ea
se
d
b
ar
ki
n
g
2
5
G
o
ld
en
re
tr
ie
ve
r
4
M
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
A
n
ti
b
io
ti
cs
(a
m
o
xi
ci
ll
in
an
d
cl
av
u
la
n
ic
ac
id
)
Fo
o
d
g
u
ar
d
in
g
;
ir
ri
ta
b
le
ag
g
re
ss
io
n
2
9
Cr
o
ss
b
re
ed
5
M
D
er
m
at
o
lo
g
ic
al
M
et
h
yl
p
re
d
n
is
o
lo
n
e
N
o
n
e
N
er
vo
u
sn
es
s;
in
cr
ea
se
d
st
ar
tl
e
re
sp
o
n
se
;
av
o
id
an
ce
b
eh
av
io
rs
;
in
cr
ea
se
d
b
ar
ki
n
g
3
0
M
ar
em
m
an
o
ab
ru
zz
es
e
sh
ep
h
er
d
4
M
D
er
m
at
o
lo
g
ic
al
P
re
d
n
is
o
lo
n
e
N
o
n
e
N
er
vo
u
sn
es
s;
ir
ri
ta
b
le
ag
g
re
ss
io
n
a
D
o
g
n
u
m
b
er
co
rr
es
p
o
n
d
s
to
n
u
m
b
er
in
Ta
b
le
2
.
Notari and Mills Possible effects of steroids on behavior 325
Appendix H
206
to suggest that, at least in some cases, behavioral changes
may occur subsequent to treatment, and that this is a
potentially valuable subject for further study. However, the
findings reported should be interpreted with caution for
several reasons. As discussed later, it is difficult to establish
from these cases the extent to which any behavioral
changes are associated with corticosteroid therapy rather
than changes in the signs or severity of the underlying
disease being treated. In addition, without a comparative
control group, it is not possible to determine the extent to
which owners may report behavioral changes when asked
to recall them without any therapeutic intervention.
The method of collecting data through the reports of
care takers, in a manner similar to that used in this study,
has been employed in several studies, both in human and in
nonhuman animals (Hall et al., 2003; Wells, 2009). It has
been argued that because owners spend considerable time
in contact with their animals, they are in the best position
to provide interpretive information on the overall patterns
of behavior of their own dogs (Wemelsfelder, 1997;
Wiseman et al., 2001). However, in this case both the
method of recruitment of owners and the style of question-
ing used are likely to have increased the reporting of behav-
ioral changes: the former as owners with concerns about
corticosteroid treatment may have been more likely to
enroll, and the latter because asking owners directly about
changes in behavior associated with corticosteroid therapy
is likely to increase the chance that such behaviors are re-
ported. In addition, owners were asked to recall retrospec-
tively about the behavior of their pet before and during
treatment, after a variable period, thereby making their
responses susceptible to variable recall biases.
Although findings are descriptive and should be inter-
preted with caution, some of the behaviors described by
owners are consistent with the predictions which might be
made from scientific reports in other species, which might
suggest a general increased reaction to stimuli, especially
potentially aversive ones. Nonetheless, it must be recog-
nized that other factors in the study population might be
important for the apparent onset of behavioral changes. For
example, the stress and discomfort associated with condi-
tions, such as pruritus and pain, that necessitate the use of
glucocorticoid therapies might alter the behavior of the
animals (Seksel, 2007). If a subject is stressed either phys-
iologically or psychologically, adrenocorticotropic hor-
mone production is enhanced, regardless of the levels of
circulating cortisol, and thus it might be expected that the
behavioral symptomatology of dogs that already have
some form of behavioral disturbance may be exacerbated
by treatment, rather than being created by the exogenous
steroid treatment (McEwen, 2000). In this article, the
main goal was to find items for future investigation through
a controlled survey and therefore owners were prompted to
use their own words to describe their dogs’ behaviors in an
open and articulate way. Among the cases in which behav-
ioral changes were reported by owners, most owners
spontaneously reported several important behavioral
changes after the first general questions (Table 1, Q1 and
Q2). These questions could easily be included in routine
follow-up monitoring in practice and may help alert practi-
tioners to potential risks they need to be aware of, especially
given that in several cases, treatment was associated with
aggression and an actual bite in 2 incidences.
Most of the dogs involved in the study suffered from
dermatological problems and were treated with oral cortico-
steroids, methylprednisolone, and prednisolone, with similar
dose ranges and therapeutic schedules, starting with a higher
dose in the first week of therapy and continuing with
half dosage for another week and, finally with the same
half dosage every 2 days for variable periods. It is noteworthy
that the reported behavioral changes seemed to appear quite
early during corticosteroid treatments and this seems to be
consistent with data reported in human studies (Warrington
and Bostwick, 2006). Two dog owners (dog 20 and dog 29)
explicitly reported a stronger association with corticosteroid
treatment rather than the clinical condition for which the
medication was prescribed, and this might be important as
the latter could be a confounding factor in many case reports.
Nonetheless, it must be acknowledged at this time that
owners may easily perceive relationships when none actually
exist, especially because some may perceive corticosteroids
as ‘‘dangerous’’ drugs (Cullen et al., 2006).
The coadministration of other therapies further compli-
cates the interpretation of the results. It has been shown that
some antibiotics can affect behavior, for example penicillin
and its analogues have been associated with sedation and
anxiety, whereas quinolones, widely used in dogs and cats
might cause, in rare cases, restlessness and irritability or, on
the contrary, lethargy (Sternbach and State, 1997; Turjanski
and Lloyd, 2005). Other drugs that are often used in dogs,
such as topical or oral antiparasitic products, can have effects
onbehavior (Florio et al., 1989; deSouzaSpinosa et al., 2000).
It is reasonable to suggest that exogenous corticosteroid
dosage might influence the onset of behavioral side effects
and, in the present study sample, dose ranges varied and
questions were directed generally to obtain information of
changes in behavior on and off therapy, without any
specific investigation about dose-related effects. Dose and
type of corticosteroid used should be more thoroughly
considered in future studies, along with other elements
related to the pharmacokinetics of these drugs; for example,
it has been reported that unbound serum prednisolone levels
are higher during periods of hypoalbuminemia (Wolkowitz
et al., 1990). Investigating the effect of corticosteroid dose
is a particularly challenging issue because they are often
prescribed in dogs with changing titrations and are adjusted
according to the desired effect. A more specific investiga-
tion at different dosages would be useful to discern any
possible correlation, as has been reported in human beings,
between dose and behavioral disturbances, although even
the human data are not consistent (Hall et al., 2003;
Felder-Puig et al., 2007).
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Other factors to consider include genetic influences on
negative feedback mechanisms that are involved in the
stress response (Gomez et al., 1998) and the rhythmicity of
hypothalamic pituitary adrenal axis activity. Cortisol is se-
creted in a pulsatory manner; circadian patterns, similar to
the ones that have been demonstrated in human beings, are
difficult to verify in dogs probably because of the very dif-
ferent housing and management conditions of individual
dogs and groups of dogs (in shelters, laboratories, in
breeder kennels in households, etc.), but it seems reason-
able to suggest that there are patterns of diurnal activity, de-
pending on dog management conditions (Kolevska´ et al.,
2003). Feeding seems to be one of the most important reg-
ulatory elements for the synchronization of HPA activity
(Leal and Moreira, 1997). Exogenous corticosteroid might
therefore interfere with the normal physiology of HPA
axis depending on the management of dogs and we cannot
exclude that some effects were influenced by external fac-
tors such as the time of feeding or the housing conditions.
The effects might also be indirect; for example, the appetite
stimulant effects of corticosteroids are widely recognized,
and if a dog is hungrier, it may be more prone to guard
food and show aggression. Other indirect relationships
might also exist with some of the other reported signs.
The aforementioned issues suggest caution in the inter-
pretation of these results, but we nonetheless suggest that
they should encourage further investigation from many
perspectives of this potentially important issue, given both
the strong theoretical basis for corticosteroids increasing
vigilance and biasing sensitivity toward aversion. Consid-
ering the lack of evidence to the contrary, we further
suggest, at this time, that veterinarians should not only
monitor for behavioral side effects but also consider
offering some precautionary behavioral management
advice to owners when dispensing these drugs.
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Behavioural changes in dogs treated with corticosteroids
Lorella Notari, Oliver Burman, Daniel Mills
Animal Behaviour, Cognition and Welfare Group, School of Life Sciences, Joseph Banks Laboratories, University of Lincoln, Lincoln LN6 7DL, UK
H I G H L I G H T S
• We aimed to identify behavioural changes in dogs treated with corticosteroids.
• Dogs on corticosteroids showed behaviour associated with a negative affective state.
• In a behavioural test, dogs on corticosteroids avoided a mildly aversive stimulus.
• Dog owners should be advised by veterinarians about behavioural risk management.
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In human medicine, psychiatric side effects among patients on corticosteroid therapy are widely reported,
but this appears to have been largely overlooked in the animal literature despite glucocorticoids being
widely used in veterinary medicine. Therefore the aim of the current study was to identify possible
psycho-behavioural changes in dogs treatedwith corticosteroids. Two differentmethodologieswereused. Firstly,
dog owners were asked to ﬁll a 12 item questionnaire aimed at further validating the initial results of a
previous survey relating to changes seen when their dog was receiving corticosteroid treatment. In a second
study, a population of dogs undertook behavioural tests aimed at objectively identifying changes when receiving
corticosteroid therapy.
In the ﬁrst study, a sample of owners whose dogs were receiving treatment for dermatological, orthopaedic or
other conditions evaluated their dogs' behaviour on and off therapy, using a seven point scale. The survey was
completed by 44 dog owners with dogs receiving treatment with a range of corticosteroid preparations (mainly
prednisolone and methylprednisolone) and 54 dog owners with dogs receiving treatment with other drugs,
mainly antibiotics and non-steroidal anti-inﬂammatory drugs. Dogs under corticosteroid treatment were
reported to be signiﬁcantly less playful, more nervous/restless, more fearful/less conﬁdent, more aggressive in
the presence of food, more prone to barking, more prone to startle, more prone to reacting aggressively when
disturbed, and more prone to avoiding people or unusual situations.
In the second study, eleven “treatment” dogs were tested both before and during corticosteroid treatment with
either methyl-prednisolone or prednisolone to assess their sensitivity to a potentially aversive sound stimulus.
Eleven control dogs were also tested at the same time intervals in the same environment. Dogs were exposed
to a brief dog growl while they explored bowls containing food and their behaviour was video recorded.
Treatment dogs were found to investigate the area in the vicinity of the bowls for signiﬁcantly less time and to
eat signiﬁcantly fewer pieces of foodwhen on corticosteroids, compared to control dogs, after hearing the growl.
These results provide the ﬁrst empirical evidence of possible adverse psycho-behavioural side effects in a
veterinary clinical setting following the use of corticosteroids, and suggest the need for concomitant behavioural
advice when these drugs are used in general veterinary practise to avoid the risks associated with these changes.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Glucocorticoids are widely used in veterinary practice but are
also among the most important mediators of the stress-response
[1,2]. This response has physiological, behavioural, cognitive and
emotional components, having the potential to inhibit positively
motivated responses and to increase anxiety-related behaviours
[3–5]. Glucocorticoids mediate changes in cognition, learning and
emotional processes through the activation of glucocorticoid recep-
tors in diverse brain areas from the prefrontal cortex through to
the hippocampus, basal ganglia and amygdale [3]. Both excesses
and deﬁcits in glucocorticoid can lead to impairment of learned and
emotional processes and responses [6].
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The therapeutic use of glucocorticoid drugs in companion animals is
associated with several well recognized physical side effects including
gastro-intestinal problems, suppression of adrenal gland function and
increased risk of infections [7,8]; possible psychological side effects
have not received much attention beyond a preliminary survey report-
ed by the authors [9]. However, in humanmedicine, several surveys and
case reports have shown that important psychiatric side effects can
occur in patients on corticosteroid therapy. It has been suggested that
the onset of corticosteroid-induced psychiatric disturbances might be
linked to pre-existing individual psychological characteristics such as
personality, with these reactions reﬂecting an extreme version of a
patient's usual stress reaction [10–12]. Increasing attention is being
given to these effects in human patients, receiving long term treatment
[11,13,14]. Neurological toxicity due to the drug itself or the synergistic
action of drugs administered concurrently have been postulated for the
unexpected behavioural and psychiatric effects of these medications
when prescribed for physical diseases [5],these effects are probably
most often related to the neurochemical cascades linked to the stress
response [14–16].
Alongside studies in humanmedicine, there is abundant evidence of
the inﬂuence of exogenous pituitary adrenal hormones on animal be-
haviour but not speciﬁcally in a therapeutic context as might occur in
companion animals. Studies in laboratory animals have shown that ex-
ogenous glucocorticoids can affect cognitive functions such as learning
and memory [6,17–19]. An effect on the emotional states of animals
has also been hypothesizedwith, for example, the experimental admin-
istration of corticosteroids to rats appearing to inﬂuence their subse-
quent emotional response to unexpected reductions in reward size
[20]. This study showed that rats treatedwith corticosteroids responded
to an unexpected downshift in reward magnitude by showing a signiﬁ-
cantly greater decrease in their consummatory behaviour – interpreted
as an expression of their emotional response – compared to a control
group subjected to the same procedure. Many of the behavioural effects
of corticosteroids would be expected if these chemicals induced a neg-
ative cognitive bias, e.g. a greater sensitivity to potentially threatening
stimuli in the environment [21].
Investigating the potential negative behavioural side effects of
glucocorticoid drugs in companion animals is clearly important in
order to make a full risk–beneﬁt analysis concerning their use, and to
ensure that appropriate advice can be given to owners and veterinarians
when these drugs are prescribed. Therefore the present study aimed to
investigate the effects of corticosteroid therapies on dog behaviour:
ﬁrstly, through a retrospective study using questionnaire responses
concerning the behaviour of dogs when on and off corticosteroid
therapy; and secondly, through a case–control study of the responses
of subjects in a behavioural test aimed at assessing the animal's
response to a potentially threatening sound stimulus.
2. Materials and methods
2.1. Questionnaire study
A 12 item questionnaire was completed by dog owners with dogs
receiving or having recently received drug treatment, preferably
for dermatological or orthopaedic conditions. The questionnaire was
informed by the results of a previous survey [9]. Seven of the 12 items
were selected on the basis of the results of a previous survey [9], with
ﬁve further questions (‘ﬁllers’) relating to other behavioural changes
not identiﬁed in the previous survey selected among behaviours
that frequently cause complaints by dog owners [22,23], but not
thought to be inﬂuenced by corticosteroids. These were inserted partly
as ‘ﬁllers’ and to aid validation of target effects [24]. The questionnaire
was published via the Internet in both English and Italian, with a
paper version also distributed to Italian veterinary clinic clients.
Questionnaires were back translated by independent mother tongue
translators to assess the consistency of the two versions. The items
were scored on a seven point scale with two scores for each question
posed: one score for the respondent's perception when the animal
was receiving pharmacological treatment for the condition and one
for when the animal was not receiving pharmacological treatment
(Fig. 1).
The introductory part of the questionnaire gathered demographic
data relating to both the owner and their dog, information about the
drugs being given to the dog at the time of survey (such as type of
drug, time of administration and doses) and information about the
type of condition/disease for which it was being used. The respondents
were asked to mention all drugs taken in the same period for the same
or other concomitant conditions. The questionnaire was to be complet-
ed on the Internet and advertised through veterinary associations, pet
websites and magazines both in Italy and UK. Paper questionnaires
were also distributed in veterinary clinics in the north of Italy.
Questions are illustrated in Table 1 and Items 1 (Play behaviour),
5 (Attention seeking), 7 (Obedience), 8 (Guarding behaviour) and
12 (Mounting behaviour) were added as additional ﬁllers.
Fig. 1. Example of question and scoring system used in owner questionnaire: Q1 Play Behaviour.
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Responses were collated and analysed using a repeated measures
multivariate GLM (SPSS 21). In this analysis treatment related
effects on behaviour when on and off drug were considered as
dependent measures; types of treatment (divided into 3 categories:
corticosteroids, corticosteroids and other drugs, only drugs other
than corticosteroids), duration of treatment (divided into 5 categories:
1week, 1–2weeks, 2–3weeks, 2–4weeks,more than 4weeks), the rea-
son for treatment (divided into 3 categories: dermatological conditions,
orthopaedic conditions and others) were considered independent
factors. This ﬁrst multivariate analysis was made to test drug effects
within-subjects, and since only treatment typewas found to be a signif-
icant factor and there was great variation in the baseline value of
subjects, a univariate GLM was then used to examine the difference
between behaviour when on and off treatment versus treatment type,
with post hoc comparisons corrected for multiple testing by means of
a Bonferroni correction procedure.
2.2. Behavioural test
2.2.1. Subjects
Eleven dogs receiving (or due to receive) corticosteroid treatment
and 11 control dogs were recruited and successfully completed two
sessions of the behavioural test. Treatment dogs were recruited from
the patients of veterinary practices in the North of Italy. Veterinarians
were asked to propose dog owners that had received prescriptions of
oral corticosteroid drugs for dermatological problems to participate
in the research. Criteria for inclusion were that dogs had not been
prescribed any other medication; the prescription dose range was
within 0.4–0.5 mg/kg of prednisone or methylprednisolone every day.
Control dogs were recruited from among the healthy patients of veter-
inary practices and clients of dog trainers. Control dogs were tested
twice in the same environment as the dogs on corticosteroids, with
the same time interval between the two tests. Details of all subjects
are given in Table 2.
The ﬁrst behavioural test for treatment dogs occurred just before
they started therapy, with a second taking place 6–7 days into the
therapy, often just before the dose of corticosteroid started being
reduced with a view to its withdrawal.
2.3. Test procedure
The tests were conducted in three different locations in order to
accommodate the travel restrictions of clients, but the set-up was the
same at each of these: a room of sufﬁcient size to accommodate the
experimental apparatus, with a chair for the owner at the opposite
end of the room. The apparatus composed of a screen covered with a
blanket that hid a loudspeaker system connected to a computer. Five
pots were placed in front of the screen, 35 cm from the loudspeakers.
The pots were placed in a way that enabled the researcher to put
small pieces of food into them at the same time (Fig. 2). For each dog,
the kind of treat used during testing was indicated by the owner as
being the dog's favourite. The same kind of treat was used in both test
trials for that subject. Two video cameras (Canon Legria HF R506)
were used to record the dog's behaviour during testing for later
Table 1
Owner questionnaire. Verbatimof questions. Scales 1–7 illustrate the level of expression of
the investigated behaviour.
Question
numbers
Details of questions
Q1 Some dogs are very motivated to play with people, other dogs or toys.
On a scale from 1 to 7 where 1 is ‘not very playful’ and 7 is ‘very playful’
how would you rate your dog's behaviour?
Q2a Thinking about your dog's temperament, how would you deﬁne its
nervousness/restlessness on a scale from 1 to 7 where 1 is ‘very nervous
and restless’ and 7 is ‘very calm’?
Q3a Thinking about your dog's general responses, for example, in the
presence of unknown people or of new, unknown stimuli (sounds, loud
voices, unknown contexts, unknown animals or children…), on a scale
from 1 to 7 where 1 is ‘extremely fearful and insecure’ and 7 is ‘very
conﬁdent’, how would you rate your dog?
Q4 Thinking about your dog's behaviour when there is food around, on a
scale from 1 to 7 where 1 is not at all aggressive and 7 is very aggressive
in the presence of food, how would you rate your dog?
Q5 Some dogs tend to be very insistent and seek physical contact with
owners by jumping up, snapping, scratching with a front paw, whining
or barking: on a scale from 1 to 7 where 1 is ‘no attention seeking
behaviours’ and 7 is ‘frequent and intense attention seeking
behaviours’, how would you rate your dog?
Q6 Some dogs bark at any time, night and day, some others bark only in
exceptional occasions. On a scale from 1 to 7 where 1 is ‘rare barking’
and 7 is ‘frequent and intense barking’, how would you rate your
dog's behaviour?
Q7 Some dogs are very obedient, for example they come when called and
go to bed when asked, while some others are less easily controlled. On a
scale from 1 to 7 where 1 is ‘not at all obedient’ and 7 is ‘very obedient’,
how would you rate your dog's behaviour?
Q8 Some dogs are very predisposed to guarding behaviour and tend to
threaten people by barking and growling, some others are friendly with
everyone and don't show any guarding behaviour. On a scale from 1 to
7 where 1 is ‘no guarding behaviour’ and 7 is ‘intense & frequent
guarding behaviour’, how would you deﬁne your dog's behaviour?
Q9 Some dogs tend to startle very easy, for example when they hear a
sound or are suddenly touched. In these cases they can react by ﬂeeing,
getting jumpy or showing aggression. On a scale from 1 to 7 where 1 is
‘low/rare startle response’ and 7 is an ‘excessive and very frequent
startle response’, how would you deﬁne your dog's behaviour?
Q10 Some dogs tend to react aggressively if someone tries to touch them or
come close while they are resting. These dogs can become aggressive
whenever the owner tries to brush them, medicate them or even simply
tries to pet them. On a scale from 1 to 7 where 1 is ‘never aggressive
when disturbed/restrained’ and 7 is ‘very aggressive when
disturbed/restrained’, how would you deﬁne your dog's behaviour?
Q11 Some dogs have a marked tendency to avoid people or situations that
are unknown or unfamiliar, for example they tend to leave the room
when unknown guests arrive or when people scream or there are loud
noises. On a scale from 1 to 7 where 1 is ‘no tendency to hide or avoid
people or situations’ and 7 is ‘High tendency to hide or avoid people or
situations’, how would you rate your dog's behaviour?
Q12 Some dogs can show a tendency to mount people (children and adults)
or other dogs, often of the same sex. On a scale from 1 to 7 where 1 is
‘no tendency to mount’ and 7 is ‘high tendency to mount’ how would
you rate your dog's behaviour?
a Reversed scale.
Table 2
Dogs involved in the study. M =male dog; F = female.
Dog n. Breed/type Gender Age Treatmenta
1 Collie M (n) 9 0.5/kg prednisone
2 Dachshund M 4 0.4/kg prednisone
3 Labrador M 5 0.4/kg methylprednisolone
4 Golden retriever F (n) 10 0.5/kg prednisone
5 Crossbreed F (n) 4 0.4/kg prednisone
6 Cocker M 9 0.4/kg methylprednisolone
7 Pitbull M (n) 7 0.4/kg prednisone
8 Jack Russell M 3 0.5/kg prednisone
9 Crossbreed M 1 0.4/kg prednisone
10 Golden retriever F 2 0.5/kg prednisone
11 Crossbreed M 4 0.4/kg prednisone
12 Crossbreed M (n) 9 No treatment
13 Crossbreed F (n) 2 No treatment
14 Crossbreed M 2 No treatment
15 Pitbull M (n) 2 No treatment
16 Shiba Inu M 1 No treatment
17 German shepherd F 1 No treatment
18 Crossbreed F (n) 7 No treatment
19 Cocker Spaniel M 6 No treatment
20 Border collie M 5 No treatment
21 German shepherd M 4 No treatment
22 Crossbreed F (n) 1 No treatment
Dog (n) = neutered.
a No dogswere receiving treatment in the ﬁrst test trial, treatment refers to medication
in use during the second test trial.
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behavioural coding. The video cameras were mounted on a tripod, one
to one side of the room and the other at the back of the room. The
part of the room within 150 cm of the screen was considered to be the
“test area” and when dogs were within this area with evident interest
in exploring it, the screen or the pots, their behaviour was considered
as ‘exploring the test area’.
Exploring the test area included:
1. Snifﬁng = The dog overtly approached the ﬂoor, the bowls or the
screen and appeared to inhale through its nose
2. Exploring = Remaining in the test area watching towards the ﬂoor,
the screen or the bowls
3. Investigating the pots= approaching the pots with nosewithin 1 cm
of pot and nose or muzzle inside pot
Behaviours such as staying far from the screen, either close to
the owner or at the opposite end of the room to the experimental
apparatus, were considered as behaviours associated with not
exploring the test area.
Dogs were brought into the test environment on a leash by their
owners. In each test trial the owner was invited to calmly restrain the
dog on the leash, sit andwear a pair of sunglasses to restrict eye contact
between dog and their owner. The researcher showed the dog a few
pieces of food and then put one small piece of food in each pot. After
this, the researcher sat on a chair in a corner of the room, showing no
overt interest in the procedure. The owner was instructed to unleash
the dog and then behave in a neutral way, pretending to read a book
provided by the researcher and completely ignoring the dog until a
signal signifying the end of the test was given. The dog was left free
to investigate the test area and take the treats from two pots.
As soon as it started to approach the third pot, playback of a three
second growl was started. Three types of dog growl recordings
were used: small dog, medium dog and large dog growls, and
these were allocated on the basis of the size of the dogs being
tested (i.e. small test dog = small dog growl) in order to minimize
the scaring effect of the growl. The growls were chosen because they
had been recorded in the context of food guarding and used in a previ-
ous study [25]. The dog's behaviourwas then observed for twominutes.
At the end of the test, the owner was asked to call the dog and put it on
its leash. This behavioural test procedure is illustrated in Fig. 3.
B = pot disposition; L = loudspeaker; OW = owner position;
R = researcher position during the test.
2.4. Behavioural observation
The video recordings of tests were analysed using Solomon Coder
(http://solomoncoder.com/). We considered the following behaviours
for analysis:
1. Latency
a. Time from release to the approach to the ﬁrst pot (nose within
1 cm of pot) (Latency 1)
b. Time from the growl/startle reaction to further investigation of
pots (Latency 2)
2. Time spent investigating the test area (TTA)
3. Time spent investigating the pots (TTP)
4. Time spent investigating the test area before the growl (Expl1)
Fig. 2. Test setting. V1 and V2= video cameras; TA = test area; S = screen;
Fig. 3. Behavioural test procedure. A= the dog is shown the food; B= a piece of food is placed into each pot; C= the owner unleashes the dog; D= the owner is instructed to behave in a
neutral way; E = the dog explores the pots; F = the dog reacts to the growl.
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5. Time spent investigating the test area after the growl (Expl2)
6. Startle reactions
a. Grade 1. The dog respondswithminimal, momentary re-orientation
of head
b. Grade 2. The dog responds with re-orientation of head, steps back
c. Grade 3. The dog responds with re-orientation of head, steps back
and takes a few seconds before coming back to the pot or leaves
the test area and does not return within 2 min
7. Eating of food. The number of food pieces eaten by each dog in each
test trial.
2.5. Data analysis
The ﬁrst observer transcribed the video recordings of both test trials
(n = 22) and scored them using the ethogram on two separate
occasions to assess intra-observer reliability. The recordings from ten
of the dogs (5 treatment dogs and 5 control dogs) were randomly
selected for their behaviour to be assessed by a second observer
who was ‘blind’ to the treatment allocation in order to evaluate
inter-observer variability. Spearman's coefﬁcient was used to measure
pairwise correlation among raters.
Data from the video analysis regarding Latency 1, Latency 2, TTP,
TTV, Expl1 and Expl2 were analysed using SPSS 21. Data were not
normally distributed and therefore an extension of the Generalized
Linear Model (GZLM), Generalized Estimating Equations (GEE) was
used in order to evaluate the results that accommodated correlated
within-subjects data and allowed comparisons between subjects.
Startle reactions were evaluated for their severity according to the
above descriptions. Eating of food was evaluated by counting the num-
ber of food pieces eaten by each dog during each test trial. Comparison
between the control and treatment dogs for these two metrics was
evaluated using Mann–Whitney U test at a given time point (e.g. either
ﬁrst or second test), with Wilcoxon's Matched Pairs Signed-Ranks Test
used to compare within groups between tests (ﬁrst versus second test).
3. Results
3.1. Questionnaire study
By the close of the survey in February 2011, 98 questionnaires had
been completed correctly by dog owners and considered suitable for
analysis. Dogs were from a variety of breeds and genders, and aged
between 1–14 years. Reasons for treatment were dermatological
conditions (n = 55), orthopaedic conditions (n = 36) and other kinds
of condition (n = 7). Treatment duration varied from one week of
treatment to long term maintenance treatment. Of the sample of
98 dogs, 44 received corticosteroids and 54 received only othermedica-
tions, mainly antibiotics (n = 20) and non-steroidal anti-inﬂammatory
drugs (n= 28), with a small proportion on other drugs (n= 6). Of the
44 dogs that received corticosteroids, 23 also received other drugs,
mainly antibiotics. The 44 dogs receiving treatmentwith corticosteroids
were subject to a variety of corticosteroid preparations, but mainly
prednisone/prednisolone (n = 32) and methylprednisolone (n = 7).
Two dogs received betamethasone and 3 dogs received dexamethasone.
Corticosteroid drug doses were between 0.1–1.2 mg/kg for prednisone
and prednisolone, between 0.5–1.5 mg/kg for methylprednisolone,
0.05 mg/kg for betamethasone and 0.1 mg/kg for dexamethasone.
Data were not normally distributed, but still suitable for analysis of
variance [26,27]. The repeated measures multivariate GLM analysis
showed that the only signiﬁcant factor related to a change in the
behaviour of dogs on and off corticosteroids was the treatment used.
The univariate GLM with post hoc correction for multiple testing
showed that the administration of treatments involving corticosteroid
(44 dogs) had a statistically signiﬁcant effect on the response to eight
items. Five behaviours, Play (F = 6.525, Nervousness (F = 6.130),
Fear (F = 13.112), Startle reactions (F = 5.705), Irritable aggression
(F = 5.080) - all signiﬁcantly changed with p b 0.01; three behaviours,
Food aggression (F = 4.793), Barking (F = 4.330), Avoidance
(F=4.463)— all signiﬁcantly changedwith p b 0.05). By contrast, treat-
ments without corticosteroids (54 dogs), produced no signiﬁcant
changes (p N 0.05) in response to any item and no signiﬁcant changes
in behaviour were related to other drugs (Table 3).
3.2. Behavioural test
The behavioural testing of dogs (11 sample dogs and 11 control
dogs) ended in October 2013.
Spearman's coefﬁcient of correlation revealed statistically signiﬁcant
positive correlations between intra-observer (n = 22) and inter-
observer (n = 10) measurements. Intraobserver correlations were
positive with r = 0.994 and p b 0.01. Interobserver correlations
were positive with r = 0.996 and p b 0.01 for all items.
GEE revealed no signiﬁcant differences in Latency1, Latency 2, TTA,
TTP, EXPL1 and EXPL2 between groups in the ﬁrst test trial, before
the ‘treatment’ dogs had been placed on corticosteroids. In the second
test trial, the total time spent investigating the test area (TTA) was
signiﬁcantly lower in the group of dogs treated with corticosteroids
(unstandardized coefﬁcient—B = 25.309; χ2(1) = 6.157; p b 0.05)
compared with the control group of dogs. In the second test trial, the
exploration time after the growl of dogs (EXPL2) in the treatment
group was signiﬁcantly lower (B = 26.18; χ2(1) = 6.600; p b 0.05)
compared with the same behaviour in the control group of dogs.
Latency times (L1 and L2), time spent investigating the area before the
growl (EXPL1) and the time spent investigating the pots (TTP) were
not signiﬁcantly different between the two groups (p N 0.05) [Latency
1: B = −3.573, χ2(1) = 0.588, p = 0.443; Latency 2: B = −9.709,
χ2(1) = 0.477, p = 0.490; EXPL1: B = −0.545, χ2(1) = 0.310, p =
0.577; TTP: B = 5.991, χ2(1) = 2.583, p = 0.108].
Startle reactions in the ﬁrst test trial were present in six dogs from
the treatment group and nine dogs from the control group. Three dogs
from the test group were graded at level 1 (S1) and four at level 2
(S2). Eight dogs from the control group were scored at level 1 (S1)
and one at level 3 (S3).
In the second test trial seven dogs from the treatment group
and nine dogs from the control group produced startle reactions (see
Table 4). No signiﬁcant differences between groups were found as far
as startle reactions were concerned (p N 0.05).
In the ﬁrst test trial, seven dogs from the treatment group ate all ﬁve
food treats, two dogs did not eat any food and two dogs ate three pieces.
In the ﬁrst test trial, eight dogs from the control group ate all the food,
two dogs did not eat any food and one dog ate three pieces. In the
second test trial, ﬁve dogs from the treatment group ate all the food,
two dogs ate four pieces, two dogs ate three pieces and two dogs did
not eat any food. In the second test trial, all dogs from the control
group ate all the food. A Mann–Whitney U test revealed a signiﬁcant
difference between groups as far as number of pieces of food eaten
was concerned (z = −2.765; p = 0.028) with control dogs eating
more than treatment dogs. Wilcoxon's Matched Pairs Signed-Ranks
Test revealed no signiﬁcant differences within groups in the two test
trials (p N 0.05) for either startle or food consumption.
4. Discussion
The results reported here from both studies are consistentwith each
other and the preliminary ﬁndings of Notari and Mills [9] reported pre-
viously. This latter study had the main goal of providing information
about the possibility that dogs receiving treatment with corticosteroids
might show behavioural analogous to those reported in humans and
was the starting point for the development of the present study. The
survey reported here was a development of the previous methodology,
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using a simple scoring system to allow the harvesting of a larger data set
and the inclusion of a control group. All of the behaviours that were
reported to change under the inﬂuence of corticosteroid drugs in the
previous study [9] were found to change signiﬁcantly in the present
study, adding weight to the reliability of these reported effects.
Dogs under corticosteroids were reported to be more nervous/restless,
more fearful/less conﬁdent, more aggressive in the presence of food,
barked more, more prone to startle, more prone to react aggressively
when disturbed, and more prone to avoiding people or unusual
situations. All theseﬁndings indicated these drugsmight bias sensitivity
towards aversion in dogs.
In addition, one further item, not previously reported, but also
possibly inﬂuenced by changes in affect i.e. amount of play behaviour,
was reported to be reduced under corticosteroid treatment and elevat-
ed highly under treatment with other drugs (Table 3). The additional
discovery of a disparate effect on play between the two classes of
pharmacological intervention could be important as the occurrence
of play is considered to be a useful indicator of animal welfare, with
animals reducingplaywhen they becomedistressed [21,28,29]. It there-
fore seems that a reduction in play would be consistent with the poten-
tial negative effects of corticosteroids, but it is worth noting that there
was a large increase in response to treatment with the other drugs
(Table 3), and this may be where the main effect lies, i.e. an elevation
in positive mood when these other interventions are used. The ﬁnding
is all the more interesting as corticosteroids are widely used for their
potent anti-inﬂammatory effects and it might be predicted that their
value in relieving pain and irritation means that their use would
increase playfulness as a result. However, these results suggest that
their negative effects on affective state might mitigate against the
predicted positive behavioural effects. It might be that corticosteroids
serve to largely increase arousal rather than induce a positive affective
state per se, as might be often assumed.
Four other behaviours were inserted as ﬁllers to prevent psycholog-
ical bias [24]. These ﬁllers where selected among the behaviours that
most frequently cause complaints by dog owners [22,23], that we did
not expect to be effected by the use of corticosteroids. The robustness
of the effects reported here are therefore further enhanced by the
ﬁnding that these four items (attention seeking, obedience, guarding
and mounting) did not show signiﬁcant effects. Corticosteroid drug
dose effect and the effects of disease on behaviour have been widely
reported in humans [1,30,31], and the impact of physiological stress
and health on the behaviour of veterinary species recently reviewed
[32], but there is still a lack of information on the relationship between
levels of circulating corticosteroid and behaviour in animals. This was
not addressed in the present study but is an area for future attention.
Behavioural tests followed the survey in order to provide, for the
ﬁrst time, objective behavioural evidence of the effect of corticosteroid
therapy on dog behaviour. Because our initial ﬁndings were interpreted
to indicate that dogs on corticosteroid therapy were more avoidant, the
Table 3
Reported changes in behaviour score on and off different treatments. Scales 1–7 represent the expression of the behaviour. Questions about nervousness and fear had reversed scales.
Response item CG Off CG On OG Off OG On
Play** Mean
(±SD)
4.80
(1.82)
4.05
(1.71)
3.80
(1.90)
4.63
(1.85)
Nervousness** Mean
(±SD)
4.57
(1.56)
3.75
(1.92)
4.69
(1.78)
5.02
(1.55)
Fear** Mean
(±SD)
4.89
(1.48)
3.95
(1.72)
4.54
(1.61)
4.94
(1.37)
Food aggression* Mean
(±SD)
2.00
(1.45)
2.57
(2.11)
2.20
(1.56)
2.07
(1.37)
Attention seeking Mean
(±SD)
3.91
(1.70)
4.14
(1.84)
3.93
(1.86)
4.15
(1.77)
Barking* Mean
(±SD)
2.73
(1.69)
3.43
(2.05)
2.74
(1.75)
2.67
(1.78)
Obedience Mean
(±SD)
5.18
(1.48)
4.91
(1.60)
5.07
(1.33)
5.04
(1.29)
Guarding Mean
(±SD)
3.39
(1.87)
3.50
(2.05)
3.20
(2.10)
3.31
(1.92)
Startle reactions** Mean
(±SD)
2.84
(1.68)
3.77
(2.07)
3.19
(1.83)
3.06
(1.62)
Irritable aggression** Mean
(±SD)
1.93
(1.47)
2.43
(1.83)
2.07
(1.46)
1.96
(1.30)
Avoidance* Mean
(±SD)
2.27
(1.80)
2.73
(2.05)
2.19
(1.48)
2.11
(1.42)
Mounting Mean
(±SD)
1.80
(1.29)
1.75
(1.48)
2.02
(1.56)
1.80
(1.19)
CG= corticosteroid group; OG = other group. Signiﬁcant differences between groups calculated with GLM univariate analysis indicated thus * = p b 0.05; ** = p b 0.01.
Table 4
Startle reactions and pieces of food eaten by dogs in the two test trials.
Dog
n.
Trial 1 Startle
score
Trial 2 Startle
score
Trial 1 Food
eaten
Trial 2 Food
eaten
1a – – 5 5
2a S1 S2 5 5
3a – – 5 5
4a – – 5 4
5a S2 S3 3 3
6a – S2 5 0
7a S2 S1 0 4
8a S2 S2 0 0
9a S1 S1 3 3
10a S2 S2 5 5
11a – – 5 5
12 S1 S1 5 5
13 – – 5 5
14 S1 S1 5 5
15 S1 S1 5 5
16 S1 S2 0 5
17 S1 S1 5 5
18 S3 S3 3 5
19 – – 5 5
20 S1 S1 5 5
21 S1 S1 0 5
22 S1 S1 5 5
S1 = The dog responds with minimal, momentary re-orientation of head.
S2 = The dog responds with re-orientation of head, steps back.
S3= The dog responds with re-orientation of head, steps back and it takes a few seconds
before coming back to the pot or never comes back.
Trial 1 Food = pieces of food eaten in trial 1.
Trial 2 Food = pieces of food eaten in trial 2.
a Dogs receiving treatment with corticosteroids in the second test trial.
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test was designed to stimulate exploration of the test areawithminimal
challenges. The introduction of a surprising, potentially negative stimu-
lus in the form of the growl, had the purpose of testing both reactivity
and avoidance tendency. Decreases in exploratory behaviour have also
been associated with negative affective states [33–35], and this is likely
to be the product of a negative cognitive bias associated with negative
affect:when in a negative affective state the desire to seeknew informa-
tion is reduced and so the animal might avoid rather than explore open
areas andnovel stimuli [36,37]. In the behavioural tests, types of cortico-
steroids and drug doses were very similar within the treatment group.
Although cytokines involved in the immune response might explain
behavioural effects such as decreased exploratory behaviour and
increased avoidance [38] reported by owners in the survey, this would
not explain the results in the behavioural tests. Some dogs suffered
from allergic dermatological conditions, that would produce a lot of
cytokines, when they were tested off treatment and no signiﬁcant
differences were found between treatment and control group dogs
at this time rather a signiﬁcant decrease in exploratory behaviour
between groups was observed only when treatment dogs were on
corticosteroids.
Unlike the dogs receiving corticosteroid treatment, control dogs did
not show a signiﬁcant change in their exploratory behaviour, when
receiving treatment. Comparisons between groups showed that the
exploratory behaviour was lower when dogs were on corticosteroids.
In laboratory animals, the administration of glucocorticoids after a
training session seemed to inﬂuence contextual fear memories and
hippocampal long term potentiation (LTP), suggesting that they
may enhance contextual fear memory consolidation via enhancing
hippocampal LTP [39].
In the behavioural test, we found dogs on corticosteroids ate signif-
icantly less food comparedwith the control group, despite increased ap-
petite being a well-recognized side effect of corticosteroid therapy.
Decreased food intake can be interpreted as part of decreased explor-
atory behaviour or as a sign of increased stress in itself [40].
In the behavioural tests three dogs treated with corticosteroids in-
creased their startle reactions and one dog decreased this reaction,
while in the control group just one dog increased its startle reaction
and no dog decreased it., The results about startle reactions did not
show any signiﬁcant differences in startle reactions between the two
groups (p N 0.05). However, in the questionnaire study dog owners
reported an increase in their dogs' startling tendency when on cortico-
steroids and the startle response has been used as a speciﬁc response
to assess a changed negative affective state in both laboratory animals
and human beings [3]. This apparent discrepancy can be explained
because startle responses have different motor features according to
whether they are triggered by emotional or voluntary responses
[41–46], and it may be that the two contexts focus on different types
of startle.
Direct testing of dogs in the behavioural test may be more reli-
able, but is more labour intensive, especially when relying on clinical
cases. The need to design a behavioural test without compromising
animal welfare meant that the chosen stimuli were not so intense
as to scare or seriously threaten the animal. As a consequence, the
magnitude of the behavioural responses that we observed may
have been less compared to reactions that the animal in treatment
might have exhibited in real life fearful or threatening conditions.
This could explain why the effects in the test seemed relatively
mild when compared to the survey results. The ﬁndings of the
surveys and the tests provide convergent validity that, together
with a consistency at the theoretical level, indicate that these results
are robust and the effects reliable.
5. Conclusion
Overall, these results indicate that in pet dogs, corticosteroid treat-
ment at therapeutic doses can bias cognition and change behaviour.
Physiological intervention with these drugs appears to increase
sensitivity towards aversion. On the basis of these results and in
the absence of evidence to the contrary, we recommend that the sup-
ply of these drugs to owners by veterinarians should be accompanied
by advice about behavioural risk management due to a possible
increase of a negative affective state, a condition that might increase
the risk of aggressive behaviours.
Acknowledgements
The Authors would like to acknowledge Professor Ádám Miklósi,
Dr. Tamás Faragó, Dr. Péter Pongrácz, Dr. Friederike Range, and
Dr. Zsóﬁa Virányi for giving the opportunity to use the same growl
sounds used in their studies. Sincere thanks to Dr. Alessia Colombo
for her important contribution to statistical analysis. Sincere thanks
are extended to all the owners that ﬁlled our questionnaires and all
owners and dogs that participated to our behavioural tests.
References
[1] H. Seyle, General Adaptation Syndrome, 2nd edition Acta Endocrinology,
Montreal, 1949.
[2] E.R. de Kloet, O.C. Schmidt, Corticosteroid receptors and HPA-axis regulation, in:
N.H.K., J.M.H.M.R.T. Stekler (Eds.), Handb. Stress Brain, Elsevier, Amsterdam 2005,
pp. 265–294.
[3] J.E. Le Doux, Emotion circuits in the brain, Annu. Rev. Neurosci. 23 (2000) 155–184.
[4] I. Akira, G. Richter-Levin, Involvement of the amygdala in the neuroendocrine and
behavioral consequences of stress, in: N.H.K., J.M.H.M.R.T. Stekler (Eds.), Handb.
Stress Brain, Elsevier, Amsterdam 2005, pp. 793–805.
[5] T. Steckler, The neuropsychology of stress, in: T. Stekler, N.H. Kalin, J.M.H.M. Reul
(Eds.), Handb. Stress Brain, Elsevier, Amsterdam 2005, pp. 25–42.
[6] J. Prickaerts, T. Steckler, Effects of glucocorticoids in emotion and cognitive
processes in animals, in: T. Stekler, N.H. Kalin, J.M.H.M. Reul (Eds.), Handb. Stress
Brain, Elsevier, Amsterdam 2005, pp. 359–385.
[7] R.K. McDonald, V.C. Langston, Use of corticosteroids and non-steroidal anti-
inﬂammatory agents, in: S.J. Ettinger, E.C. Feldman (Eds.), Textb. Vet. Intern. Med.
Dis. Dog Cat, 4th editionWb Saunders Co, Toronto 1995, pp. 284–293.
[8] C.A. Sousa, Glucocorticoids in Veterinary Dermatology, Saunders, U.S.A., 2009
400–405.
[9] L. Notari, D. Mills, Possible behavioral effects of exogenous corticosteroids on
dog behavior: a preliminary investigation, J. Vet. Behav. Clin. Appl. Res. 6
(2011) 321–327.
[10] S. Brody, Psychiatric observation in patients treated with cortisone and ACTH,
Psychosom. Med. 14 (1952) 94–103.
[11] E.S. Brown, P.A. Chandler, Mood and cognitive changes during systemic corticoste-
roid therapy, prim. care companion, J. Clin. Psychiatry. 3 (2001) 17–21, http://dx.
doi.org/10.4088/PCC.v03n0104.
[12] R. Felder-Puig, C. Scherzer, M. Baumgartner, M. Ortner, C. Aschenbrenner, C.
Bieglmayer, et al., Glucocorticoids in the treatment of children with acute
lymphoblastic leukemia and Hodgkin's disease: a pilot study on the adverse
psychological reactions and possible associations with neurobiological,
endocrine, and genetic markers, Clin. Cancer Res. 13 (2007) 7093–7100.
[13] A.S. Hall, G. Thorley, P.N. Houtman, The effects of corticosteroids on behavior in
children with nephrotic syndrome, Pediatr. Nephrol. 18 (2003) 1220–1223,
http://dx.doi.org/10.1007/s00467-003-1295-x.
[14] O.M. Wolkowitz, D. Rubinow, A.R. Doran, A. Breier, W.H. Berrettini, M.A. Kling, et al.,
Prednisone effects on neurochemistry and behavior. Preliminary ﬁndings, 1990.
[15] E.R. De Kloet, S.M. Korte, N.Y. Rots, M.R. Kruk, Stress Hormones, Genotype, and Brain
Organization. Implications for Aggression, Ann. N. Y. Acad. Sci., 1996 179–191.
[16] J.J. Kim, J. Haller, Glucocorticoid hyper- and hypofunction: stress effects on cognition
and aggression, Ann. N. Y. Acad. Sci. 1113 (2007) 291–303, http://dx.doi.org/10.
1196/annals.1391.014.
[17] G.A. Cottrell, S. Nakajima, Effect of corticosteroids in the hippocampus on passive
avoidance behavior in the rat, Pharmacol. Biochem. Behav. 7 (1977) 277–280.
[18] E.R. Kloet, M. Oitzl, M. Joëls, Stress and cognition: are corticosteroids good or bad
guys? TINS 22 (1999) 422–426.
[19] J.L.W. Yau, J. Noble, J.R. Seckl, Continuous blockade of brain mineralocorticoid
receptors impairs spatial learning in rats, Neurosci. Lett. 277 (1999) 45–48,
http://dx.doi.org/10.1016/S0304-3940(99)00858-7.
[20] M. Bentosela, E. Ruetti, R.N. Muzio, A.E. Mustaca, M.R. Papini, Administration of
corticosterone after the ﬁrst downshift trial enhances consummatory successive
negative contrast, Behav. Neurosci. 120 (2006) 371–376.
[21] A.F.S. Oliveira, A.O. Rossi, L.F.R. Silva, M.C. Lau, R.E. Barreto, Play behaviour in
nonhuman animals and the animal welfare issue, J. Ethol. 28 (2010) 1–5.
[22] B.V. Beaver, Owner complaints about canine behavior, J. Am. Vet. Med. Assoc. 204
(1994) 1953–1955.
[23] D.L. Wells, P.G. Hepper, Prevalence of behaviour problems reported by owners
of dogs purchased from an animal rescue shelter, Appl. Anim. Behav. Sci. 69
(2000) 55–65.
615L. Notari et al. / Physiology & Behavior 151 (2015) 609–616
Appendix H
215
[24] G. Domino, M.L. Domino, Psychological Testing: An Introduction, Cambridge
University Press, Cambridge, 2006 434.
[25] T. Faragó, P. Pongrácz, F. Range, Z. Virányi, Á. Miklósi, “The bone is mine”: affective
and referential aspects of dog growls, Anim. Behav. 79 (2010) 917–925.
[26] L. J.K., The uses and limits of linear models, Stat. Comput. 5 (1995) 87–89.
[27] G.a. Ballinger, Using generalized estimating equations for longitudinal data
analysis, Organ. Res. Methods 7 (2004) 127–150, http://dx.doi.org/10.1177/
1094428104263672.
[28] A. Boissy, G. Manteuffel, M.B. Jensen, R.O. Moe, B. Spruijt, L.J. Keeling, et al.,
Assessment of positive emotions in animals to improve their welfare, Physiol.
Behav. 92 (2007) 375–397, http://dx.doi.org/10.1016/j.physbeh.2007.02.003.
[29] S.D.E. Held, M. Špinka, Animal play and animal welfare, Anim. Behav. 81
(2011) 891–899.
[30] B.G. Bender, J.A. Lerner, J.E. Poland, Associationbetween corticosteroids andpsychologic
change in hospitalized asthmatic children, Ann. Allergy 66 (1991) 414–419.
[31] S.J. Larson, A.J. Dunn, Behavioral effects of cytokines, Brain. Behav. Immun. 15 (2001)
371–387, http://dx.doi.org/10.1006/brbi.2001.0643.
[32] D. Mills, C. Karagiannis, H. Zulch, Stress—its effects on health and behavior: a guide
for practitioners, Vet. Clin. North Am. Small Anim. Pract. 44 (2014) 525–541.
[33] S.A. Cavigelli, M.M. Stine, C. Kovacsics, A. Jefferson, M.N. Diep, C.E. Barrett,
Behavioral inhibition and glucocorticoid dynamics in a rodent model, Physiol.
Behav. 92 (2007) 897–905.
[34] R. Rygula, N. Abumaria, G. Flügge, E. Fuchs, E. Rüther, U. Havemann-Reinecke,
Anhedonia and motivational deﬁcits in rats: impact of chronic social stress, Behav.
Brain Res. 162 (2005) 127–134.
[35] F.J. H. H. van Dijken, J. Mos, J. A. van der Heyden, Characterization of stress-induced
long-term behavioural changes in rats: evidence in favor of anxiety, Physiol. Behav.
Volume 52 (1992) 945–951.
[36] O. Burman, R. McGowan, M. Mendl, Y. Norling, E. Paul, T. Rehn, et al., Using
judgement bias to measure positive affective state in dogs, Appl. Anim. Behav. Sci.
132 (2011) 160–168.
[37] E.J. Harding, E.S. Paul, M. Mendl, Animal behaviour: cognitive bias and affective
state, Nature 427 (2004) 312.
[38] H. Anisman, Z. Merali, Anhedonic and anxiogenic effects of cytokine exposure, Adv.
Exp. Med. Biol. 461 (1999) 199–233.
[39] K. Abrari, A. Rashidy-Pour, S. Semnanian, Y. Fathollahi, Post-training adminis-
tration of corticosterone enhances consolidation of contextual fear memory
and hippocampal long-term potentiation in rats, Neurobiol. Learn. Mem. 91
(2009) 260–265.
[40] G.J. Morton, T.H. Meek, M.W. Schwartz, Neurobiology of food intake in health and
disease, Nat. Rev. Neurosci. 15 (2014) 367–378 (http://www.ncbi.nlm.nih.gov/
pubmed/24840801).
[41] M. Davis, D.S. Gendelman, M.D. Tischler, P.M. Gendelman, A primary acoustic startle
circuit: lesion and stimulation studies, J. Neurosci. 2 (1982) 791–805.
[42] E.W. Cook, T.L. Davis, L.W. Hawk, E.L. Spence, C.H. Gautier, Fearfulness and startle
potentiation during aversive visual stimuli, Psychophysiology 29 (1992) 633–645.
[43] M. Koch, The neurobiology of startle, Prog. Neurobiol. 59 (1999) 107–128.
[44] P.J. Lang, M.M. Bradley, B.N. Cuthbert, Emotion, attention, and the startle reﬂex,
Psychol. Rev. 97 (1990) 377–395.
[45] J.S. Baschnagel, L.W. Hawk, C.R. Colder, J.B. Richards, Motivated attention and
prepulse inhibition of startle in rats: using conditioned reinforcers as prepulses,
Behav. Neurosci. 121 (2007) 1372–1382.
[46] Y.E.M. Dreissen, M.J. Bakker, J.H.T.M. Koelman, M.A.J. Tijssen, Exaggerated startle
reactions, Clin. Neurophysiol. 123 (2012) 34–44.
616 L. Notari et al. / Physiology & Behavior 151 (2015) 609–616
Appendix H
216
